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Tumour cells release lipid particles known as extracellular vesicles (EV) that 
contribute to cancer metastasis, to the immune response, and to thrombosis. There 
are many types of identified EV, and most live tumour cells spontaneously shed EV. 
For example, microvesicles (MV; 0.1-1 µm), are released by the direct budding of the 
membrane whereas a smaller type (50-200 nm), called exosomes, are shed via the 
endosomal pathway. Intriguingly, if tumour cells are exposed to chemotherapy or 
radiotherapy, one of the consequences of cell death is the abundant cell membrane 
release of another type of EV; the apoptotic vesicles (ApoV).  
 This research has first compared the three types of EV using a multitude of 
structural and molecular parameters. This led to their characterisation and creation 
of a distinguishable identity for each of them. This research then aimed to 
investigate and compare their functionality. We have addressed this by comparing 
the three EV types as prophylactic tumour vaccines and by their ability to clot the 
blood. The latter was investigated because the second leading cause of death in 
cancer patients undergoing chemotherapy is thrombosis (blood clot).  Strikingly 
among the three EV, ApoV demonstrated superiority in both systems; superior 
protection against cancer and significantly rapid blood coagulation was induced by 
ApoV, as compared to the other EV types. Further investigation showed that ApoV 
possessed dramatically higher levels of procoagulant activity compared to 
exosomes, MV, or even equivalent protein fractions from intact living or dying 
tumour cells. 
In addition, we have identified that the superior procoagulant activity of 
ApoV was dependent on phosphatidylserine and the extrinsic coagulation factor 
tissue factor. Surprisingly, the intrinsic coagulation pathway (Factors VIII and IX) 
was dispensable for the procoagulant activity of ApoV. We have also identified the 
endogenous expression of coagulation Factor V on ApoV and determined it to be 
functional but non-essential for the optimal procoagulant activity of ApoV. 
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To investigate the contribution of melanoma EV to lymph node metastasis, 
we examined primary tumour growth and lymph node metastasis in mice lacking 
the EV receptor (CD169; sialoadhesin). Although CD169-/- mice displayed a lower 
level of lymph node metastasis, as compared to C57BL/6 mice, this failed to reach 
statistical significance. Similarly, primary tumour progression and the response to 
immunisation with ApoV in CD169-/- mice were lower and higher, respectively, 
compared to wild type mice. However, the results suggest that the CD169 receptor 
has no major role in tumour growth and metastasis.  
Together, these results emphasise the complexities of interaction between 
the host and tumour vesicles, and suggest an important role for ApoV released 
during chemotherapy in immunity, as well as in cancer / chemotherapy-related VTE. 
These findings illustrate how ApoV have the ability to “aid or aggravate” outcomes 
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Chapter I: Introduction 
2 
 
Section A: The immune system: a brief introduction 
1.1 Overview of the Immune System 
The clearance of the body’s foreign materials and abnormal cells, such as 
cancer cells, is largely conducted by the immune system [1]. Although functionally 
intertwined, immunity in vertebrates may be described as having two components 
[2]. The first component, known as the (non-specific) innate immune system, is the 
first line of defence. The innate fraction is broadly defined as physical barriers (such 
as the skin, the gastrointestinal and respiratory tract), secretory defences (such as 
mucus, tears, bile, and sweat), and finally, the cellular components (innate 
leukocytes; ref. [1]). The function and type of innate leukocyte varies greatly. For 
example, the natural killer (NK) cells are capable of inducing apoptosis in 
compromised host cells such as intracellularly infected or transformed 
(tumourigenic) cells [1, 3]. This cytotoxic ability by NK cells is orchestrated by their 
released perforin and granzymes that induces pores and initiate apoptosis, 
respectively, on the target cell [3]. Another important set of innate cells are the 
phagocytes such as macrophages [1, 4]. In addition to being able to engulf 
extracellular pathogens (phagocytosis) and scavenge cellular debris, macrophages 
are also antigen presenting cells (APC) with the ability to present antigens to the 
cells of the adaptive immune system [4].  
There are two main pathways by which antigens are processed and 
presented for recognition by the adaptive immune system. The endogenous 
pathway occurs when antigens are processed within the cytoplasm by the 
proteasome [1, 5]. In a virally infected cell, for example, viral peptide fragments are 
transported into the endoplasmic reticulum to be loaded onto the major 
histocompatibility complex class I (MHC-I; ref. [5]). The MHC-I loaded complexes are 
then transported within vesicles to the cell surface [1, 5, 6]. MHC-I molecules are 
expressed on almost every nucleated cell within the body, and the molecule’s 
absence activates NK cells [1, 7]. The second class of MHC, MHC-II, is normally 
confined to APC. Antigens processed and loaded on MHC-II molecules originate from 
an extracellular source via phagocytosis [1, 6]. The most specialised APC of the 
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immune system are the (weakly phagocytic) dendritic cells (DC; ref. [1, 8]). DC are 
important messengers between the innate and the adaptive immune system; the 
second fraction of the immune system [8].  
One of the main features of adaptive immunity is the ability to develop 
specific immune receptors and memory to antigens [1]. The cells responsible for this 
specific memory response are B and T lymphocytes [1]. B lymphocytes (B cells) 
express immunoglobulin (Ig) structures as a membrane bound B cell receptor, or as 
a secreted form (antibodies; ref. [9]). Members of the Ig protein superfamily are 
largely associated with cellular adhesion, recognition, and binding [1, 10]. Antigen 
receptors, antigen presenting molecules, and cell adhesion molecules (such as 
antibodies, MHC-I/II, and intercellular cell adhesion molecule; intercellular 
adhesion molecule-1; ICAM-1 respectively) are but a few examples of the 765 
members of the immunoglobulin family identified in the human genome [1, 10-12].  
B cells and their released antibodies play a vital role in humoral immunity 
through complement activation, activation of immune effector cells, and by 
enhancing phagocytosis (opsonisation; ref. [1]). The other set of cells of the immune 
system, the T lymphocytes (T cells), form a dominant component of cell-mediated 
immunity [1]. There are two main subsets of T cells; T helper cells (Th1 and Th2) 
express surface receptors known as cluster of differentiation 4 (CD4), these act as 
fundamental intermediates of the immune system [13, 14]. In addition to 
augmenting the potency of macrophages, Th1 can enhance the proliferation of the 
CD8 expressing cytotoxic T cells [1, 13]. Akin to the function of NK cells, activated 
CD8+ T cells use the pro-apoptotic and antimicrobial peptide for direct killing of 
intracellularly infected cells and recognised tumourigenic cells [1, 15]. To ensure a 
correct response, the stimulation of a CD8+ T cell requires two signals: the binding 
of a co-stimulatory receptor and the surface T cell receptor to a co-stimulatory 
molecule and the MHC-I of an APC respectively [1, 15].  
Immune system signalling is largely conveyed by signalling molecules known 
as cytokines [16]. Cytokines are released by a wide range of cells and are classified 
as pro-inflammatory or anti-inflammatory [1, 16]. For example, the pro-
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inflammatory cytokine interferon gamma (IFN-) is predominantly produced by T 
cells and NK cells [1, 17]. Cytokines therefore determine the fate of an immune 
response to either activation or suppression [16]. However, to avoid autoimmune 
disorders, the immune system has evolved a suppressive mechanism (tolerance) 
towards the body’s self-antigens, thus granting it the ability to distinguish self from 
foreign antigens [18]. There are two major mechanisms of immune tolerance 
induced by the adaptive immune system: central and peripheral tolerance [1, 18]. 
The former occurs in early stages and involves the elimination or deactivation of 
potentially autoreactive immature lymphocytes [1, 19]. Central tolerance occurs 
within the thymus and bone marrow; the maturation sites of T and B cells 
respectively [1, 20]. Developed in later stages and in regions distinctive to 
maturation sites, peripheral tolerance acts by silencing or induction of anergy in 
autoreactive mature lymphocytes that have escaped central tolerance [1, 19]. 
Peripheral self-antigens and immunologically inert environmental proteins have 
been known to be abundantly captured and presented by immature DC to 
autoreactive T cell [21]. The fate of such T cells is either deletion or transformation 
into a thymus-derived T regulatory cell (T-reg; ref. [1, 19, 22]). T-reg cells are 
suppressor cells that induce tolerance in an antigen-specific manner [23]. The 
mechanisms by which T-reg cells induce tolerance have been suggested to include 
the release of the anti-inflammatory cytokines interleukin 10 (IL-10) and 
transforming growth factor-β (TGF-β; ref. [1, 23, 24]). 
 
1.2 The Lymphatic System 
 The absorption and transport of fatty acids and removal of intestinal fluids 
are achieved by network conduits known as the lymphatics [1, 25]. However, with 
its nomenclature derived from “lymphocytes” the fundamental role of the lymphatic 
system is to initiate adaptive immunity. Organs of the lymphatic system is broadly 
divided into two categories: central and peripheral organs [1]. The thymus and bone 
marrow comprises the central (or primary) lymphoid organs of the lymphatic 
system [1, 26]. As mentioned before, the thymus and bone marrow are centres for 
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the selection and maturation of T and B cells respectively. Following maturation, 
(naïve) lymphocytes have not yet been exposed to antigens [1, 27]. Therefore, naïve 
lymphocytes frequently circulate in/out of the blood and the peripheral (or 
secondary) organs of the lymphatic system; where antigens are drained into [27].  
 The spleen is the largest secondary lymphatic organ; a specialised area of the 
spleen organ (the red pulp) mechanically filters red blood cells, whereas the other 
space (the white pulp) harbours T and B cells [28]. The other main subtype of 
secondary lymphatic organ is formed where lymphatic vessels converge, forming 
highly organised nodule structures known as lymph nodes (LN; ref. [29]). Similar to 
the spleen, LN accommodate lymphocytes within different compartments. For 
example, the paracortical area, primary lymphoid follicle, and medullary cords 
mostly contain T cells, B cells, and macrophages respectively (Figure 1.1; ref. [1, 
29]). Mature B cells migrate to, and proliferate within, spherical structures known 
as germinal centres.  The spleen’s marginal zone and the outermost layers of the LN 
(the subcapsular sinus) function to capture blood-borne and lymphoid antigens, 
respectively [30, 31]. These zones contain CD169+ macrophages which may 













1.3 Macrophages and Sialoadhesin/CD169 
 The strongly phagocytic macrophage cells are present in nearly all tissues in 
the body, though through different guises. Depending on the tissue of residence, 
macrophages have different characterising properties. For example, the liver 
contains a population of macrophages, known as Kupffer cells, vital for liver 
regeneration, immune tolerance during liver transplantation, and protection against 
toxic insult [32, 33]. Within the subcapsular sinus of LN (Figure 1.1) macrophages 
are the first to be exposed to antigens and have a role in presenting the captured 
antigens to B cells [34]. Interestingly, a macrophage-restricted receptor known as 
sialoadhesin (CD169; Siglec-1) is abundantly expressed on the surface of 
macrophages within the subcapsular sinus of LN, marginal zones of the spleen and 
liver (Kupffer cells; ref. [35]). CD169 is a member of the sialic-acid binding Ig-like 
lectin family of proteins; this enriched level of CD169 expression allows these 
CD169+ macrophages to bind to glycoproteins containing sialic acids [36]. However, 
CD169 has a low (mM) affinity to sialic acids and thus only heavily sialylated 
Figure 1.1 Organisation of the lymph node (LN). The different anatomical 
compartments of lymph nodes. Each area contains most specialised immune cells 



















structures are able to strongly bind to CD169+ macrophages [37]. Moreover, CD169 
has a ‘preferred’ (i.e. three-fold more) affinity to α2,3- than α2,6-linked sialic acids 
[38, 39]. In this regard, the McLellan laboratory has determined that CD169 
mediates the capture of extracellular vesicles (known as exosomes; discussed later) 



















Section B: Tumour biology and metastasis  
1.4 Cancer and the Immune System 
Abnormal cellular proliferation is the core definition of a tumour. The 
transformation of a cell into a tumourigenic cell may arise as a repercussion of 
overexpression, mutation, or inactivation of several genes [41, 42]. Clinically, a 
tumour may be characterised via its growth phase; mounting from localised phases 
to the spreading (metastasising) to other distal organs [42, 43]. If cancer is detected 
in its early stages, treatments such as irradiation and surgery often prove successful 
[44, 45]. Nevertheless, our judgment regarding the survival of early stage tumours 
remains poor, apart from viral-induced cancers [46, 47].  
 It has been suggested that tumours may be recognised and eliminated by the 
immune system, a process known as immunosurveillance. However, this theory was 
only accepted by the late 1990s due to the availability of improved mouse models 
with genetic immunodeficiency [48-50]. For example, Shankaran et al. showed that, 
compared to immunocompetent (wild-type) mice, lymphocyte-deficient mice are 
highly susceptible to develop tumours spontaneously upon exposure to a 
carcinogen [51]. Moreover, mice were highly susceptible to developing tumours 
when they lacked IFN-γ responsiveness [51, 52]. Henceforth, numerous genetically-
deficient mouse studies have demonstrated the importance of macrophages, T cells, 
B cells, and NK cells in the control of cancer [53-56]. Collectively, these findings 
converged to the concept and importance of immunosurveillance [55, 57]. However, 
the term cancer 'immunosurveillance' is now not regarded as an accurate depiction 
of the interaction of the immune system and tumours, as it implies that the immune 
system is only involved in the initial stages of cancers [48]. Moreover, it is now 
known that the interaction of the immune system with tumours does not solely 
comprise of a reactive, protective or prophylactic role [48]. A comparative 
experiment by Shankaran et al. studied transplanted tumours from either tumour-
bearing immunocompetent or immunodeficient mice into immunocompetent mice 
[51]. Interestingly, tumours derived from the immunocompetent group gave rise to 
tumour-bearing mice 100% of the time, whereas approximately one-half of the 
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tumours from the immunodeficient group were rejected by wild-type mice [48, 51]. 
Thus, the interaction of the immune system with tumours is clearly dependent on 
the immunocompetency of the host [48, 51]. Cancer immunoediting is a complex 
process, and is postulated by Schreiber, Old, and Smyth to progress through three 
different phases: elimination, equilibrium, and escape (Figure 1.2; ref. [48]). 
Since the elimination phase of tumours occurs at the early stages of cancer, it 
has not yet been directly observed in vivo. Nevertheless, the elimination of tumours 
largely depends on the high immunogenicity of tumour cells [57]. Potent elimination 
of 'immunogenic' tumours largely relies on the CD8+ and CD4+ T cells [58, 59]. 
Moreover, antigens from an early tumour-bearing tissue may be transported to 
lymphoid organs by DCs where adaptive immunity takes place to eliminate the 
transformed cells [60]. Innate immune cells such as NK cells or eosinophils also play 
a critical role for the elimination of cancers [61-63]. Therefore, the successful 
elimination of tumour cells required both the innate and adaptive immune 
responses. In rare occasions, some tumour cells may resist the elimination process 
by the immune system, and enter the equilibrium phase (Figure 1.2). In the 
equilibrium phase, the outgrowth of the resisting tumour mass is prevented by the 
immune system giving rise to a state of tumour ‘dormancy’ [57]. It is believed that 







Figure 1.2 The concept of cancer immunoediting. The interactions between 
the immune system and cancer are postulated to occur in three distinct phases: 
elimination, equilibrium, and escape. In the elimination phase, tumour cells are 
eliminated in the early stages of cancer due to the high immunogenicity of the 
transformed cells. However, in rare cases, if a transformed cell is not eliminated 
by the immune system, the transformed cell may enter the equilibrium phase 
whereby its outgrowth can be eliminated resulting in a state of tumour 
dormancy. Tumour immunogenicity occurs in the equilibrium phase. Due to the 
constant immunological pressure, some tumour cells may escape the immune 
system by becoming (i) insensitive to effector immune cells, (ii) unrecognisable 
by the immune system, or (iii) inducing an immunosuppressive 
microenvironment. Figure from Schreiber et al. 2011.  
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During a prolonged equilibrium state, genetic mutation of tumour cells may 
result in their immune escape; the third phase of immunoediting [48]. Reduced 
antigen levels, elevated resistance to immune responses, or upregulation of 
oncogenic factors can help the escape and proliferation of tumour cells [57, 64, 65]. 
Tumour cells may escape the primary tumour site to either proliferate, lie dormant, 
or even die at the secondary site [43, 66].  
The main clinical issue is that this escape of tumours may be a source of 
metastasis and is not detectable using current diagnostic tools due to the 
micrometastatic nature of the tumours [43]. It might be after years or even decades 
post-treatment that a detectable metastatic growth is observed. Detection of 
metastasis is critical as the major cause of death in cancer patients is metastasis and 
(usually) not primary tumours [67]. Probably one of the major factors allowing 
tumour cells to metastasise is the failure of the immune system’s surveillance 
mechanisms [68]. This failure may be associated with the transformed cells 
outgrowing the immune system elimination and/or their ability to manipulate 
(suppress) the immune system. CD95 ligand (FasL; CD178) induces apoptosis in 
target cells expressing CD95 (Fas); hence the over expression of CD95L in certain 
tumour cells may result in direct killing of lymphocytes via apoptosis initiation [69, 
70]. Animal studies by Strand et al. have shown that hepatocellular carcinoma (HCC) 
cells within HCC patients display an increase of CD95L expression with a 
concomitant loss of the CD95 receptor [69]. Tumour cells have also been identified 
to overexpress other immunosuppressive cytokines such as IL-10 and TGF-β [71]. It 
is well established that IL-10 can effectively suppress pro-inflammatory cytokine 
production such as IFN- [17], while Thomas and Massagué demonstrated that TGF-
β downregulated the gene expression of numerous T cells including granzyme 
proteins, CD95L, and perforins. To coincide with that study, Yun et al. showed that 
neutralisation of the systemic TGF-β in mice restored the T cell cytotoxicity and 
tumour clearance within a thymoma mouse model [72]. Melanoma cells (the most 
deadly of skin cancers), have been noted to reconstruct their connective tissue into 
lymphoid-like structures to promote tolerance via the recruitment and maintenance 
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of T-reg cells [73]. It is therefore clear that tumour immune-suppression warfare is 
critical for tumour growth and metastasis. 
 In addition to bypassing the anti-tumour response, tumour cells require a 
nutrient rich environment to sustain them due to their rapid proliferative rate. 
Angiogenesis (the growth of new blood vessels) is a process involved in embryo 
development and wound healing [74]. Numerous proteins that activate 
angiogenesis have been identified in cancers; including growth factors such as the 
vascular endothelial growth factor (VEGF) family, TGF, and angiogenin [75-77]. 
Interestingly, sufficient evidence suggests that tumour cells encourage angiogenesis 
to expand their mass and/or metastasise [74, 78, 79]. Similarly to normal events, 
tumours are able to promote angiogenesis by secreting growth factors such as VEGF 
and TGF-β [80]. Within a tumour mass, the tumour cells most distal from the blood 
vessel (>100 µm), and thus oxygen diffusion, become deprived of oxygen (hypoxic; 
ref. [81, 82]). It is thought that mainly hypoxia causes a switch in tumour cell 
phenotype to become angiogenic [81, 83].  
 The mechanisms by which tumours can convey immune escape, grow, and 
metastasise are vast (Figure 1.2; ref. [48, 57]). Nonetheless, novel mechanisms are 
being discovered and more appreciated. For example, evidence suggests that 
tumour-released vesicles (small lipid sacs) play a fundamental role in metastasis 
(discussed later). 
 
1.5 Mechanisms of Tumour Dissemination  
 The sentinel/draining LN is hypothetically the first LN to have cancer cells 
draining into it. One of the most important events of tumour metastasis is the 
migration of tumour cells from the primary site to the draining LN (Figure 1.3; ref. 
[84]). Invading tumour cells eventually spread to other LN in a sequential fashion 
starting and ending from the closest (draining) to most distal LN respectively [85]. 
This is called lymphatic dissemination and is believed to only occur if the draining 
LN is invaded by the tumour cells [86]. In the clinic, the excision of the primary 
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tumour along with its draining LN is a clinical standard to contain the spread of 
tumour cells [87]. Ishigami et al. have suggested that early gastric carcinoma 
patients with high NK cell infiltration show less invasion to LN and thus a more 
favourable prognosis [88]. Tumour cells can also detach from the primary site and 
enter the blood stream, a metastatic process known as haematogenous 
dissemination [89]. Interestingly, and although sometimes necessary, surgical 
removal of the tumours may promote tumour metastasis [90-92]. Angiogenesis is a 
natural post-surgical response by the body, and thus may help the development of 
secondary tumours [93-95]. In addition, surgical interventions often lead to a post-
surgical hypercoagulable state which promotes metastasis [96-99]. For example, 
Seth et al. have found that lung metastasis was significantly reduced in mice when 
blood coagulation is inhibited and that it is linked to NK cell function [100]. CD8+ T 
cells and NK cells become suppressed post-surgery [101] and Seth et al.’s findings 
have shown these ‘surgically stressed’ NK cells can in fact enhance lung metastasis 
if transplanted into NK cell-depleted/deficient mice [100]. In addition, Coupland et 
al. showed that when NK cells were depleted, lung metastasis is increased in mice 























Figure 1. 3 Invasion of tumour cells into the draining LN. In addition to lymphatic 
dissemination (white arrows) the diagram shows the overall anatomy of a LN and 
the routes of LN flow that supports fluid percolation through the intercellular spaces 
of the lymphoid parenchyma. B, B cell area of the LN; T, T cell area of the LN. 
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Section C: Extracellular Vesicles 
1.6 Types of EV 
 Communication between cells of multicellular organisms involves not only 
direct cell: cell interactions, but also communication via secreted products [103]. 
This mode of communication involves ions, nutrients, metabolites and polypeptides 
secreted into the extracellular spaces of multicellular organisms [104, 105]. 
However, the extracellular space also contains small released spherical structures 
known as vesicles that are limited by a membrane enclosing a variety of bioactive 
cargos, including micro Ribonucleic acids (miRNA) and oncogenes [106, 107]. The 
term extracellular vesicle (EV) is a term that describes membrane particles released 
from most eukaryote cells, as well as prokaryote microorganisms [108]. Depending 
on their intracellular site of origin, EV differ in terms of size, composition, density 
and other biochemical and structural properties [106, 109]. EV can be isolated via 
differential ultracentrifugation based on their relative size and density. Exosomes, 
one of the smallest type, are released from a large spectrum of living cells and can 
range from 40-100 nm in diameter (purified at sedimentation speeds of ≥100,000 
×g; ref. [40]). Wolfers et al. have shown that both murine and human tumour cell 
lines constitutively release exosomes [110]. In addition to their size, exosomes can 
also be characterised via their mechanism of release. Multi-vesicular bodies (MVB) 
are formed via the inward budding of the endosomal membrane[111]. In later 
stages, MVB are destined to fuse with either lysosomes within the cell (for 
destruction and recycling) or with the cell membrane whereby exosomes are 
released [35, 111]. After their discovery by electron microscopy in 1981 [112], 
numerous studies have shown that exosomes may function as intracellular 
messengers [107]. Following their release, exosomes can adhere to other cells such 
as DC or T cells due to surface adhesion proteins such as ICAM-1 and lymphocyte 
function-associated antigen-1 (LFA-1; ref. [113, 114]). It has been suggested that 
exosomes can carry antigens, and upon fusion and degradation by the recipient cell, 
the antigen may be loaded and presented on either MHC-I and/or MHC-II molecules 
[115]. Further studies, however, reveal that exosomes may either be immune 
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suppressive or stimulatory. Although it is not clear why the immunological effects 
of exosomes differ across the literature; possible reasons may be their exhaustive 
purification protocols [116] resulting in different preparations in different 
laboratories, or perhaps the identity and state of their parent cells. For example, 
immature DC treated with IL-4 and IL-10 may allow the release of exosomes with 
anti-inflammatory properties [117]. On the other hand, exosomes from 
unstimulated DC have been shown to stimulate CD8+ T cells in vitro [118]. However, 
as seen with gliomas, there is evidence that tumour-derived exosomes can transfer 
oncoproteins (pro-tumour proteins) thereby enhancing metastasis [119].  
Living cells may also secrete larger membrane-derived EV commonly known 
as microvesicles (MV). These were first described by Chargaff and West in 1946 and 
were later characterised as a predominant product of platelets (Figure 1.4; ref. [120, 
121]). MV can range in size (0.1 - 1 µm in diameter) and have been shown to be 
constitutively released by tumour cells potentially carrying oncogenes [122]. During 
apoptosis, the cell’s contents are packaged into apoptotic blebs (0.03 – 5 µm) for 
clearance with a minimal perturbation/inflammation to the surrounding tissues 
[106, 123]. The term ‘apoptotic bodies’ usually refers to the larger (1 – 5 µm) bleb 
fraction [111, 124]. Apoptosis-induced EV that measure smaller than apoptotic 
blebs have a variable size range due to the different sedimentation speeds used to 
purify them (10,000 – 110,000 ×g; ref. [106, 125-127]). It remains to be confirmed, 
however, if the studies that purify smaller apoptotic blebs at high speeds (≥ 100,000 
×g) were not contaminated with exosomes due to the identical sedimentation speed 
conditions. In addition, there is no consensus regarding the nomenclature for the 
smaller fraction of apoptotic blebs (0.03 - 1 µm). For example, the terms apoptotic 
microparticles, small apoptotic vesicles, and even apoptotic bodies have been used 
to define the smaller apoptotic blebs [106, 125, 128, 129]. For this reason, the term 
apoptotic vesicle(s) (ApoV) will be used in this thesis to describe this smaller 
fraction of membrane EV released from dying (apoptotic) cells. Unlike exosomes, 
ApoV are formed when the outward budding of the plasma membrane is facilitated 
by contractions of cytoskeletal structures which is orchestrated by membrane actin-











Figure 1.4 Relative size of major extracellular vesicles (EV) types. Most 
released apoptotic vesicles (ApoV) and microvesicles (MV) overlap in size with 
bacteria whereas exosomes can be as small as viruses. Apoptotic bodies are the 
largest types of released EV and are shed along with ApoV as part of apoptosis.   
(Adapted from György et al., 2011). 
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The exposure of phosphatidylserine (PS) on the outer leaflet of EV 
membranes is a common feature among EV [107, 130, 131]. PS is a membrane 
aminophospholipid that is actively kept within the intracellular level (inner leaflet) 
of a living cell by the predicted ATP-dependent membrane lipid transporters known 
as flippases [132, 133]. Segawa et al. have identified adenosine triphosphatase type 
11C and cell division cycles protein 50A to be the two major flippases responsible 
for the active keeping of PS within the inner leaflet of cell membranes [134]. 
Simultaneously, the other predicted lipid (ATP-binding cassette; ABC) transporter, 
ABCB4, transports choline- and amino-phospholipids towards the outer leaflet and 
is referred to as a floppase [135]. The rate of floppase activity is usually ten times 
slower compared to flippase [136]. However, during apoptosis or cell activation, 
flippase is believed to be inhibited and another lipid transporter, scramblase, is 
activated. Unlike the other two lipid transporters, scramblases are calcium 
dependent and do not need ATP hydrolysis (energy) for activation [132]. The main 
scramblase transporter that supports phospholipid scrambling during apoptosis is 
XK-related protein 8 [137]. The activity of scramblase transporters moves all major 
classes of phospholipids back and forth, thereby destroying the phospholipid 
asymmetry orchestrated by flippases and floppases [138]. The presence of PS at the 
extracellular leaflet by scramblase is a key marker of apoptosis and is believed to be 
a tag for phagocytosis [132]. The exposure of PS is also well known to promote the 
aggregation of coagulation factors in the blood and thus trigger coagulation, 
granting vesicles such as ApoV potential players in thrombotic disorders [132]. 
 
1.7 Cell Death, Apoptotic Blebbing, and Chemotherapy 
At present, five cellular processes lead to cellular death have been described: 
apoptosis, necrosis, mitotic catastrophe, autophagy, and senescence [139, 140]. 
Apoptosis is a highly controlled process and it is believed that proteins that would 
otherwise trigger an immune response are packaged within apoptotic blebs for 
clearance by the immune system [141, 142]. In contrast to apoptosis, necrosis is a 
process of cell death that typically results in inflammation due to the breakdown of 
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the cell membrane and consequent release of intracellular contents and 
proinflammatory molecules into the extracellular matrix [143, 144]. Several 
pathological conditions such as infection, ischaemia, or inflammation can cause 
necrosis and that is generally characterised by cellular swelling and organelle 
degradation [145, 146]. Apart from apoptosis, autophagy is the only other type of 
cell death that is also characterised by membrane blebbing [139, 144]. Autophagy is 
triggered when redundant or unwanted proteins are targeted for degradation by the 
cell’s proteolytic mechanisms [139]. One of the main mediators of autophagy is 
ubiquitin and degradation takes place in the proteasomes [147]. Excessive 
autophagic triggers occurring during cellular development, differentiation, and 
nutrient starvation may lead to cell death [139, 148]. During eukaryotic cell division 
(mitosis), somatic cells can lose or gain a single chromosome (an aneuploid state) 
that, if left unchecked, could lead to severe genomic instability [149, 150]. 
Deoxyribonucleic acid (DNA)-damaging agents (such as chemotherapeutic drugs 
and irradiation) can also interfere with the mitotic process. This may result in an 
irreversible damage and the aberrant dividing cell will be forced die in a manner 
known as mitotic catastrophe [140, 150]. Although the molecular mechanisms 
regulating mitotic catastrophe remain to be elucidated, it is characterised by nuclear 
fragmentation and multiple micronuclei [139, 151]. Prior to the discovery of mitotic 
catastrophe, Hayflick et al. showed that normal (fast dividing) cells eventually cease 
to divide in vitro [152]. In fact the cells would remain alive for several weeks but fail 
to divide despite the favourable conditions present to allow cell growth [152]. This 
mechanism, defined as senescence, is now known to be triggered by several signals 
such as DNA damage or shortened/dysfunctional telomeres [139, 153]. Senescence 
may trigger an inflammatory response and cellular characteristics involve 
cytoplasmic flattening and an increase in cellular granularity [139, 140, 154]. It 
remains unknown, however, whether the five cellular death mechanisms are strictly 
independent, or they all eventually overlap to some degree. Nevertheless, due to the 
significant importance of apoptosis in this thesis, the other four modes of cell death 
will not be discussed further. 
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Apoptosis can occur via two main pathways; the extrinsic (or receptor) 
pathway is characterised by the binding of a ligand to a death receptor of a cell [155]. 
Activation of these death receptors by their ligands may lead to the assembly of the 
Fas-associated death domain (FADD) and caspase-8 [156]. Apoptosis is 
orchestrated via the activation of (usually inactive) a cytoplasmic family of proteins 
known as caspases [157-159]. The activation of one may lead to the activation of 
another and thus initiate apoptosis in a cascade fashion. Hence, within the extrinsic 
pathway, recruited, activated caspase-8 cleaves caspase-3 which will cleave other 
caspases, eventually leading to apoptosis [159, 160]. The other pathway, known as 
the intrinsic pathway, also converges at caspase-3 However, the intrinsic (or 
mitochondrial) pathway is usually triggered via stress signals which may lead the 
mitochondrion to leak pro-apoptotic factors, such as cytochrome c, into the 
cytoplasm [157, 159, 160]. This leak results in the formation/activation of several 
protein complexes including caspase-9. Caspase-9 then cleaves caspase-3 which, 
from henceforth, leads to the outcome of the intrinsic pathway [160]. There is also 
evidence that apoptotic cells induce an immunosuppressive milieu by means of anti-
inflammatory cytokines such as TGF-β or IL-10 [161-163]. Interestingly, this 
immunosuppressive outcome has been observed alongside the release of apoptotic 
blebs [161, 164-166].  
As discussed earlier, membrane PS exposure is linked to ApoV formation. 
However, the mechanism by which the ApoV forms and buds off remains unclear. 
Current literature suggests that caspase-3 may be the initiator of this blebbing 
phenomenon by cleaving the rho-associated, coiled-coil-containing protein kinase-
1 (ROCK-1) protein, transforming it into a constitutive truncated form [167-169]. 
Activated ROCK-1 protein phosphorylates the myosin regulatory chain (MLC), 
which in turn initiates myosin-dependent contractility of the cell membrane [167, 
168]. Inhibition of ROCK-1 leads to a lack of blebbing upon apoptosis [167, 169].  
Most therapeutic anti-cancer treatments aim to eliminate cancer cells 
through the initiation of apoptosis [170, 171]. Anthracyclines such as doxorubicin 
are one of the most potent and widely administered cytotoxic drugs in oncology, 
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with the ability to interact with DNA by intercalation, thereby inhibiting 
macromolecular synthesis [172]. Although unclear, the mechanism of action of 
doxorubicin is related to DNA damage [173, 174]. Several studies point to the 
inhibition of a critical enzyme in DNA replication (topoisomerase II) as one main 
mode of action by doxorubicin [175, 176]. Other studies have also identified that 
doxorubicin can undergo reduction by the intracellular enzymes oxidoreductase 
forming a doxorubicin-semiquinone radical [177, 178]. Due to the cell’s metabolism, 
the doxorubicin-semiquinone radical is re-oxidised which subsequently forms 
reactive oxygen species and hydrogen peroxide; both induce oxidative stress (and 
then apoptosis) to the cell [179, 180].  
In addition to their potency, anthracyclines have a wide spectrum of activity 
among malignancies including lymphomas, breast, and lung cancers [172, 181]. 
Platinum containing drugs such as cisplatin also work by interacting with cellular 
DNA disrupting cell division and therefore triggering apoptosis [182, 183]. 
However, the dose of chemotherapeutic drugs can be directly proportional to their 
ability to induce adverse effects [184, 185]. For example, cumulative dosing of 
doxorubicin can lead to congestive heart failure [186, 187]. Alternatively, a 
combination of two or more chemotherapy drugs can be given to patients to 
optimise the drug dose without intolerable side effects [188-190]. However, cancer 
cells may be intrinsically resistant to chemotherapeutic agents, or may develop 
resistance due to mutation, or epigenetic changes, including the production of 
altered splice variants encoding cellular drug targets [191]. 
Although the mechanism of resistance is not always clear, recent studies with 
solid tumours have shown the association of chemoresistance with epithelial-to-
mesenchymal (EMT)-like transition of the cancer types [192-194]. The transition 
may be stimulated by prolonged exposure of the drug with cancer cells; as witnessed 
by Yang et al. by chronically exposing colon carcinoma with oxaliplatin [195]. This 
phenomenon was also observed by Shah et al. whereby resistant pancreatic tumour 
cells to the anti-cancer agent gemcitabine (a nucleoside analogue) expressed EMT 
markers [196]. Animal tumour models have shown that cancer cell resistance may 
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be reduced and survival enhanced if the right combination therapy and regiments 
are manipulated [197]. Severe adverse effects and resistance to chemotherapy 
drugs by cancer cells are the two main issues of cancer therapy that must be 
challenged and researched thoroughly. Moreover, chemotherapy may introduce 
additional complications within patients such as the formation of blood clots within 




















Section D: Coagulation of the blood 
1.8 Overview of Coagulation 
Blood coagulation (or haemostasis) is the defensive ability to prevent 
bleeding, with the terminal reaction being the conversion of fibrinogen to fibrin. The 
coagulation system in the blood is carefully controlled via the anticoagulant system; 
which, under normal physiological conditions, out-competes the procoagulant 
system [198]. Any abnormality within the natural balance of the procoagulative and 
anticoagulative systems may result in excessive bleeding or thrombotic disorders. 
 Blood coagulation is considered to be one of the most complex biological 
systems. Between the year 1940 and 1950, it was becoming more obvious that the 
formation of a fibrin clot stemmed from coagulation factors flowing in the blood 
[199, 200]. However, scientists failed to unlock how these factors interact with each 
other to ultimately form a clot. It was only in the 1960s that two biochemists 
proposed that the mechanism is orchestrated in a "waterfall" or cascade fashion 
whereby each activated factor activates another [201]. Many discoveries have been 
made since then, and it is now known that, in addition to coagulation factors, the key 
players in the coagulation cascade activation are thrombin (Factor IIa; FIIa); a 
critical enzyme capable of forming a clot by converting fibrinogen to fibrin, anionic 
phospholipids such as PS; providing a niche for coagulative factor aggregation, and 
platelets [202-204]. Platelets are anucleate cells released into the blood from the 
cytoplasm of megakaryocytes residing in the bone marrow [205]. They are 
abundant in the blood and involved in the initial stages to prevent bleeding by 
aggregating; otherwise known as platelet plug formation [198, 206].  
 Collagen is found in almost every site of the body other than the lumen of a 
blood vessel [198, 206]. The blood vessel contains inactivated platelets and a factor 
known as the von Willebrand factor (vWF; ref. [207]). Upon vascular injury, sub-
endothelial collagen becomes exposed to the blood that seeps into it and the vWF 
attaches to the collagen (Figure 1.5). The vWF provides a strong anchor for platelet 
adhesion to the collagen. This results in platelet activation characterised by 
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morphological changes of platelets from a disc-shaped structure to a rounded 
structure with blebs or pseudopodia. Endothelial cells (the main source of vWF 
expression) and activated platelets (by means of granules) release more vWF 
molecules and provide a positive feedback loop for vWF [205, 208]. This amplifies 
platelet aggregation and activation to initiate the formation of the platelet plug; a 
temporary seal to the vascular wound [205]. Activated platelets then bind to 
fibrinogen in the blood via the activated platelet receptor IIb/IIIa moderately 
strengthening the platelet plug [209]. It is estimated that one activated platelet can 
bind up to 45,000 fibrinogen molecules [210].  
Activated platelets release procoagulant molecules via granules that 
comprise of two types: the alpha and dense granules [211]. The alpha granules 
contain many growth factors but also coagulation factors such as vWF, fibrinogen, 
and FV (discussed later; ref. [212, 213]). The released dense granules contain 
important coagulation cascade activators such as calcium (previously named FIV; a 
critical component for the coagulation cascade activation), and anionic 
polyphosphates (polyP; activators of the intrinsic pathway; ref. [214, 215]). For the 
platelet plug to strengthen, fibrinogen needs to be converted to fibrin; the final 





Figure 1.5 Summary of the platelet plug formation. (1) Under healthy 
conditions, inactivated platelets and von Willebrand factors (vWF; bound to factor 
VIII) flow within the blood vessels. Endothelial cells are the major source for vWF.                              
(2) Following vascular injury, blood can seep in and contact the surrounding 
collagen and vWF from the blood attaches tightly to collagen and platelets. (3) 
Platelets change in shape, become activated, and degranulate releasing 
polyphosphates and more vWF resulting in platelet aggregation. (4) Activated 
platelets then bind to fibrinogen via the platelet receptor IIb/IIIa, forming a 
platelet plug. The fibrinogen of this relatively unstable plug is then converted to 































1.9 The Extrinsic Coagulation Pathway 
The surface of extravascular cells (such as sub-endothelial cells) is rich in an 
allosteric cofactor known as tissue factor (TF; also known as FIII; ref. [198]). Similar 
to almost all blood coagulation zymogens, a single-chain glycoprotein, FVII, 
circulates the blood [216]. Interestingly, a fraction of activated FVII protein (FVIIa) 
circulates in blood and is immediately available in an event of a vascular injury to 
bind TF and activate the extrinsic coagulation pathway (Figure 1.6; ref. [216, 217]). 
This interaction triggers the cleavage of the zymogens FIX and FX to their functional 
forms FIXa and FXa respectively [217]. A positive feedback loop may develop when 
the FVII bound to TF is cleaved to its active form by FVIIa, FIXa, and FXa [218, 219]. 
Simultaneously, FXa can activate FIX into its intermediate active form FIX-α which 
is then converted to FIXa by the TF-FVIIa complex [220]. The cell bearing the TF acts 
as a dock for the activated factors IXa and Xa; these factors may diffuse into the blood 
and bind to the surface of activated platelets that constitute the primary platelet 
plug [218, 220, 221]. 
The TF-FVIIa complex is susceptible to its inhibitor the tissue factor pathway 
inhibitor (TFPI; ref. [206, 222]). In addition, TFPI can inhibit FXa and, with higher 
affinity, the TF-FVIIa-FXa complex [206]. Nevertheless, some of the activated FX can 
escape the TFPI protein and cleave the prothrombin to its active form; thrombin 
[206, 222]. Thrombin converts fibrinogen to fibrin, which polymerise and seals off 
the wound site [223]. The amount of thrombin released is, however, relatively small 
and, to amplify it, some of the activated thrombin can simultaneously activate the 
plasma cofactors FV and FVIII to FVa and FVIIIa respectively [198, 218, 223]. FVa 
bound to platelets acts as a receptor for FXa molecules generated by the TF-FVIIa 
complex. This prothrombinase complex (FXa-FVa) requires calcium and results in a 
105-fold accelerated generation of thrombin compared to FXa alone [223, 224]. 
As mentioned above, thrombin can also result in FVIIIa generation, which can 
also bind to a negatively charged surface such as platelets [208]. Inactive FVIII 
usually circulates in the blood bound to the adhesive protein vWF [206, 208]. The 
attached FVIIIa may also allow the dissociation and activation of FVIII from vWF to 
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FVIIIa, thereby creating a positive amplification loop [208, 225]. Platelet-adhered 
FVIIIa enables the aggregation of FIXa (previously generated by the TF-FVIIa 
complex; ref. [99, 206]). The resulting FVIIIa-FIXa complex (commonly known as the 
tenase complex) can rapidly activate FX to FXa [206, 223]. This is 50-fold more 
efficient than the generation of FXa by the TF-FVIIa which is hampered by the TFPI 
protein [198, 226]. Thus, the tenase complex is considered the major generator of 
FXa [227].  
Interestingly, cells within the blood, such as monocytes, can express TF under 
pathological conditions such as filovirus infections [228]. Although TF is a potent 
initiator of coagulation, most cell associated TF is non-functional and is referred to 
as cryptic TF [229]. The conversion mechanism of cryptic TF to procoagulant 
(decrypted) TF is hotly debated to be elusive. Experiments involving exposed PS 
being blocked by annexin V showed reduced procoagulant activity of active TF [228, 
230], however, it remains debatable whether TF decryption solely depends on PS 
exposure. There is evidence that the structure of cryptic and decrypted TF differs 
from one another. It has been suggested that cryptic TF exists as a dimer form and, 
upon calcium influx into the cell’s cytoplasm, the structure is converted to decrypted 
(procoagulant) monomers [228]. Much research is directed at this matter, and there 
are now at least four different models proposed for TF decryption. Interestingly, an 
ex vivo blood model by Østerud et al. proposed that platelets may partake in 
supplying PS to TF-bearing cells (such as monocytes; ref. [231]). In their model they 
show that platelets fuse with monocytes and exchange available PS subsequently 
resulting in a significant upregulation of active monocytic surface TF [231]. Taken 
together with the PS-blocked model, the experiments suggest that PS exposure may 
be implicated in the TF decryption [232].  
TF has two disulphide bonded loops on its extracellular domain (Cys49-
Cys57 and Cys186-Cys209; ref. [228, 230]). Recent studies suggest that 
encryption/activation of TF is dominated by the disulphide status of Cys186-Cys209 
[233, 234]. The hypothesis states that TF is encrypted when Cys186 and Cys 209 are 
unpaired and that TF is decrypted (and active) when these Cysteine domains are 
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paired by disulphide bonding [234]. Moreover, the studies claim that the protein 
disulphide isomerase (PDI) is critical for the decryption of TF by switching on/off 
the disulphide bonds between Cysteine 186 and Cysteine 209 [234]. However, the 
experiments performed to support this hypothesis were strongly based on (i) the 
removal of the disulphide bonding by mutating the cysteines to serine or alanine 
(impairing TF activity), and (ii) treatment with HgCl2 to oxidise thiols to disulfides 
(increasing TF activity; ref. [234, 235]). However, other studies have clearly shown 
that HgCl2 increases the exposure of anionic phospholipids on cell surfaces [236, 
237]. In addition, altering the expression or exogenous supplementation of PDI has 
no effects of the activity of TF [237]. Thus, the importance of disulphide bonding in 
TF decryption remains to be directly associated. This shows that more work is 





Figure 1.6 The extrinsic coagulation pathway. (1) Under normal conditions, the 
blood has limited access to functional TF, however, (2) following vascular injury, 
blood can seep in and contact the sub-endothelial cells whereby TF switches to a 
procoagulative form. TF then binds with active factor VII (FVIIa) from the blood. 
This is followed by the binding and activation of FIX and FX; a small amount of FIXa 
and FXa may leak into blood circulation. (3) The FXa in blood can cleave 
prothrombin (FII) to thrombin (FIIa) which will in turn activate FVIII and FV to 
FVIIIa and FVa respectively. (4) FVIIIa and FVa will dock on an anionic 
phospholipid-rich surface (e.g. a platelet within the vicinity of the wound) to form 
the tenase complex (FVIIIa - FIX - FX) and the prothrombinase complex (FVa - FXa 
- FII). The tenase complex will cleave and supply FXa to the prothrombinase 
complex whereby, with calcium, thrombin is numerously generated. Thrombin 










































1.10 The Intrinsic Coagulation Pathway 
Coagulation can also be activated independently of TF. This intrinsic 
coagulation pathway is initiated by the Hageman factor (FXII; ref. [238, 239]). The 
intrinsic pathway is initiated by contact of the Hageman factor (FXII) to an anionic 
surface such as glass or collagen (Figure 1.7; ref. [206]). Similar to platelet 
activation, collagen may become exposed upon vascular injury and provide an 
anionic niche to activates FXII to FXIIa [240]. Moreover, the dense granules released 
by platelets contain inorganic polyP that also cleave FXII to FXIIa [215]. Activated 
FXII then cleaves FXI to FXIa (thromboplastin), which in turn activates FIX [238, 
239]. In addition, FXIIa can also cleave plasma prekallikrein to kallikrein, which in 
turn activates more FXII [238]. The cleavage of FXII to FXIIa by kallikrein can be 
amplified by the plasma cofactor known as High-molecular-weight-kininogen 
(HMWK; ref. [238, 241]). Once FIX is activated, the cascade follows the path of the 
tenase and prothrombinase complex formations (Figure 1.6). Thus, because the 
intrinsic and extrinsic coagulation converge at the prothrombinase complex stage, 
the complex is interchangeably known as the common coagulation pathway (Figure 
1.7; ref. [242]). However, the intrinsic coagulation pathway is not important in 
tissue injury-related coagulation and therefore deficiencies in this cascade do not 
result in severe bleeding disorders, except for FXI, which leads to moderate bleeding 
disorders [243, 244]. 
 As previously noted, the active factors generated following the activation of 
the coagulation cascade either form complexes on anionic surfaces or circulate 
freely in plasma. Certain activated factors such as FIIa, FIXa, and FXa, can actively be 
bound to the inhibitor antithrombin (AT; ref. [245]). This is important as AT acts to 
isolate the coagulation in situ preventing the systemic diffusion of the activated 
factors [198]. In addition, FVa and FVIIIa are regulated by protein C; a key regulator 
of the coagulation cascade that is paradoxically activated by thrombin [246]. The 
anticoagulant role of thrombin occurs during an intact vascular system, whereby 
thrombomodulin (an integral membrane protein of vascular endothelial cells) forms 
a complex with thrombin that would cleave protein C to activated protein C [198]. 
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Thus, the procoagulant and anticoagulant reactions compete to produce a 
threshold-limited reaction system allowing only a highly intense stimulus to achieve 




Figure 1.7 Summary of haemostasis. Upon vascular injury, platelets aggregate 
at the vascular opening to form the platelet plug. The plug (containing Factor I; 
FI; fibrinogen) requires the activation of the coagulation cascade to form fibrin 
(FIa). The sub-endothelial cells contain inactivated (cryptic) tissue factor (TF) by 
which the presence of blood decrypts TF and the extrinsic coagulation pathway 
is initiated. Alternatively, exposed collagen and polyphosphates (polyP) released 
from platelets provide an anionic trigger for the intrinsic coagulation pathway to 
be triggered. Both coagulation pathways lead to the common pathway whereby 
the final product is fibrin.  
Key:
TF: Tissue Factor
F#: Inactivated Coagulation Factors

















































Section E: The links Between Cancer and Tumour EV 
1.11 Tumour EV and CD169 
CD169 is highly conserved in humans and mice and is expressed on tissue-
resident macrophages which allows them to recognise sialic acid ligands [247]. 
CD169+ macrophages specifically mediate the capture of B cell-derived exosomes in 
vitro as well as in vivo (section A:1.3; ref. [35]). In addition, when CD169-/- mice were 
used, they showed an enhanced immune response to antigen-pulsed B cell-derived 
exosomes [35]. Concurrently, Myake et al. showed that CD169+ macrophages 
induced immune suppression in response to apoptotic cells [248]. Although these 
data hint that CD169 plays a role in regulating the immune system and promoting 
tolerance, numerous findings suggest a controversial inflammatory function [36, 
249-251]. In an experimental model for allergic encephalitis, CD169-/- mice showed 
a decreased disease severity with decreased numbers of inflammatory Th1 cells as 
well as an elevated T-reg number [252]. In cancer, much of the literature report in 
favour of CD169 being important in an anti-tumour immune response [249, 253-
255]. However, these studies use a macrophage-depleted model for CD169+ 
macrophages, rather than the specific absence of the CD169 molecule from 
otherwise intact macrophage populations. 
Intriguingly, the diagnostic profile of the draining LN from melanoma 
patients almost always show the accumulation of tumour cells within the 
subcapsular sinus of LN [256]. It remains enigmatic, however, whether this 
phenomenon is due to either: (i) the subcapsular sinus region being anatomically 
the first zone to be exposed to tumour cells invading the draining LN (i.e. “gate 
keeper”), or (ii) the CD169+ macrophages capture of the invading tumour cells via 
surface sialic acids on the tumour cells. In support of the latter theory, primary and 
metastasising tumour cells usually have an elevated expression of surface sialic 
acids [257, 258]. When van den Berg et al. tested the binding affinity of 
macrophages, B cells, T cells, DC, and TK-1 (a myeloid leukaemia cell line) against 
CD169+ macrophages in vitro, the tumour cell line (TK-1) displayed the strongest 
binding [259], affirming the elevated sialylation on tumour cells. 
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Since the McLellan laboratory have reported that B cell-derived exosomes 
express high levels of α2,3 and α2,6-linked sialic acids, we hypothesise that primary 
tumour cells may release exosomes, MV, and following chemotherapy, ApoV.  These 
EV could be captured by CD169+ macrophages of the draining LN. Following their 
capture, we predict that this will provide an immunosuppressive environment able 
to facilitate the invasion of tumour cells from the primary site to the LN and, 










Figure 1.8 Metastatic spread via tumour EV - a hypothesis.  Tumour cells can 
drain from the primary site via lymphatic routes to the first LN they encounter (i.e. 
the sentinel LN). The subcapsular sinus of LN is rich in macrophages expressing the 
surface molecule CD169. Tumour cells and their released EV (e.g. exosomes, MV, and 
ApoV) are enriched in surface sialylated ligands. CD169+ macrophages can bind to 
these EV in a sialic acid-dependent manner. Our laboratory has previously identified 
that, upon exosome immunisation, mice elicit an enhanced cytotoxic response when 
the CD169 molecule is absent. This leads to the hypothesis that CD169 may facilitate 



























1.12 Thrombosis in Cancer and the Link to Tumour EV  
Thrombosis is a pathophysiological condition characterised by localised 
clotting of the blood within a blood vessel leading to a blockage of blood flow [260, 
261]. The stem of arterial thrombosis involves the accumulation of lipid deposits 
and lipid-laden macrophages (known as foam cells) within the artery wall [260, 
262]. The accumulation eventually leads to the formation of an atherosclerotic 
plaque; cholesterol and TF rich necrotic cells [260, 262]. If left to accumulate, the 
plaque causes the artery wall to rupture and the content is released into the lumen 
of the artery [260]. The coagulation cascade initiates and a platelet-mediated fibrin 
clot begins to form (thrombus) due to collagen and vWF becoming enriched in situ 
[260-262]. The thrombus will eventually grow due to the rapid aggregation of 
platelets ultimately leading to a blockage of the artery [260].  
In contrast, in venous thrombosis (VT), the wall of the endothelium remains 
intact but may transform from an anticoagulant to a procoagulant surface [260, 
261]. The third leading cause of cardiovascular-associated death is VT which can be 
broadly categorised as either deep vein thrombosis (DVT) or pulmonary embolism 
(PE; ref. [261, 263]). The blockage of large veins (usually of the legs) are usually 
referred to as DVT whereas PE is a complication of DVT; part of the thrombus breaks 
away, travels, and settles within the lungs [260, 264]. Pulmonary embolism leads to 
the blockage of a pulmonary artery thus disruption of blood flow [260]. The source 
of VT is complex and may involve multiple factors including genetic predispositions 
and environmental factors such as alcoholism, immobility, oral contraceptives, and 
obesity [265-268]. In obesity, for example, the biochemical analyses show that the 
obese have increased systemic inflammation as well as coagulation [263]. In 
addition, the body size of the obese may also increase the risk due to impaired 
venous blood return, trapping red blood cells within fibrin networks; also known as 
“red clots” [263]. On the other hand, inherited VT may be the result of expressing 
procoagulant or anticoagulant factors at a high or reduced level respectively [269]. 
Absent or dysfunctional anticoagulants such as antithrombin and protein C 
(inhibitors of thrombin and FV respectively) are known to predispose patients to VT 
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[269, 270]. Alternatively, the Factor V Leiden mutation in the FV gene can cause the 
amino acid arginine to be replaced with glutamine resulting in the expression of a 
FV that is unable to be switched off by activated protein C [271]. However, one of 
the most potent factors increasing the risk of VT is chemotherapy (discussed below; 
ref. [272-276]). 
It is estimated statistically that cancer patients have a four-fold increased risk 
of developing VT [275, 277]. Strikingly, this risk is increased to more than six-fold 
when the patients are receiving chemotherapy [277, 278]. The risk of VT depends 
on the cancer type and stage as well as the type of anti-cancer drug administered, 
which may alter the haemostatic state in patients [272]. The pathogenicity of 
chemotherapy-associated thrombosis remains poorly understood. However, 
several potential mechanisms have been proposed by which chemotherapy may 
provoke a procoagulant state [272, 274, 275, 279]. For example, the anti-cancer 
drug fluorouracil (5FU) has been implicated in increased VT risk (especially in 
patients with disease stage IV) by directly damaging the endothelial wall of arteries, 
thereby exposing TF as well as lowering the levels of protein C and antithrombin in 
patients [274, 280]. Moreover, cisplatin can increase TF activity (without increasing 
expression), endothelial damage in patients, and enhance platelet activation in vitro 
[274, 281]. Doxorubicin has also been identified to be implicated in increasing the 
chance of VT in mouse models and cancer patients [282-285]. Patients receiving 
combination chemotherapy have also had an increased rate of thrombotic events 
[274, 276, 286] For example, a combination therapy of 5FU, cyclophosphamide 
(DNA alkylating agent), and methotrexate (anti-folic acid) have been observed to 
exhibit a decreased level of fibrin hydrolysis [274]. The combination therapy 
enhanced the expression of plasminogen activator inhibitor-1 (PAI-1); a protein 
involved in the inhibition of fibrinolysis [274]. Although this can result in an 
imbalanced haemostatic state, it was documented that chemotherapy-stimulated 
PAI-1 was not sufficient to cause thrombosis [147].  
It is now evident that the leading cause of death in cancer patients receiving 
chemotherapy is VT [272, 274]. Evidently, cancer patients undergoing 
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chemotherapy often require an anticoagulation co-therapy. This can decrease the 
risk of VT but also increase the risk of haemorrhage in cancer patients receiving 
anticoagulation co-therapy [272]. One common anticoagulant used with 
chemotherapy is warfarin [287] that decreases blood coagulation by inhibiting the 
enzyme vitamin K epoxide reductase [288]. Several coagulation factors such as FVII 
and prothrombin require carboxylation by (reduced) vitamin K1 to be activated 
[288]. Oxidised vitamin K1 is then recycled by the enzyme vitamin K epoxide 
reductase to its reduced form; warfarin targets the recycling stage and thus 
coagulation is reduced [288]. Very low doses of warfarin have been found to reduce 
the risk of VT by 85% in stage IV cancer patients receiving chemotherapy [289]. 
Alternatively, low-molecular-weight heparin (LMWH) can bind to AT and increase 
its activity by 1000-fold thereby inhibiting FXa and thrombin [287, 290]. A study 
and review by Hull et al. revealed that LMWH was more effective than vitamin K 
antagonist therapies for preventing VT in cancer patients; LMWH reduced the 
recurrence rate of VT in cancer patients [290]. Although they enhance survival rates, 
anticoagulants almost always cause bleeding complications and patients require 
extensive monitoring [289, 290]. 
The association of tumour-derived EV and thrombotic risk is becoming more 
appreciated [291-295]. It is well established that cancer patients have a significantly 
higher number of circulating EV compared to healthy controls [294-296]. In 1981, 
the shedding of procoagulant EV from human cancer cells was first reported [297]. 
Following a decade, it has been identified the main procoagulant components of MP 
are TF and PS exposure [291]. Therefore, it is to no surprise that in vitro assays 
indicate that these EV elicit a strong clotting potential [298]. In clinical research, 
pancreatic cancer patients undergoing chemotherapy are known to possess a 
significantly elevated level of TF-bearing EV thus increasing the risk of VT [291]. 
This phenomenon was observed by Zwicker et al.  when they concluded that TF-
bearing EV were associated with VT in cancer patients [295]. In contrast, a study by 
Tesselaar et al., showed that the majority of cancer patients who had developed VT 
did not display elevated TF-bearing MP [294]. Additionally, Campello et al. observed 
a non-significant increase of TF-bearing MP in patients undergoing chemotherapy 
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[299]. The controversial findings by which TF-bearing EV are involved in an 
increased risk of developing VT in cancer patients is an indicative of the need of 
further research on the topic. A review by Date et al. suggested that such findings 
may potentially be inaccurate due to timing of sample acquisition and/or 
inappropriate methodologies [291]. In addition, one should also consider the 
association of EV with VT in terms of cancer type and stage, type of chemotherapy 
undertaken, and most importantly the specific type of released EV. The latter 
includes proper identification of EV subtypes: ApoV, MV, apoptotic bodies, or 
exosomes. Figure 1.9 describes the mechanisms by which tumour-derived EV such 



















Figure 1.9 Procoagulant effects of tumour-released ApoV - a hypothesis.  
Tumour cells spontaneously shed EV such as exosomes and MV. Chemotherapy-
exposed tumour cells may initiate apoptosis and trigger the release ApoV. EV 
express tissue factor (TF) and harbour an anionic-rich surface due to 
phosphatidylserine (PS) exposure. This procoagulant complex may enable ApoV in 
the blood to activate the extrinsic coagulation cascade, thereby increasing the risk 




















Aims of thesis  
This research set out to characterise and explore the effects of one of the least 
appreciated populations of tumour-released extracellular vesicles: the ApoV. A wide 
range of tumour cells (human and murine) as well as different chemotherapeutic 
drugs have been selected to induce ApoV release. The first set of results (chapter 
three) characterises and compares B16 melanoma-derived ApoV with MV and 
exosomes using cryo-electron microscopy (cryo-EM), flow cytometry, western blots, 
and full comparative proteomics. The chapter then explores the effects of tumour-
derived ApoV, MV, and exosomes on cancer through two perspectives: (1) their 
prophylactic anti-tumour effects, and, (2) their procoagulant effects. In vitro fibrin 
and thrombin generation assays were employed. Chapter four then investigates the 
procoagulant mechanisms induced by tumour ApoV generated from a wide 
selection of human and murine tumour cell lines. Factor-deficient plasma as well as 
neutralising antibodies and other ligands were used to pinpoint the contributing 
factors for coagulation in ApoV.  Finally, the fifth chapter examines the effects of the 


























Chapter II:  
Materials and Methods 
43 
 
2.1 Tumour cell lines 
Table 2.1 List of tumour cell lines used. 
Cell line Disease Tissue Organism Notes 
B16F0-OVA Melanoma Skin 
Murine 
(C57BL/6) 
B16F0 cell line 
transfected with full 
length ovalbumin (OVA) 
gene, a gift from Edith 
Lord, University of 
Rochester, NY, USA. 








B16F10-LacZ Melanoma Skin 
Murine 
(C57BL/6) 
B16F10 cell line 
transfected with β-
galactosidase (LacZ) 
gene, a gift from Ann 
Chambers, University of 
Western Ontario 




DU-145 Carcinoma Prostate Human ATCC 




EL4-huTF Lymphoma  T cells 
Murine 
(C57BL/6) 
EL4 transfected with a 
pcDNA3.1+ vector 
containing HindIII-ApaI 
insert of the full length 
human TF gene 
(encoding amino acids 
1-295; NM_001993.4) 
EL4-muTF Lymphoma  T cells 
Murine 
(C57BL/6) 
EL4 transfected with a 
pcDNA3.1+ vector 
containing an HindIII-
BamHI insert of full 
length murine TF gene 
(encoding amino acids 
1-294; NM_0101) 
Jurkat E6.1 Leukaemia T cells Human ATCC 




MCF-7 Adenocarcinoma Breast Human ATCC 
NCI-H460 Carcinoma Lung Human ATCC 




All mice were bred at the Hercus Taieri Resource Unite (HTRU), University 
of Otago, under specific pathogen-free conditions. C57BL/6 mice were originally 
acquired from Jackson Laboratories (JAX, USA). B6.SJL-Ptprca Pep3/BoyJArc (Ptp; 
CD45.1+) mouse strain was obtained from the Animal Resources Centre, Canning 
Vale, WA, Australia. CD169-deficient (CD169-/-) mice on a C57BL/6 background 
were obtained from Prof. Paul Crocker (University of Dundee, Scotland).  All animal 
studies were approved by the University of Otago Animals Ethics Committee (AEC, 
Dunedin, New Zealand). 
 
2.3 Media and solutions 
2.3.1  Dulbecco’s Phosphate Buffered Saline (PBS) 
For 1 L: 1 PBS sachet (Gibco #21600-010) 
  Total volume of 1 L was made up using milli-Q water 
  pH 7.3 
  Filter sterilised (0.22 µm pore filters; Cole-Parmer® #EW-02915-52) 
2.3.2   RPMI-1640 Medium 
For 1 L: 1× RPMI-1640 medium sachet (Gibco #31800-022) 
  2 g sodium bicarbonate 
  10 mL Penicillin / Streptomycin (100 U/mL / 100 µg/mL; Gibco  
#15140) 
  55 µM β-mercaptoethanol (Gibco #21985) 
  Total volume of 1 L made up using milli-Q water 
  pH 7.3 





2.3.3  RPMI-1640 + Foetal Calf Serum (FCS) 
R5:  95% RPMI-1640 medium 
  5% FCS (PAA #A15-101) 
R10:  90% RPMI-1640 medium 
  10% FCS (PAA #A15-101) 
2.3.4   Bovine Serum Albumin (10% BSA; in PBS) 
For 100 mL: 10 g BSA (Gibco #30063-572) 
  Total volume made up to 100 mL with PBS 
  Filter sterilised (0.22 µm pore filters) 
2.3.5  Serum-Free Medium (SFM) 
For 1 L: 488.8919 mL DMEM/F12 (Gibco #11320) 
  488.8919 mL RPMI-1460 medium (antibiotic-free) 
 10 mL Penicillin / Streptomycin (100 U/mL / 100 µg/mL) 
  10 mL 10% BSA/PBS (Final conc. 100 mg/mL) 
  1 mL 5mg/mL bovine insulin (Final conc. 5 µg/mL; Sigma #I-5500) 
  1 mL 5mg/mL bovine holo-Transferrin (Final conc. 5 µg/mL; Sigma 
#T1283-50MG) 
  100 µL 0.1mM sodium selenite (Final conc. 10 nM; Sigma #S5261) 
  100 µL 0.5 mM hydrocortisone (Final conc. 50 nM; Sigma #H0888) 
  16.2 µL 0.308 µM Triiodothyronine (Final conc. 5 pM; Sigma 
#IRMM469-1EA) 
2.3.6  10× Tris Buffered Saline (TBS) 
For 1 L: 90 g sodium chloride  
  60.5 g Tris (Gibco #28358) 
  Total volume of 1 L was made up using milli-Q water 
  milli-Q water used to make 1× working solution (pH 7.6)  





2.3.7  Resazurin solution 
  0.12 g/L resazurin (Sigma #R7017-1G) 
  0.01 g/L methylene blue 
  0.4 mM potassium ferricyanide 
  0.4 mM potassium ferrocyanide 
  0.1 M phosphate buffer 
  pH 7.4   
 
2.3.8   Coomassie Blue G-250 
  0.25% Brilliant Blue G-250 
  40% methanol 
  10% glacial acetic acid  
  49.75% milli-Q water 
2.3.9   Coomassie Destain 
For 1L: 100 mL glacial acetic acid  
  250 mL methanol  
  Total volume made to 1 L using milli-Q water 
2.3.10  Cell lysis buffer 
  0.02% sodium azide 
  150 mM sodium chloride 
  0.25% CHAPS detergent 
  0.5% Triton-X100 (Sigma #T8787) 
  100 mM Tris 
  pH 8.0 







2.3.11  Immunohistochemistry reagents 
  1% paraformaldehyde (PFA) / PBS 
  Meyer’s Haematoxylin (Sigma #MHS1) 
  1× TBS 
  25% ethanol / 75% acetone 
  Eosin (Thermo Fisher #6766007) 
  Glycerol / gelatine at 60◦C for mounting 
2.3.12  X-gal solution 
Buffer: 5 mM potassium ferricyanide 
  5 mM potassium ferrocyanide 
  2 mM magnesium chloride 
  100 mL PBS 
Stock:  20 mg X-gal (Sigma # 11680293001) 
  0.5 mL N, N dimethylformamide (DMF) 
Working:  Pre-warmed X-gal stock solution (37◦C) 
  Diluted 1:20 in X-gal buffer solution (Final conc. 1 mg/mL)  
2.3.12  Western blot reagents 
  NuPAGE LDS sample buffer (Invitrogen #NP0007) 
  NuPAGE reducing agent (Invitrogen #NP0009) 
  NuPAGE 12 % Bis-Tris gel (Invitrogen #NP0342BOX) 
  NuPAGE MOPS-SDS running buffer (Invitrogen #NP0001) 
  Antioxidant (Invitrogen #NP0005) 
  Nitrocellulose membrane (GE Healthcare #GE10600018) 
  NuPAGE transfer buffer (Invitrogen #NP0006) 







2.3.13  Chemotherapy and cytotoxic drugs (all aqueous) 
  Doxorubicin (Baxter Healthcare Ltd, NZ) 
  Fluorouracil (5FU; Baxter Healthcare Ltd, NZ) 
  Gemcitabine (Baxter Healthcare Ltd, NZ) 
  Cisplatin (Baxter Healthcare Ltd, NZ) 
  Staurosporine (LC Laboratories #S-9300) 
2.3.14  Annexin V binding buffer 
For 10×: 0.1 M HEPES (pH 7.4) 
  1.4 M sodium chloride 
  25 mM calcium chloride  
  milli-Q water used make 1× working solution 
2.3.15  Permeabolisation buffer 
  0.2% Tween20 
  1% BSA 
  0.02% azide 
  5% rat serum (sourced from HTRU. University of Otago, Dunedin) 
  Total volume made up with PBS 
 
2.4. Coagulation-specific reagents 
2.4.1  Thrombin 
  Human thrombin (Sigma #T-6884)  
2.4.2  Commercial human citrated platelet-poor plasmas (PPP) 
  Standard PPP (Siemens #ORKL17) 
  Coagulation FII-deficient PPP (Siemens #OSGR13) 
Coagulation FV-deficient PPP (Siemens #ORSM17) 
Coagulation FVII-deficient PPP (Siemens #OTXV13) 
Coagulation FVIII-deficient PPP (Siemens #OTXW17) 




2.4.3   FV function assay-specific reagents 
50 µM thrombin substrate Boc-L-FPR-ANSNH-C2H5 (SN-20; Hemtech 
#SN-20) 
  1 mg/mL BSA/PBS 
50 mM HEPES (Sigma #1001473148) 
100 mM NaCl 
  10 pM FXa (Hemtech #HCXA-0060) 
  500 nM prothrombin (Hemtech #HCP-0010) 
  5 mM calcium chloride 
2.4.4  Thrombin generation assay reagents 
750 nM specific activity thrombin calibrator (Thrombinoscope 
#TS20.00) 
20 µL Fluo-Substrate containing calcium (FluCa; Thrombinoscope 
#TS50.00) 















Table 2.2 List of antibodies and proteins used in experiments 




Conjugation Clone Isotype Source 
Anti-mouse CD9 Biotin KMC8 Rat IgG2a BD Pharmingen (#558749) 
Anti-mouse CD81 Biotin Eat2 Hamster IgG, κ BD Pharmingen (#559518) 
Anti-mouse CD49f APC GoH3 Rat IgG2a BioLegend (#313615) 
Anti-mouse CD49d Biotin 9C10 Rat IgG2a, κ BioLegend (#313615) 
Anti-mouse CD51 Biotin RMV-7 Rat IgG1, κ BioLegend (#104104) 
Anti-mouse CD29 Biotin Ha2/5 Hamster IgM, κ BD Pharmingen (#555004) 
Anti-mouse TF - - Goat IgG R&D Systems (#AF3178) 
Anti-mouse TF Biotin - Goat IgG R&D Systems (#BAF3178) 
Anti-mouse TF - 1H1 Rat IgG2a, κ Genentech 
Anti-mouse TF - - Rabbit IgG Seksui (#4515) 
Anti-mouse β-actin - AC-15 Mouse IgG1 Sigma (#A1978) 
Anti-mouse Clathrin 
heavy chain 
- 23 Mouse IgG1 BD Pharmingen (#610500) 
Anti-mouse CD147 - G-19 Goat IgG Santa Cruz (#sc-9757) 
Anti-OVA - - Rabbit IgG Polysciences (#23744) 
Anti-goat HRP - Rabbit IgG Sigma (#5420) 
Anti-mouse HRP - Goat IgG Sigma (#A3682) 
Anti-goat Alexa Fluor® 594 - Rabbit IgG ThermoFisher (#A-11080) 
Anti-rabbit DyLight 800 - Donkey IgG 
ThermoFisher (#SA5-
10044) 
Anti-mouse DyLight 680  Donkey IgG 
Thermofisher (#SA5-
10170) 
MAL-II / anti-sialic 
acids (α2,3 linkage) 
Biotin - - Vector Labs (#B-1265) 
SNA-I / anti-sialic 
acids (α2,6 linkage) 
Biotin - - Vector Labs (#B-1305) 




- - BioLegend (#405207) 
Annexin V - - - eBioscience (#BMS306) 
Annexin V Biotin - - BD Pharmingen (#556418) 




2.6 Cell culture 
All human and murine tumour cell lines (stored in liquid nitrogen) were 
thawed by immediate resuspension in R5 at 37◦C using a plastic pasteur pipette. The 
cells were then pelleted at 453 ×g for five minutes and supernatant discarded. The 
cells were then cultured and maintained daily at 37◦C with 5% CO2 in R5 and 
maintained at approximately 1-2 × 105 cells/mL (equivalent to ~70% confluence for 
adherent cell lines). For exosome preparations, 50% FCS in RPMI-1640 was spun at 
100,000 ×g overnight at 4◦C to deplete any FCS-derived EV. For B16F0-OVA, the 
transfected cells were selected via the supplementation of 50 µg/mL Geneticin. 
 
2.7 EV release and purification 
Tumour cells were grown in cell culture medium (as described above) in 175 
cm2 flasks until 70-80% confluence (approximately 1-5 × 105 cells/mL). The 
medium was removed and replaced with fresh R5 (30 mL for adherent cell lines and 
50 mL for non-adherent cell lines). The cells were then incubated for 48 hours either 
with (for ApoV release) 30 µM doxorubicin, 150 µM 5FU, or 30 µM gemcitabine or 
without (for MV and exosome release) at approximately 1 × 105 cells/mL at 37◦C 
with 5% CO2. The concentration of the drugs were determined when at least 50% of 
cell death was observed using cell viability assay (see below section 2.12) and when 
a high yield of ApoV was obtained. To obtain vesicle-rich fractions, the cells and 
debris were first depleted from the supernatant by differential centrifugation at 453 
×g for five minutes followed by 3,200 ×g for 20 minutes at 4◦C in a 225 mL conical 
tube (Falcon, In vitro Technologies, Auckland, NZ). ApoV (from drug-treated 
cultures) and MV (from untreated cultures) enriched fractions were then pelleted 
by centrifugation at 25,000 ×g for one hour at 4◦C (J-26XP High-Speed Centrifuge, 
Beckman Coulter Inc.). For exosome purification, the supernatant was first depleted 
of MV (at 25,000 ×g) for one hour then filtered using a 0.22 µm pore filter (Cole-
Parmer® #EW-02915-52). Exosomes were then pelleted at 120,000 ×g for one hour 
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at 4◦C (Optima L-90K Ultracentrifuge, Beckman Coulter Inc.). All EV were washed 
twice in PBS and final pellet resuspended in PBS. 
2.8 Continuous and discontinuous sucrose purification 
of EV 
Purified EV (from section 2.7) were either purified by a discontinuous 
sucrose cushion or a linear sucrose gradient. For the sucrose cushion, EV were first 
resuspended in 10 mL of PBS and then overlaid onto 4 mL of sucrose cushion (30% 
sucrose/200 mM Tris/deuterium oxide; D2O) contained in a Polyallomer tube 
(Beckman #337986). The tube was then spun at 100,000 ×g for 75 minutes at 4◦C 
and vesicles at the interphase aspirated (approximately 2 mL). Alternatively, 
purified ApoV were subjected to continuous sucrose gradient separation. The 
purified ApoV pellet was resuspended in 1 mL of 2.5 M sucrose / 20 mM HEPES, pH 
7.2, transferred to a Polyallomer tube (Beckman #337986) and then a linear sucrose 
gradient (0.25-2 M sucrose / 20 mM HEPES, pH 7.2) was overlaid onto the ApoV 
suspension using a gradient maker (HoeferTM SG Series Gradient Makers, #SG500). 
The tube was then centrifuged at 100,000 ×g for 18 hours at 4◦C. Fractions (1 mL) 
were collected and their densities determined using an Abbe refractometer (Tokyo, 
Japan). 
 
2.9 Cryo-EM visualisation and sizing of EV 
Purified EV (4 µL) were loaded onto plasma glowed-discharged Quantifoil® 
holey carbon 2/2 grid and blotted to remove excess liquid. The grid was frozen by 
plunging onto -180◦C liquid ethane using a plunge freezing device (Leica KF80; C. 
Reichert, Austria). The grids were stored in liquid nitrogen before being mounted 
into a pre-chilled Gatan 914 cryo holder and visualised using Jeol JEM220FS EM 
equipped with a field emission gun at an operating voltage of 200 kV to image the 
samples. Zero-loss images were acquired using an omega filter width of 20-25 eV 
through a TVIPS F416 camera. The EM was operated by Richard Easingwood at the 
Otago Centre for Electron microscopy. The diameters of EV collected from multiple 
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images were measured using the software IMOD (University of Colorado). 
Alternatively, the EV size was measured by subjecting purified EV to dynamic-light 
scattering (DLS; Zetasizer Nano-ZS; Malvern Instruments, UK).  
 
2.10 EV and cells preparation for flow cytometry 
For EV analyses, 10 µg of purified EV were supplemented with PBS (total of 
100 µL) before adding 25 µL of aldehyde-sulfate beads (4 µm diameter; 1.4 × 109 
beads/mL; Invitrogen #A37304) and incubated rotating overnight at 4◦C for bead-
EV conjugation. Henceforth, the steps were performed on ice. The conjugated beads 
were blocked with 0.05% BSA/PBS for 15 minutes, pelleted at 7,000 ×g at 4◦C, and 
quenched with 0.5 mL of glycine/PBS for 30 minutes. The beads were then pelleted 
at 7,000 ×g at 4◦C, washed in 1 mL of 0.05% BSA/PBS, and finally pelleted beads 
resuspended in 100 µL of 0.05% BSA/PBS. Vesicle-conjugated beads (3 µL/reaction) 
(or cells; approximately 5 × 104) were then analysed for α2,3- or α2,6- linked sialic 
acid expression with biotinylated (bio) lectins MAL-II (5 µg/mL) or SNA-I (0.5 
µg/mL) respectively, or labelled with 5 µg/mL bio-rat anti-mouse CD9, bio-hamster 
anti-mouse CD81, APC-conjugated-rat anti-mouse-CD49f, bio-rat anti-mouse 
CD49d, bio-rat anti-mouse CD51, bio-hamster anti-mouse CD29, or goat anti-mouse 
TF diluted in 0.05% BSA/PBS for 15 minutes on ice. For PS detection, 5 µg/mL bio-
annexin V binding buffer on ice was used instead of 0.05% BSA/PBS. Biotin was 
detected using 1 µg/mL SA-APC on ice, primary anti-TF was detected using rabbit 
anti-goat IgG-Alexa Fluor® 594. Table 2 contains details of the antibodies and 
proteins used. A murine TF-Fc (human IgG1) fusion protein was produced by fusing 
the human Ig kappa signal sequence to DNA encoding amino acids 29-251 from the 
murine TF extracellular domain (Campbell Sheen, Callaghan Innovations, NZ). This 
insert was cloned in frame into the BamHI / NheI sites of pCMV-SPORT-Fc. TF-Fc 
was produced by transient transfection in HEK293 and purified by Protein A affinity 
chromatography. Where stated, 10 µg/mL soluble murine TF-Fc was pre-incubated 
with the primary anti-mouse TF antibody for 30 minutes on ice, prior to cell 
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labelling. Goat IgG control was used as a control for TF detection while BSA-beads 
were used as a control for the remaining EV labelling molecules.  
 
2.11 Western blot analyses 
Purified B16F1-derived EV fractions or cells were first lysed in lysis buffer 
(section 2.3) for 30 minutes on ice. The lysates were then spun at 6000 ×g to deplete 
and pellet unwanted nuclear and membrane materials. The supernatant (containing 
the lysate) was stored at -80◦C or processed for western blotting. For the latter, 
lysate samples (10 µg in 10 µL PBS) were added to 9 µL of NuPAGE LDS sample 
buffer and 1 µL of NuPAGE sample reducing agent. The samples were then boiled for 
five minutes and immediately plunged onto ice. A 12% Bis-Tris gel was inserted into 
an electrophoresis tank (XCell SureLockTM Mini-Cell Electrophoresis System, 
Thermo Fisher) and tank was filled with NuPAGE MOPS-SDS running buffer with the 
inclusion of 0.5 mL of antioxidant (to maintain the reduced state of proteins). The 
wells were thoroughly washed using Gel-WellTM pipette tips before the addition of 
the prepared lysate samples (20 µL); a well containing a molecular weight marker 
(4 µL; SeeBlue® Pre-stained Standard, Thermo Fisher #LC5700) was dedicated to 
provide size estimation of the detected protein bands. The gel was run for two hours 
at 150 V and 126 mA on ice. The gel (containing electrophoresed samples) was then 
placed onto Amersham Protran nitrocellulose membrane (GE Healthcare 
#GE10600018), placed on the XCellTM Blot Module. The blot module was placed in 
the XCell SureLockTM tank and filled with NuPAGE transfer buffer for one hour at 30 
V and 170 mA on ice. Membranes were stored in PBS overnight at 4◦C to increase 
the binding of the proteins to the membrane. Membranes were then blocked with 
1% BSA/PBS for one hour on a rocker then incubated with either 0.5 µg/mL mouse 
anti-mouse β-actin, 1 µg/mL mouse anti-mouse clathrin heavy chain, 1 µg/mL goat 
anti-mouse CD147, 5 µg/mL bio-goat anti-mouse TF, 1 µg/mL bio-MAL-II, or 1 
µg/mL bio-SNA-I in 1% BSA/PBS for two hours on a rocker before being washed 
thrice with 0.02% Tween20/PBS on a shaker for five minutes each washing step. 
Primary antibodies were then detected with goat anti-mouse IgG-HRP for clathrin 
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and β-actin, rabbit anti-goat IgG-HRP for CD147, and SA-HRP for TF, MAL-II, and 
SNA-I. All secondary antibodies/proteins were diluted 1/1000 in 1% BSA/PBS and 
applied for one hour on a rocker. Membranes were washed as described above and 
rinsed with milli-Q water and HRP signal was developed with DAB and hydrogen 
peroxide in milli-Q water. Reactions were stopped (four minutes) by rinsing 
multiple times with milli-Q water. For OVA protein quantification (on B16-OVA-
derived EV), membranes were blocked with 0.1% caseinate/PBS for two hours. 
Membranes were then incubated with 5 µg/mL rabbit anti-OVA or anti-mouse β-
actin for two hours. The primary antibody was then detected using donkey anti-
rabbit-IgG-DyLight-800 or donkey anti-mouse IgG-dylight680 diluted 1/10,000 in 
0.1% caseinate/PBS for one hour in the dark. Membranes were then visualised with 
an Odyssey Fc imaging system (LI-COR, Lincoln, NE, USA). Quantification of OVA was 
performed using the Image Studio Lite software (Lincoln, NE, USA) using titrated 
OVA (500, 250, 125, 62.5 ng) as a standard (Sigma #A5503). All incubations and 
washes were performed at room temperature. See sections 2.3.10, 2.3.12, and Table 
2 for details of the reagents used.  
 
2.12 Cell viability assays 
Tumour cells were (1 × 104 cells) were seeded onto a flat bottom 96-well 
plate in 200 µL of R5. The wells were then replaced with fresh R5 and supplemented 
with either doxorubicin (at doses of 500 µM, 50 µM, 5 µM, or 0.5 µM) or PBS in 100 
µL of R5. The cells were incubated for 24 or 48 hours at 37◦C with 5% CO2. The media 
was then gently discarded (without disturbing the cells) and replaced with fresh R5. 
Resazurin was added at 10% of well volume (20 µL) (final conc. 12 mg/L). Cells were 
then incubated for 4-6 hours at 37◦C with 5% CO2. The supernatant (150 µL) was 
then aspirated and transferred onto a 96-well flat bottom black plate. The wells 
were then subjected to fluorometric analysis at excitation/emission wavelengths of 




2.13 Proteomic analyses of EV 
Purified B16F1-derived EV were further purified by a sucrose cushion 
(sections 2.7 and 2.8) and dialysed (10 kDa cut off) against PBS for 3 days (with PBS 
replaced at least five times) to remove sucrose and D2O. The samples were then 
given to the Centre for Protein Research (University of Otago, Dunedin) for lysing 
and mass spectrometric processing. Briefly, EV lysates were buffer exchanged and 
purified by filter-aided sample preparation (FASP) method using 0.5 mL 
ultrafiltration units with a molecular weight cut-off of 3 kDa (Millipore #UFC-
500308). Reduction, alkylation, and tryptic protein digestion were performed on 
filter. The recovered tryptic peptides of each samples were then subjected to liquid 
chromatography coupled tandem mass spectrometry using an Ultimate 3000 
uHPLC-system inline coupled to nanospray source of a LTQ Orbitrap XL mass 
spectrometer. Raw data were processed through the Proteome Discoverer software 
(Thermo Fisher) and searched against the mouse reference sequence database 
(http://www.ncbi.nlm.nih. gov/refseq; 57928 sequence entries) using the MASCOT 
(www.matrixscience.com), Sequest HT (Thermo Fisher) and MS Amanda search 
engines [300]. The Percolator algorithm was used to adjust the score threshold to 
an estimated peptide false discovery rate of 1%. Only proteins with two significant 
peptide hits were considered as significantly identified. Relative protein 
abundances between the different samples were estimated through using the TOP3 
approach [301]. The TOP3 intensities values were calculated using the Proteome 
Discoverer software and normalised to the β-actin ion intensity of each sample. 
 
2.14 Fibrin Generation Assay (FGA) 
Citrated PPP was either obtained from Siemens or prepared in-house. For the 
preparation of the latter, tri-sodium citrate (0.106 M) was added to 1/10 of the 
screened blood volume collected from healthy adult donors (with approval of the 
University of Otago Human Ethics committee) and immediately spun at 2000 ×g for 
15 minutes at 4◦C. The clear yellow layer (plasma) at the top of the buffy coat was 
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aspirated and stored at -80◦C. Purified EV or cells (15 µg or otherwise stated) in 20 
µL PBS were added to 100 µL of citrated PPP in a 96-well flat-bottom clear plate 
(Thermo Fisher). Coagulation was initiated by the addition of 10 mM calcium 
chloride and absorbance at OD405nm was immediately measured at periodical cycles 
of 10, 20, or 30 seconds over 30 minutes at room temperature (21-23◦C) using a 
plate reader (Varioskan® Flash, Thermo Fisher). Area under the curve (AUC) was 
calculated from the initiation point until the PBS control line formed a positive slope 
(5% of maximum fibrin). All samples were performed in triplicate. Where stated 
coagulation factor deficient PPP were used or 20 µg/mL goat anti-mouse TF, rat 
anti-mouse TF, rabbit anti-mouse TF, DNase I (Roche #1284932), or 100 µg/mL 
annexin V for blocking experiments (see section 2.5, Table 2 for details of the 
blockers).  
 
2.15 Thrombin Generation Assay (TGA) 
Purified B16F1-derived EV (quantities as stated) in 20 µL of PBS or 20 µL of 
thrombin calibrator (715 nM specific activity) was added to 80 µL of standard PPP 
in a 96-well clear flat bottom plate (Thermo Fisher). Henceforth, instructions were 
followed as per the Thrombinoscope software. Briefly, the plate was pre-warmed at 
37◦C in the Fluoroskan Ascent Fluorometer (Thermo Fisher), 20 µL of FluCa (1:40) 
was dispensed, and thrombin activity measured for one hour. Refer to section 2.4 
for details of the reagents used.  
 
2.16 FV function detection assay 
Purified B16F10-derived EV (15 µg) in 12 µL of PBS, 12 of µL FCS, R5, or SFM 
were added to a black 96-well flat bottom plate (Nunc). The samples were with 50 
mM HEPES, 1 µg/mL BSA, 100 mM sodium chloride, 10 pM FXa, 50 µM SN-20, and 
500 mM prothrombin. CaCl2 (5 mM) was added to initiate the reaction and wells 
immediately measured fluorometrically (excitation 352 nm / emission 470 nm) at a 
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periodical cycle of 10 seconds for one hour at room temperature (21-23◦C) using a 
plate reader (Varioskan® Flash, Thermo Scientific). 
 
2.17 LN metastasis studies  
B16 cells were first harvested from logarithmically growing cultures using a 
cell scraper, filtered through a 70 µm cell strainer, and resuspended in PBS. C57BL/6 
wild-type and CD169-/- mice were injected with 1 × 106 B16F10 or B16F10-LacZ 
cells in 25 µL of PBS subcutaneously (s.c.) into the ventral-carpal aspect of the 
forelimb. Mice were monitored daily for pain symptoms, dehydration, and weight 
loss before euthanasia by CO2 asphyxiation at day 12. The draining LN (brachial and 
axillary) were immediately excised, gently washed using PBS, transferred into a 
plastic mould containing Optimal Cutting Temperature freezing media (OCT; 
SAKURA Finetek, USA), and frozen at -80◦C for at least 24 hours. Sections (6-7 µm 
thick) were prepared using a cryostat (Leica CM 1850 UV) and -18◦C and sections 
mounted onto Histobond® adhesion slides (Marienfeld, Germany). The slides were 
left to air dry at room temperature overnight before being subjected to 
immunohistochemistry staining (see 2.18). For metastasis quantification by flow 
cytometry, LN (brachial or axillary) were excised from wild-types or Ptp euthanised 
mice, pierced and teased out using watchmaker forceps, and finally passed through 
a 70 µm cell strainer. The cells were then washed with 0.1 % BSA/PBS/2 mM EDTA 
at 453 ×g for five minutes at 4◦C, counted using a Neubauer haemocytometer slide, 
and incubated with 1 µg/mL APC-Cy7-conjugated mouse anti-mouse CD45.1, APC-
conjugated-rat anti-mouse-CD49f, bio-rat anti-mouse CD49d, bio-rat anti-mouse 
CD51, bio-hamster anti-mouse CD29. Biotin was detected using 1 µg/mL SA-APC on 
ice and samples were subjected to flow cytometric analysis (see 2.21). Where stated 





2.18 Immunohistochemistry for LN metastatic studies  
Draining and non-draining LN sections (from brachial and axillary; see 
section 2.17) were fixed with 1% PFA/PBS for 10 minutes, rinsed with PBS and 
stained with Meyer’s haematoxylin for 4-6 minutes. The slides were then washed 
with PBS and flooded with TBS until blued. The slides were then counterstained 
with eosin for five seconds and mounted in warm (60◦C) glycerol / gelatine and left 
to sit overnight at room temperature. Alternatively, for the detection of LacZ in 
B16F10-LacZ cells present in the draining LN, PFA-fixed sections were stained with 
pre-warmed (37◦C) X-gal solution for 24 hours, washed with PBS thrice and once 
with milli-Q water. The sections were then counterstained with nuclear fast red 
(Sigma #229113) for five minutes, rinsed with milli-Q water, immediately mounted 
in warm (60◦C) glycerol / gelatine and left to sit overnight at room temperature. 
 
2.19 EV mice immunisation and tumour challenge  
B16F0-OVA-derived EV were prepared as described in section 2.7 with the 
inclusion of 200 µg/mL OVA protein (Sigma-Aldrich #A5503). C57BL/6 mice (wild-
type or CD169-/-) were immunised s.c. with either 50 µL of PBS, or 25 µg of OVA-
pulsed purified (or otherwise stated) B16F1-derived ApoV, MV, or exosomes (in 50 
µL of PBS) in the flank. Seven days later, B16F10-OVA cells (cultured in R5 or SFM; 
grown logarithmically) were used (1 × 105 cells in 50 µL of PBS) to challenge mice 
s.c. in the opposite flank relative to the immunisation site. Tumour growth was 
determined by measuring the length and width using calipers every 1-2 days while 
monitoring the mice for any pain and dehydration symptoms. Results are expressed 
as the mean product diameters. Mice were removed from the study when tumour 





2.20 Coomassie blue protein concentration spot test  
A BSA standard was prepared from 2 mg/mL to 0.062 mg/mL and test 
samples (purified EV or cell lysates) diluted 1/3, 1/9, and 1/27 in PBS. A 1 µL aliquot 
from each of the diluted BSA standard and test samples were pipetted onto a filter 
paper and allowed to air dry. The filter paper was then flooded with Coomassie Blue 
G-250 stain for no longer than 20 seconds. The blue stain was removed and replaced 
with Coomassie Destain for 20 minutes on a rocker. The protein concentration was 
estimated by comparing colour intensities of the test samples with the BSA 
standards while the filter paper remains wet. 
 
2.21 Flow cytometry acquisition and analysis  
All sample acquisition was performed using a BD LSRFortessa flow 
cytometer with BD FACSDiva software. The flow cytometer was equipped with a 488 
nm blue, 561 nm yellow-green, 640 nm red, and 405 violet laser. Flow cytometer 
voltages were set with unconjugated beads or unstained cells for EV-conjugated 
beads or whole cell samples respectively. For all experiments, 10,000 events were 
acquired. Analysis of flow cytometric data was performed using the software 
FlowJo. Data was subjected to both forward scatter (FSc) and side scatter (SSc) 
doublet discrimination prior to FSc and SSc gating of conjugated beads or cells. 
 
2.22 Descriptive statistics 
All statistical analyses were performed using GraphPad Prism 6 (GraphPad, 
San Diego, CA). Coagulation experiments such as FGA and TGA, and FV functional 
assays were analysed using one-way ANOVA with Bonferroni post-correction test. 
LN tumour invasion by melanoma B16 cells were measured using the area 
calculation function of the software ImageJ (National institute of Health, USA) with 
the current researcher blinded to the treatment and mouse strain. Survival data 
were represented as tumour growth curves or as Kaplan-Meier survival plots and 
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analysed using the Mantel-Cox test. All error bars are represented in terms of 































Chapter III - Results:  
Molecular and Functional 
Characteristics of EV 
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3.1 Introduction  
Most studied tumour cells can constitutively release EV [302, 303]. In 
contrast, activation, transformation, immortalisation, and initiation of apoptosis are 
often required in primary cells for the release of EV [106, 116, 123, 304]. 
Angiogenesis, immune modulation, metastasis, and coagulation are examples of the 
vast biological functions that tumour-derived EV can induce [119, 298, 305-307].  
ApoV are one of the least studied type of EV, it was therefore critical to fully 
characterise ApoV and fully distinguish them from MV. The melanoma B16 cell line 
is one of the most studied cell lines and thus was the model cell line of choice [308]. 
We have selected the EV fractions exosomes, MV, and ApoV to be characterised and 
compared. Furthermore, due to the implication of ApoV in chemotherapy, this study 
extended its investigation on ApoV. Size, yield, surface and intracellular (proteins, 
lipids, and sialic acids) content were the parameters of choice to characterise the 
three EV types. Moreover, functional comparisons such as cancer and coagulative 
effects were explored. The latter may be influenced by ApoV since cancer patients 
undergoing chemotherapy have an increased risk to develop VT to six-fold [293]. 
 
3.2 Visualisation, sizing, and yield of EV  
We first visualised purified B16F1-derived EV using cryo-EM (composite 
cryoEM images; Figure 3.1A –3.1C). We have then measured the diameters of 150 
randomly chosen particles from each vesicle sample under cryoEM. As shown in 
Figure 3.2A, exosomes were the smallest of vesicles exhibiting a diameter range of 
51–478 nm (geometric mean; GM 135.5 nm ± 65.5 SD), MV had a range of 67–677 
nm (GM 210 nm ± 114 SD), and ApoV had a range of 103–816 nm (GM 330 nm ± 147 
SD). Using dynamic-light scattering (DLS), a similar pattern of values was detected: 
exosomes range of 78–164 nm (GM 117.4 nm ± 32 nm); MV range 122.4–459 nm 
(GM 258.6 nm ± 112.8 SD), and ApoV range 220–531 nm (GM 357 nm ± 112.1 SD; 
Figure 3.2B). The yield of ApoV, as determined by protein, was consistently higher 


















































































































































































































































































Figure 3.2 Size range and yield of B16F1-derived EV. Exosomes (Exo), 
microvesicles (MV) or apoptotic vesicles (ApoV) were purified by differential 
centrifugation of cell supernatant from live or doxorubicin-treated B16F1 cells 
and EV visualised by cryo-EM. Diameter of all three vesicle types determined by 
(A) cryo-EM (n = 150 EV) with a bin width of 5 nm or (B) dynamic light scattering. 
(C) Yield of exosomes, MV, and ApoV per mL of tissue culture; error bars 
represent mean ± SD. One-way ANOVA with Bonferroni post-correction test 
performed: ns = not significant; **P < 0.01; ***P < 0.001. Results are 
representative three experiments. 
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3.3 Flow cytometric, western blot, and proteomic 
analysis of exosomes, MV, and ApoV  
To widen our understanding in B16F1-derived EV, we have first selected a 
number of surface proteins including tetraspanins, adhesion molecules such as 
integrins and CD44, and  sialic acids, to be analysed by flow cytometry (Figure 3.3A). 
The use of beads of known size to conjugate with EV facilitated their gating by flow 
cytometry. In parallel, sucrose cushion-purified B16F1-derived exosomes, MV and 
ApoV were dialysed (10,000 Da cut off) and analysed by mass spectrometry using a 
LTQ Orbitrap XL mass spectrometer Table 3.1, Figure 3.4, and Appendix A). By both 
flow cytometry and mass spectrometry, ApoV showed low expression of the 
tetraspanin protein CD9, while MV exhibited intermediate CD9 expression and 
exosomes the highest CD9 expression. All three EV were positive for the tetraspanin 
protein CD81 (Figure 3.3A), but with higher CD81 ion scores obtained for exosomes, 
as compared to MV and ApoV (Table 3.1). In terms of integrin molecules, EV did not 
express detectable αV subunits. Exosomes showed the highest expression for the α4 
subunit followed by MV, then ApoV. The β1 integrin subunit was highest in MV 
followed by exosomes, then ApoV (Figure 3.3A and Appendix A). While low levels of 
α6 were detected in all three vesicles, MV showed the highest expression for α6 
(Figure 3.3A and Appendix A).  
All three EV showed high level sialic acid expression, which may contribute 
to the capture of EV in lymphoid tissue (Figure 3.3A; ref. [35, 309]). The vesicular 
nature of our preparations was confirmed by the presence of CD147 and the coat 
protein clathrin by western blot and proteomic analysis (Figure 3.3B). As expected 
from previous reports [310-312], there was a preferential association of CD147 and 
clathrin with vesicles, as compared to the B16 parental cell line (Table 3.1 and 
Appendix A). 
We represented the proteomic data into graphical form in Figure 3.4. EV 
differed in the abundance of several proteins, with particular enrichment of histones 
and heat shock proteins in exosomes, as compared to MV and ApoV. Notably, the ten 
most abundant ion scores in exosomes included the histones (H2A, H2B, H3.1 and 
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H4), heat shock proteins (GRP78 and HSC71) and the tetraspanin CD81. Only ApoV 
showed enrichment for the melanoma tumour-associated antigen PMEL (Figure 
3.4D and Appendix A). The raw data for the total 553 proteins identified by mass 





















Figure 3.3 Surface expression comparison of B16F1-derived vesicles using 
flow cytometry. (A) Vesicles conjugated to aldehyde-sulfate microspheres were 
analysed by flow cytometry using biotinylated (bio) antibodies for the indicated 
tetraspanins, adhesion molecules, and biotinylated lectins for sialic acids (MALII 
for α2,3- and SNA for α2,6-linked sialic acid). Biotin was detected using 
streptavidin-allophycocyanin (SA-APC). Grey shaded peaks represent BSA-bead 
control. (B) Vesicle lysates were subjected to PAGE and western blotted with goat 
anti-mouse CD147 (detected with anti-goat IgG-HRP), mouse anti-mouse clathrin 
heavy chain, and mouse anti-mouse β actin IgG-HRP (detected with anti-mouse 
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Sucrose cushion purified B16F1-derived apoptotic vesicles (ApoV), microvesicles 
(MV), and exosomes (Exo) were subjected to mass spectrometry and data 
processed and searched against the mouse reference sequence database using the 
MASCOT, Sequest HT, and MS Amanda search engines. The TOP3 precursor ion 
intensities normalised to β-actin of the highest 40 protein intensities present in 
the exosome samples are represented for all EV types. Proteomic data for the total 






Table 3.1 Proteomic analyses of B16-derived extracellular vesicles 
Accession (gi) Protein Description Exo MV ApoV 
568893484 histone H4  3.37 0.14 0.08 
31981690 heat shock cognate 71 kDa protein   2.70 0.22 0.09 
28316760 histone H2B type 1-B   2.49 0.10 0.05 
256773209 histone H2A.V   2.14 0.08 0.03 
254540166 78 kDa glucose-regulated protein precursor   1.87 0.12 0.06 
755495449  immunoglobulin superfamily member 8 isoform X1   1.42 0.14 0.06 
148277591 syntenin-1 isoform 2   1.41 0.10 0.02 
755502152  LQ PROTEIN: uncharacterized protein LOC105244409   1.27 0.15 0.01 
30061339 histone H3.2   1.25 0.04 0.00 
19526794 CD81 antigen   1.20 0.11 0.06 
755490905 
 LQ PROTEIN: ubiquitin-40S ribosomal protein S27a-like 
isoform X1   
1.01 0.20 0.08 
6671509 actin, cytoplasmic 1   1.00 1.00 1.00 
149273202  glyceraldehyde-3-phosphate dehydrogenase   1.00 0.42 1.30 
568901980  MLV-related proviral Env polyprotein-like   0.99 0.22 0.06 
755511141  MLV-related proviral Env polyprotein   0.98 0.21 0.06 
755496111  LQ PROTEIN: uncharacterized protein LOC105244006   0.79 0.44 0.06 
16716569 protease, serine, 1 precursor   0.68 0.45 0.41 
51491845 clathrin heavy chain 1   0.50 0.07 0.10 
6755901 tubulin alpha-1A chain   0.46 0.12 0.26 
6679439 peptidyl-prolyl cis-trans isomerase A   0.43 0.09 0.16 
258547156 programmed cell death 6-interacting protein isoform 3   0.41 0.04 0.01 
6680297 dnaJ homolog subfamily A member 1   0.40 0.01 0.00 
45504394 integrin beta-1 precursor   0.39 0.12 0.08 
7106439 tubulin beta-5 chain   0.38 0.09 0.17 
568907654  tubulin alpha-4A chain isoform X1   0.37 0.12 0.20 
126032329 elongation factor 1-alpha 1   0.35 0.20 0.43 
171846253 transmembrane glycoprotein NMB precursor   0.34 0.02 0.06 
21450277 
sodium/potassium-transporting ATPase subunit alpha-1 
precursor   
0.33 0.32 0.26 
568960833  pyruvate kinase PKM isoform X1   0.32 0.11 0.28 
755509256  alpha-enolase isoform X1   0.31 0.10 0.18 
22165384 tubulin beta-4B chain   0.30 0.05 0.12 
13430890 histone H1.4   0.30 0.01 0.00 
269914154 uncharacterized protein LOC239673   0.29 0.05 0.03 
238637279 4F2 cell-surface antigen heavy chain isoform b   0.28 0.24 0.15 
114326554 integrin alpha-4 precursor   0.28 0.06 0.04 
226874906 14-3-3 protein epsilon   0.27 0.06 0.05 
6677813 40S ribosomal protein S8   0.25 0.02 0.01 
6753060 annexin A5   0.24 0.08 0.23 
9845257 histone H1.2   0.24 0.02 0.00 








Figure 3.4 Graphical representation of the proteomic analysis of B16F1-
derived EV. Sucrose cushion purified B16F1-derived apoptotic vesicles (ApoV), 
microvesicles (MV), and exosomes (Exo) were subjected to mass spectrometry and 
data processed and searched against the mouse reference sequence database using 
the MASCOT, Sequest HT, and MS Amanda search engines. TOP3 precursor ion 
intensities normalised to β-actin (y-axis) are represented in rank order (x-axis) for 
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3.4 Analysis of the coagulation factors PS and TF 
Due to the importance of the procoagulant effects elicited by EV we have 
analysed the levels of PS and TF in B16F1-derived EV (Figure 3.5A). ApoV showed 
the highest level of PS expression followed by MV, then exosomes. Because the levels 
of TF were below the detectable limit for all three EV types, we confirmed the 
functionality of the TF-specific polyclonal antibody by labelling TF-transfected EL4, 
as well as the parental B16F1 line, in the presence or absence of soluble TF-Fc 
protein. The results showed detectable TF expression on EL4-TF and parental 
B16F1 cells. In addition, the specificity of the labelling was demonstrated by a loss 
in binding of the antibody to cells in the presence of excess, soluble TF-Fc protein 
(Figure 3.5B). A few bands for TF were detected by western blot (Figure 3.5C). The 
bands at 45-60 kDa may represent glycosylated TF [313].  
 
3.5 The anti-cancer effects of B16-derived exosomes, 
MV, and ApoV 
To determine if tumour derived-EV could play a role in inducing immunity 
against the B16 tumour we first immunised mice s.c. with EV derived from B16-
ovalbumin (B16F0-OVA) in the flank. We then challenged all mice, seven days later, 
with B16-OVA cells at the opposite flank. Even though B16F0-OVA cell line 
expresses ovalbumin at sufficient levels to act as a surrogate tumour antigen for 
protection in ovalbumin-vaccinated mice [314, 315], no protection was observed 
when exogenously supplied OVA was omitted from the vaccine B16-OVA ApoV 
preparations (Figure 3.6). B16-OVA cells were therefore treated (pulsed) with 
additional soluble OVA (200 μg/mL) prior to the isolation of vesicles. Mice 
immunised with OVA-pulsed ApoV showed the highest protection with only one 
mouse developing a B16-OVA tumour that reached maximum size at day 69 (Figure 
3.7A and 3.7B). This level of protection was followed by the mice immunised with 
OVA-pulsed MV, where three mice reaching maximum tumour size at days 36, 46, 
and 57. All mice immunised with OVA-pulsed exosomes reached maximum B16-
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OVA tumour sizes at 16, 22, 28, 36, and 44 (Mantel-Cox analysis; MV vs. exosomes: 
P < 0.0022; ApoV vs. exosomes: P < 0.0005; ApoV vs. MV; not significant). We then 
measured the levels of OVA present on our OVA-pulsed EV and surprisingly, the 
weakly protective exosomes contained a greater quantity of ovalbumin, as 
compared to MV and ApoV (Figure 3.7C). Therefore, the superior protection 
afforded by ApoV may not have been solely dependent on the enhanced OVA loading 
into this EV subtype. 
Since the anti-cancer protection observed by ApoV was superior to exosomes 
and MV, we next inquisited if this protection conveyed by ApoV was not due to 
contaminating macromolecules. The cells were therefore cultured in serum-free 
medium (SFM) instead of foetal calf-serum (FCS) supplemented medium. In 
addition, we have further purified the SFM-stimulated ApoV fraction using a 30% 
sucrose/D2O cushion. We have then immunised mice with the sucrose cushion and 
SFM-derived ApoV-OVA at doses of 25, 5, and 1 µg followed by a tumour challenge 
seven days later (Figure 3.8A and 3.8B). Even though protection was lower 
compared to ApoV derived in FCS, ApoV conveyed significant protection to tumour 
growth. Strikingly, the protection remained significant even with 1 µg of ApoV 
immunisation (Mantel-Cox analysis; 25 µg of ApoV / PBS (P < 0.0004); 5 µg of ApoV 
/ PBS (P < 0.0072); 1 µg of ApoV / PBS (P < 0.0072). Western blot analysis confirmed 
OVA expression on co-purified with sucrose/D2O cushion ApoV (Figure 3.8C). In 
addition, cryo-EM revealed that there was no structural change observed between 














Figure 3.5 Detection of tissue factor and phosphatidylserine lipids on 
B16F1-derived vesicles. (A) Vesicles conjugated to aldehyde-sulfate 
microspheres were analysed by flow cytometry using bio-annexin V for 
phosphatidylserine (PS) and goat anti-mouse tissue factor (TF). (B) TF 
expression on B16F1, EL4, or TF-transfected EL4 (EL4-muTF) cells as analysed 
by flow cytometry. Soluble TF was used to block TF-reactivity of the anti-TF 
polyclonal antibody. TF was detected using rabbit anti-goat IgG Alexa Fluor® 
594. Grey shaded peaks represent BSA-bead control, goat IgG control for TF bead 
samples; black lines represent vesicle-beads/cells; dotted lines represent TF 
antibody neutralised cells or beads. (C) Vesicle lysates were subjected to PAGE 
and western blotted with anti-mouse bio-TF (detected with SA-HRP). MW in kDa 
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Figure 3.6 The importance of the supplementation of OVA in the anti-cancer 
effects of ApoV. Mice were injected subcutaneously (s.c.) with either 25 µg of 
ApoV derived from B16F0-OVA (without the supplementation of OVA; ‘unpulsed’) 
or PBS in the flank before challenged s.c. with B16-OVA cells at the opposite flank 
seven days later. Tumour size was recorded until tumors reached 150 mm2. (A) 
Percent survival of the two mouse groups (n=6 mice / group). Unpulsed ApoV / 
PBS (not significant) by Mantel-Cox test. (B) Tumour size represented for 




Figure 3.7 The anti-tumour effects of exogenously-pulsed B16-OVA vesicles 
on tumour growth. Mice were injected s.c. with 25 µg of ApoV, MV, Exo (isolated 
by differential centrifugation of ovalbumin-pulsed B16-OVA-derived vesicles), or 
PBS in the flank before challenged with B16-OVA cells at the opposite flank seven 
days later. Tumour size was recorded until tumours reached 150 mm2. (A) Percent 
survival of the four mouse groups (n=6 mice/group). ApoV/Exo (P < 0.0005); 
ApoV/MV (not significant); MV/Exo (P < 0.0022); PBS/Exo (P < 0.004) by Mantel-
Cox test. (B) Tumour size represented for individual mice; 150 mm2 tumour size 
cut-off is represented by the dashed lines. The protective results for ApoV were 
confirmed in an additional experiment. (C) OVA-pulsed Exo, MV or ApoV were 
probed by western blotting with rabbit anti-OVA and detected with donkey anti-
rabbit IgG-DyLight-800. A titrated OVA standard was used to quantify the amount 
of OVA in each sample. Note, endogenously expressed ovalbumin in the B16-OVA 
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Figure 3.8 Confirming the anti-cancer effects of B16F0-OVA-derived ApoV 
generated in serum-free medium and purified by sucrose cushion. B16F0-
OVA cells were cultured in serum-free medium (SFM) and treated with 
doxorubicin and OVA to generate OVA-pulsed ApoV. ApoV were then purified via 
differential centrifugation followed by sucrose cushion purification. Mice were 
injected s.c. with 25, 5, or 1 µg of ApoV-OVA, or PBS in the flank before challenged 
s.c. with B16-OVA cells at the opposite flank seven days later. Tumour size was 
recorded until tumours reached 150 mm2. (A) Percent survival of the four mouse 
groups (n=6 mice / group). 25 µg of ApoV / PBS (P < 0.0004); 5 µg of ApoV / PBS 
(P < 0.0072); 1 µg of ApoV / PBS (P < 0.0072); by Mantel-Cox test. (B) Tumour size 
represented for individual mice; 150 mm2 tumour size cut-off is represented by the 
dashed lines. Representative of two experiments performed. (C) Sucrose-purified 
OVA-pulsed ApoV or B16F1-derived “unpulsed” ApoV were probed by western 
blotting with bio-rabbit anti-OVA and detected with SA-HRP. Cryo-electron 
microscopy images of OVA-pulsed ApoV were taken; scale bar = 50 nm. 
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3.6 The procoagulant activity of B16-derived exosomes, 
MV, and ApoV  
Since tumour-derived EV have been implicated in cancer-related thrombosis, 
we next determined the procoagulant potential of the three types of EV using a fibrin 
generation assay (FGA; Figure 3.9A). ApoV generated significantly more fibrin as 
compared to MV and exosomes. Based on normalised protein content, exosomes 
were the least coagulative of the EV types. TF is known to be implicated in cancer-
related thrombosis [291, 295, 298, 307]. Despite the lack of TF detection by flow 
cytometry (Figure 3.5), the procoagulant activity of ApoV was inhibited by anti-TF 
antibody and annexin V (Figure 3.9B). Furthermore, the importance of TF/ extrinsic 
pathway, was confirmed using coagulation factor VII depleted (FVII-) plasma 
(Figure 3.9C). Since TF is critical for the procoagulant activity of ApoV, we have 
compared the polyclonal anti-TF antibody with two additional commercially 
available anti-TF monoclonal antibodies (Figure 3.10A). Using equal concentration 
of antibodies (25 µg/mL) suppression of the procoagulant activity of ApoV was 
observed (Figure 3.10). However, only the polyclonal (R&D) antibody significantly 
blocked the procoagulant activity. It was expected that the monoclonal rat anti-
mouse 1H1 antibody would not significantly block fibrin deposition since inhibition 
in the FGA was only marginal at >50 µg/mL [316]. A polyclonal IgG control from 
non-immune goat serum failed to inhibit the FGA (Figure 3.10B). 
 Since the procoagulant level of MV was close to that of ApoV, we next tested 
and compared the two EV using a FGA with a titrating dose of MV and ApoV              
(50–0.5µg; Figure 3.11). As expected, ApoV remained superior at inducing 
coagulation at all doses. After that, we have tested and compared the contribution 
of PS in the procoagulant activity of MV and ApoV using annexin V (Figure 3.12). 
Similar to our previous results (Figure 3.9B) the procoagulant activity of MV was 
significantly suppressed when PS was blocked. 
We then determined if the procoagulant activity of B16-derived ApoV was 
not due to contaminating macromolecules. We have therefore purified the ApoV 
fraction using a 30% sucrose/D2O cushion and subjected them to a FGA (Figure 
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3.13A). Only the interface with density ρ ≤ 0.21 g/cm3 showed procoagulant activity. 
This indicates that it is unlikely any non-vesicle associated proteins, polyphosphates 
or nucleic acids contributed to the procoagulant activity initiated by ApoV. In order 
to further fractionate the procoagulant activity present in the vesicle fractions, we 
next subjected ApoV to continuous linear sucrose gradient and tested different 
density fractions for fibrin generation (Figure 3.13B). Although there was some 
heterogeneity within the coagulative ApoV fractions, the 1.12–1.15 g/cm3 density 




















Figure 3.9 Fibrin generation assays comparing B16F1-derived EV. Equal 
amounts of purified EV (15 μg) were added to platelet-poor plasma (PPP) 
supplemented with CaCl2 to initiate coagulation. Fibrin generation was monitored 
at 405 nm until the negative control (PBS) started to generate detectable fibrin. (A) 
Fibrin generation induced by B16F1-derived ApoV, MV, and Exo. (B) Fibrin 
generation assay of ApoV with inclusion of 20 μg/mL anti-mouse TF or 100 μg/mL 
annexin V (AV) to block PS. (C) Fibrin generation assay of ApoV using factor VII 
depleted plasma (FVII-) standard PPP (Ctr). Error bars represent mean ± SD. One-
way ANOVA with Bonferroni post-correction test performed on the area under the 
curves (AUC): ns = not significant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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Figure 3.10 Comparison of different αTF antibodies on the procoagulant activity 
of ApoV. (A) Equal amounts of purified ApoV (15 μg) supplemented with 20 µg/mL 
of various αTF antibodies (Ab); polyclonal goat anti-mouse tissue factor (R&D); 
monoclonal rat- (1H1); or monoclonal rabbit (Seksui), were added to platelet-poor 
plasma (PPP) supplemented with CaCl2 to initiate coagulation. Fibrin generation was 
monitored at 405 nm until the negative control (PBS) started to generate detectable 
fibrin. (B) ApoV (15 μg) either with the addition of 20 µg/mL anti-mouse TF antibody 
or a goat IgG control were added to PPP. Error bars represent mean ± SD. One-way 
ANOVA with Bonferroni post-correction test performed on the area under the curves 
(AUC): ns = not significant, ***P < 0.001, ****P < 0.0001. Samples were loaded in 
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Figure 3.11 Procoagulant activity of ApoV and MV in different doses. Purified 
B16F1-derived ApoV or MV (50, 25, 15, 10, 5, or 0.5 μg), were added to platelet-poor 
plasma (PPP) supplemented with CaCl2 to initiate coagulation. Fibrin generation was 
monitored at 405 nm until the negative control (PBS) started to generate detectable 
fibrin. Error bars represent mean ± SD. Samples were loaded in triplicate. One-way 
ANOVA with Bonferroni post-correction test performed on the area under the 
curves (AUC) for each dose. 50 μg ApoV/MV (not significant; ns); 25 μg ApoV/MV 
**P < 0.01; 15 μg ApoV/MV (ns); 10 μg ApoV/MV **P < 0.01; 5 μg ApoV/MV (ns); 1 
μg ApoV/MV (ns); 0.5 μg ApoV /MV (ns). Comparative control experiment 

















D a t a  6













Figure 3.12 The effects of annexin V on the coagulation activity of ApoV.  (A) 
Purified B16 doxorubicin-derived apoptotic vesicles (ApoV) or microvesicles (MV) 
were incubated with ± 100 µg annexin V for 30 minutes on ice. The ApoV or MV 
were then added to PPP followed by the addition of CaCl2 to initiate coagulation.  
Each sample was tested in triplicate and results are representative of two 
experiments. (B) One-way ANOVA with Bonferroni post-correction test performed 
on the area under the curves (AUC): ns = not significant, *P < 0.05, **P < 0.01,         
***P < 0.001. Error bars represent mean ± SD. Samples were loaded in triplicate. 
Control experiment representative of two experiments. 
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Figure 3.13 Fibrin deposition assays of sucrose purified B16F1-derived 
ApoV. Following differential centrifugation, B16F1-derived apoptotic vesicles 
(ApoV) were further purified using sucrose gradients. The fractions (F1-14) were 
tested for in the fibrin deposition assay, monitoring absorbance at 405 nm for    
500 s. (A) ApoV purified in a 30% sucrose cushion/D2O. Arrow indicates the 
interface of the sucrose cushion. Vesicle-free 30% sucrose/D2O was used as a 
control (Ctr); error bars represent mean ± SD. (B) ApoV purified by a linear 
sucrose gradient. For each experiment, 20 µL of each fraction was assayed. Results 




3.7 The thrombin generation potential of B16-derived 
exosomes, MV, and ApoV  
 While fibrin deposition measure coagulant activity as determined by the 
turbidity of the clot, thrombin determination measures the activity of enzyme 
directly responsible for conversion of prothrombin to thrombin. Due to its 
sensitivity, measuring thrombin is also the common assay used to obtain a 
comprehensive image of thrombotic tendencies of patients with high risk for 
thrombosis/bleeding [317]. We therefore utilised a Thrombinoscope to further 
analyse the procoagulant activities of B16-derived ApoV, MV, and exosomes using 
the thrombin generation assay (TGA). The TGA is automated to be divided into four 
distinct phases (Figure 3.14 and refs:[317, 318]): 
- Initiation phase: thrombin is generated in small quantities immediately 
after the lag phase, Factor VIIa/EV-tissue factor complex formation as well 
as the activation of Factor IX and X; no detectable thrombin is produced. 
- Amplification phase: the extrinsic activities (Factor VIIa/EV-tissue factor) 
and activated Factor X generate a small scale of thrombin which activates 
FVIII, FV, and (if present) platelets. One of the main functions of platelets is 
exposing their PS lipids to bind with activated factors (such as FIXa, VIIIa, and 
Va) and/or activate FX and FII (pro-thrombin). In our TGA, however, platelet-
poor plasma is used and B16-derived EV are known to be rich in externalised 
PS. This grants the B16-derived EV to enhance coagulation in a similar 
manner to platelets.   
- Propagation phase: the initial thrombin generated results in a positive 
feedback loop for more thrombin to be generated and intrinsic coagulation 
factors become fully activated thereby causing a thrombin burst.  
 
- Tail phase: the production of thrombin ceases because of the endogenous 
anticoagulants suppressing its effects. 
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We therefore compared the ability of tumour-derived ApoV to generate fibrin 
and thrombin, by subjecting the vesicles to a fibrin generation assay (FGA) and 
thrombin generation assay (TGA). As shown in Figure 3.14, fibrin generation was a 
rapid event with peak time for ApoV determined as 1.83 min (± 0.33 SD), compared 
to the thrombin peak time of 19.89 min (± 0.87 SD). 
To further confirm the ability of the three B16-derived EV types to generate 
thrombin, we subjected purified vesicles to the TGA (Figure 3.15). Although results 
indicate that ApoV and MV were faster than exosomes at generating thrombin, 
significance between samples was not observed (mean lag time: ApoV 15.89 min ± 
1.34 SD; MV 15.89 min ± 0.16 SD; exosomes 20.22 ± 4.96 SD; Figure 3.15A). Similar 
to our FGA (Figure 3.9 and 3.10), thrombin generation was retarded for all EV by the 
inclusion of neutralising anti-TF antibody in the TGA (Figure 3.15B). To ensure that 
phospholipid was not limiting for the activity of TF, we supplemented the reaction 
with phospholipid microparticles (MP; Figure 3.15C and 3.15D). Although only a 
small decrease in lag time to peak thrombin production was noted following the 
addition of phospholipid, blocking TF in the presence of excess MP significantly 
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Figure 3.14 Comparison of the two tests of procoagulant activity of ApoV 
measuring thrombin (TGA) or fibrin (FGA) production. Apoptotic vesicles 
(ApoV) were purified by differential centrifugation of cell supernatant from 
doxorubicin-treated B16F1 cells and ApoV (15 µg) were added to PPP 
supplemented with CaCl2 to initiate coagulation. Fibrin generation (FGA) was 
monitored at 405 nm for 10 minutes and the first derivative of the curved was taken. 
Alternatively, for thrombin generation assay (TGA), ApoV were incubated with PPP 
and reaction initiated by the addition of FluCa reagent. The TGA can be marked for 
four distinct phases: (1) the initiation phase where thrombin production is initiated, 
but is undetectable by the relatively insensitive TGA and fibrin is produced, (2) the 
amplification phase; where fibrin production plateaus, and detectable thrombin is 
generated, (3) the propagation phase; a positive feedback loop for thrombin 
generated resulting in large amount of thrombin, and (4) The tail phase where the 
production of thrombin ceases. Samples were loaded in triplicates. Results are 






Figure 3.15 Thrombin generation assays B16F1-derived EV. Platelet-poor 
plasma was incubated with 2.5 µg of the indicated EV and the reaction was 
initiated by the addition of FluCa reagent. (A) Thrombin generation assay of the 
ApoV, MV, and Exo. (B) Thrombin generation by three EV types blocked with 20 
µg/mL anti-mouse TF antibody (αTF). Arrows indicate peak thrombin values for 
MV, ApoV, and exosomes obtained in absence of anti-TF antibody. (C) Thrombin 
generation by ApoV with the addition of lipid microparticles (MP) ± anti-TF.       
(D) Bar graphs represent statistical analyses between samples in terms of lag 
time. One-way ANOVA using Bonferroni’s multiple comparisons test was 
performed: **P < 0.01; ***P < 0.001. Samples were loaded in triplicates. Results 
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3.8 Concluding remarks 
• In addition to being the largest vesicle, ApoV were generated at greater 
proteins levels / mL of tissue culture compared to exosomes and MV. 
 
• ApoV, MV, and exosomes were best distinguished by means differential 
expression levels of markers rather than the absence or presence of unique 
markers. For example, the expression of the tetraspanin CD9 was present in 
all three EV types, but markedly lower in ApoV compared to MV and 
exosomes.  
 
• The flow cytometric data was confirmed using mass spectrometry for most 
proteins, such as CD9 an integrin subunits α6 and β1. Interestingly, the 
proteomic scan revealed that exosomes were enriched in histones and heat 
shock proteins.  
 
• Although PS was detected in all three EV types, ApoV exposed PS at a slightly 
higher level. TF was below the detectable level for all three EV types. 
 
• Prophylactic ApoV immunisation gave a superior protection against cancer 
compared to MV and exosomes. Factors contributing to this effect remain to 
be identified. 
 
• ApoV generate fibrin significantly faster than MV and exosomes. Although it 
was below the detectable limit, TF (alongside with PS) was a critical molecule 
for this procoagulant effect. An indication that the extrinsic coagulation 
pathway was involved. 
 
• Exosomes were the weakest fraction to generate thrombin. This was 
followed by ApoV and then MV (being the highest). Using an antibody to 
block TF, the thrombin generation by all three EV types was hindered; 













Chapter IV – Results: 






Using doxorubicin to induce apoptosis, the procoagulant effects induced by 
B16-derived ApoV were investigated and shown in chapter III. To determine if 
different chemotherapy drugs generated similar procoagulant ApoV, we have 
additionally used 5-Fluorouracil (5FU) and gemcitabine. In addition, we have 
generated ApoV from a wide-spectrum of tumour cell lines with murine and human 
origin and compared their procoagulant activity with their cells of origin. 
Doxorubicin was the drug of choice due to it’s ability to generate high yields of ApoV 
(data not shown). In chapter III, it was shown that the procoagulant activity of ApoV 
is due to TF and PS. The utility of FVII-depleted plasma further confirmed that the 
extrinsic coagulation pathway is likely at play. We have therefore explored the 
possible implication of the intrinsic coagulation pathway using intrinsic factor 
depleted plasmas. Moreover, following our and other studies’ discovery of FV in 
tumour-derived EV (chapter III; appendix A and refs:[319-321]), we have 
investigated the role of endogenous FV in the procoagulant activity of ApoV. 
 
4.2 Different chemotherapy drugs generate superior 
procoagulant ApoV 
We first analysed the cell viability using the resazurin assay. Resazurin is a 
weakly fluorescent dye which becomes highly fluorescent upon being irreversibly 
reduced by mitochondrial coenzymes, such as the oxidised form of nicotinamide 
adenine dinucleotide (NADH) within viable cells and is therefore a convenient 
measure of cellular metabolism [322, 323]. Treatment of B16 cells with doxorubicin 
resulted in a significant loss of viability that was maximal at 48 hours (Figures 4.1A 
and 4.1B). In addition, we have measured PS exposure (using annexin V binding) as 
an indicator of apoptosis in doxorubicin-treated cells (Figure 4.1C). The 48 hour 
time point of the resazurin assay and annexin V staining corresponded to each other 
(Figure 4.1).  
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We next determined if ApoV derived from tumour cells exposed to various 
chemotherapy drugs exhibited similar procoagulant activity in comparison to their 
corresponding parental cells (live or dead; Figures 4.2A and 4.2B). ApoV generated 
from 5FU- or doxorubicin-treated B16 or LLC cells were significantly more 
procoagulant than their (live or dead) cell of origin. ApoV derived from cells exposed 
to 5FU induced the highest procoagulant effect, as opposed to the gemcitabine-
treated ApoV with the least coagulative property (with doxorubicin-generated ApoV 
as an intermediate). Similar to Figures 3.9 and 3.10, when 5FU-generated ApoV are 
blocked with annexin V (for PS) or anti-TF antibody, fibrin generation was 














Figure 4.1 Cell viability and apoptotic analyses of doxorubicin-treated cells. 
(A) Cell viability was determined by resazurin assay. B16F10 cells were treated 
with 0.5, 5, 50, or 500 µM doxorubicin (Dox) for 48 hours or (B) treated with 30 
µM Dox immediately ("<5 min"), for 24 hours, or 48 hours. Cells were then 
incubated with resazurin solution and cell viability quantified by fluorometric 
analysis. Graphs plotted as relative percentage to untreated (live) cells. One-way 
ANOVA with Bonferroni post-correction test performed, ns = not significant;    
***P < 0.001; ****P < 0.0001. Error bars represent mean ± SD of triplicate samples.      
(C) Cells were incubated with 30 µM doxorubicin for 24 or 48 hours. In selected 
wells, Dox was added immediately prior to harvest ("<5 min") to determine the 
contribution of Dox to background fluorescence of living cells. Cells were analysed 
by flow cytometry for phosphatidylserine (PS) externalisation using biotinylated 
annexin V staining detected with streptavidin-BV421 (SA-BV421). Results are 






























































































































































Figure 4.2 The procoagulant activity of chemotherapy-generated ApoV.     
(A) B16F10 or (B) LLC cell lines were treated with doxorubicin (Dox), 5-
fluorouracil (5FU), or gemcitabine (Gem) to generate ApoV. ApoV were then 
purified by differential centrifugation of cell supernatant. ApoV, live or 
chemotherapy-exposed cells (15 µg) were then subjected to a FGA. One-way 
ANOVA with Bonferroni post-correction test performed on the area under the 
curves (AUC): ns = not significant; *P < 0.05; **P < 0.01; ***P < 0.001;                      
****P < 0.0001. Error bars represent mean ± SD of triplicate samples. Results are 
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Figure 4.3 TF and PS are critical for the procoagulant activity of 5FU-derived 
ApoV. (A) Equal amounts of purified EV (15 μg) were added to platelet-poor 
plasma (PPP) supplemented with CaCl2 to initiate coagulation with inclusion of       
20 μg/mL anti-mouse TF or 100 μg/mL annexin V (AV) to block PS. (B) One-way 
ANOVA with Bonferroni post-correction test performed on the area under the 
curves (AUC): ***P < 0.001; ****P < 0.0001. Error bars represent mean ± SD. 
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4.3 Superior procoagulant activity of tumour-derived 
ApoV compared to parental cells 
To test the procoagulant effects of tumour-derived ApoV, we selected a range 
of murine tumour cells and used doxorubicin as a model drug. As seen in             
Figures 4.4 A-C, ApoV derived from melanoma B16, colorectal CT26, and lung LLC 
tumour cell lines were significantly more procoagulant than their cell of origin (live 
or dead). T cell lymphoma EL4 (live or dead) or EL4-derived ApoV failed to generate 
detectable fibrin (Figure. 4.4D). To further confirm this result, we selected human 
tumour cell lines and compared the procoagulant effects of intact cells with their 
ApoV (Figures 4.5A–D). Doxorubicin-treated melanoma SK-MEL5, prostate DU-145, 
lung NCI-H460, and breast MCF-7 cell lines released ApoV that were significantly 
more procoagulant than their cell of origin. When input levels of protein content of 
procoagulant ApoV and intact cells were increased from 15 μg to 60 μg, FGA activity 
induced by ApoV remained superior to that of dead cells, but ApoV FGA activity was 
not significantly different from that induced by living cells (Figure 4.6). In addition, 
annexin V could significantly reduce FGA activity when cell numbers were further 
increased (Figure 4.6), confirming the critical role of PS in the procoagulant activity 
of intact cells and ApoV. 
 
4.4 Factors II, V, and VII are critical for the 
procoagulant activity of tumour ApoV  
To further investigate the mechanisms of the procoagulant effects induced 
by tumour-derived ApoV, we subjected ApoV to the FGA using coagulation factor-
depleted plasma preparations (Figures 4.7A and 4.7B). There was no consistent 
reduction in coagulation using plasma-depleted for the FVIII and FIX components of 
the intrinsic coagulation cascade in the experiments performed. However, the 
procoagulant effects of ApoV was significantly reduced when the extrinsic factor 
FVII was removed – affirming the importance of TF/FVII pathway in the 
procoagulant effects of tumour-derived ApoV (Figures 3.9, 3.10, and 4.3). As 
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expected, the absence of FII (prothrombin) significantly blocked fibrin generation 
(Figure 4.8). Interestingly, there was a small but consistent enhancement within the 
procoagulant effect of ApoV generated from B16F10, DU-145, and NCI-H460 cells 
using the FIX-depleted plasma. The critical requirement for the prothrombinase 
complex was demonstrated using FV-depleted plasma (Figure 4.7). We also 
compared the fibrin generation ability of ApoV to APTT (PS reagent) and PT (PS + 
TF reagent) controls (Figure 4.9). Using the first derivative curves of triplicate 15 
seconds’ readings, extrapolated peak times were determined as PT 22.8 seconds 
(±0.00 SD, n=2), APTT 103.3 seconds (±8.47 SD, n = 2), and ApoV 117.0 seconds 
(±7.81 SD, n = 2). It was recently suggested that plasma DNA contributes to the 
procoagulant activity of breast cancer cells and their derived vesicles [324, 325]. 
Therefore, to rule out the possibility that the procoagulant activity induced by ApoV 
was due to DNA residues contaminating the ApoV samples, ApoV were subjected to 
a FGA with the inclusion of DNase I (Figure 4.10). However, there was no significant 
reduction in fibrin generation, suggesting that the free-DNA present does not 














Figure 4.4 The procoagulant activity of murine tumour-derived ApoV.              
(A) B16F10 (B) CT26, (C) LLC, or, (D) EL4 cell lines were treated with doxorubicin 
to generate ApoV. ApoV were then purified by differential centrifugation of cell 
supernatant. ApoV, live or chemotherapy-exposed cells (15 µg) were then 
subjected to a fibrin generation assay by the inclusion of PPP and then 
supplemented with CaCl2 to initiate coagulation. Fibrin generation was monitored 
at 405 nm for until the control (PBS) showed detectable fibrin. Error bars represent 
mean ± SD. One-way ANOVA with Bonferroni post-correction test performed on the 
area under the curves (AUC): ns = not significant; **P < 0.01; ***P < 0.001;             
****P < 0.0001. A positive control (0.1 U thrombin) was added for the EL4 study. 
Samples were loaded in triplicate. Results are representative of at least three 
experiments. 
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Figure 4.5 The procoagulant activity of human tumour-derived ApoV.               
(A) SK-MEL5 (B) DU-145, (C) NCI-H460, or, (D) MCF-7 cell lines were treated with 
doxorubicin to generate ApoV. ApoV were then purified by differential 
centrifugation of cell supernatant. ApoV, live or chemotherapy-exposed cells          
(15 µg) were then subjected to a fibrin generation assay by the inclusion of PPP and 
then supplemented with CaCl2 to initiate coagulation. Fibrin generation was 
monitored at 405 nm for until the control (PBS) showed detectable fibrin. Error 
bars represent mean ± SD. One-way ANOVA with Bonferroni post-correction test 
performed on the area under the curves (AUC): ns = not significant; **P < 0.01;      
***P < 0.001; ****P < 0.0001. Samples were loaded in triplicate. Results are 













































































































































































































































Figure 4.6 Procoagulant comparison of high and low doses of ApoV and their 
cell of origin with respect to phosphatidylserine. B16F10 cell line was treated 
with doxorubicin to generate ApoV. ApoV were then purified by differential 
centrifugation of cell supernatant. ApoV, doxorubicin-exposed (dead), or live cells 
(15 µg or 60 µg) were added to PPP with the inclusion of 100 µg/mL annexin V 
(AV) to block phosphatidylserine (PS) before being subjected to a FGA. One-way 
ANOVA with Bonferroni post-correction test performed on the area under the 
curves (AUC): ns = not significant; *P < 0.05; **P < 0.01; ****P < 0.0001. Error bars 





Figure 4.7 The impact of the coagulation cascade factors on the 
procoagulant activity of tumour ApoV. (A) B16F10, DU-145, NCI-H460, or 
Jurkat tumour cell lines were treated with doxorubicin to generate ApoV. ApoV 
were then purified by differential centrifugation of cell supernatant. ApoV (15 µg) 
were then subjected to a fibrin generation assay by the addition of either 








 PPP and then supplemented 
with CaCl2 to initiate coagulation. Fibrin generation was monitored at 405 nm for 
until the control (PBS) showed detectable fibrin. (B) Area under the curve (AUC) 
for each experiment were calculated as relative coagulative potential of ApoV in 
standard PPP (100%). Error bars represent mean ± SD. One-way ANOVA with 
Bonferroni post-correction test performed on AUC of the original curves: ns = not 
significant; *P < 0.05, **P < 0.01; ***P < 0.001, ****P < 0.0001. Samples were 
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Figure 4.8 Pro-thrombin (FII) is critical for the procoagulant activity of 
tumour-derived ApoV. B16F10 cell line was treated with doxorubicin to 
generate apoptotic vesicles (ApoV). ApoV were then purified by differential 
centrifugation of cell supernatant.  ApoV (15 µg) were added to either a 
prothrombin-depleted (FII
-
) PPP or standard PPP. CaCl2 was added to initiate 
coagulation. (A) A fibrin generation assay was performed by monitoring 
absorbance at 405 nm. (B) One-way ANOVA with Bonferroni post-correction test 
performed on the area under the curves (AUC): **P < 0.01. Error bars represent 
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Figure 4.9 Comparing ApoV with APTT and PT controls. B16F10-derived 
ApoV were purified by differential centrifugation of cell supernatant. (A) ApoV 
(15 µg), PT, or APTT reagents were added to standard PPP and subjected to a FGA 
and the (B) first derivative of the curves was plotted. Samples were loaded in 
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Figure 4.10 The procoagulant activity of ApoV is independent of DNA. Equal 
amounts of purified ApoV (15 μg) were PPP supplemented with CaCl2 to initiate 
coagulation. Fibrin generation was monitored at 405 nm until the negative control 
(PBS) started to generate detectable fibrin. (A) Fibrin generation induced by 
B16F1-derived ApoV with inclusion of 20 μg/mL DNase I to digest any double 
stranded DNA that may be present. (B) Error bars represent mean ± SD. One-way 
ANOVA with Bonferroni post-correction test performed on the area under the 
curves (AUC): ns = not significant. Samples were loaded in triplicate.  
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4.5 ApoV harbour functional FV derived from foetal calf 
serum 
We and others have previously detected FV in tumour-derived EV by mass 
spectrometry (Appendix A and refs:[319, 321]. We therefore further investigated 
the possibility that endogenous FV could be contributing to the observed 
procoagulant activity of ApoV. As noted above for Figure 4.7, the procoagulant 
effects of ApoV in FV-depleted plasma was significantly reduced, indicating that 
even if FV was endogenously expressed on vesicles, it would likely be unable to 
compensate for a loss of exogenous FV in the FGA. Nevertheless, we have tested the 
procoagulant activity of tumour ApoV with the inclusion of an anti-FV antibody 
using FV-depleted plasma (Figure 4.11). Even though there was indication of 
suppressed fibrin generation once the anti-FV antibody is included, the supplier of 
the FV depleted plasma does not guarantee the removal of the residual 1% or lower 
of FV within the FV-depleted plasma. Thus, although this result shows that FV may 
be present within the vesicles, there was a possibility that the suppression observed 
by the antibody was due to the residual FV present in the FV depleted plasma. Hence, 
we have performed a FV-sensitive assay to confirm a more sensitive test to further 
investigate the possibility that ApoV-associated FV was functional in some 
circumstances, we added ApoV to assay buffer containing FXa, prothrombin and 
thrombin substrate (Figure 4.12). While strong FV activity was observed using ApoV 
isolated from FCS-cultured cells, ApoV derived from SFM-cultured cells did not 
exhibit detectable FV activity (Figure 4.12A). The addition of FCS to SFM-prepared 
ApoV reconstituted FV activity, demonstrating that bovine sera-derived FV/FVa 
could function as a coagulation factor together with ApoV membranes. There was 
no significant difference in fibrin generation between ApoV derived from FCS- or 







Figure 4.11 Fibrin deposition of tumour-derived ApoV in FV-depleted plasma. 
NCI-H460, Jurkat, or DU-145 tumour cell lines were treated with doxorubicin to 
generate ApoV. ApoV were then purified by differential centrifugation of cell 
supernatant. ApoV (15 µg) were then subjected to a fibrin generation assay using 
FV-depleted PPP with the inclusion of 20 µg/mL human anti-FV antibody followed 
with CaCl2 to initiate coagulation. AUC for each experiment were measured; error 
bars represent mean ± SD. One-way ANOVA with Bonferroni post-correction test 
performed on AUC of the original curves: ns = not significant; *P < 0.05. Samples 
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Figure 4.12 Endogenous FV detection in B16F1-derived ApoV. (A) B16F1 
tumour cell line cultured in 5% foetal calf serum (R5) or serum-free medium (SFM) 
were treated with doxorubicin to generate ApoV. ApoV were then purified by 
differential centrifugation of cell supernatant. ApoV (15 µg) were then subjected to 
a FV functionality test quantified by the cleavage of the fluorescent thrombin 
substrate SN-20. (B) Fibrin generation assay comparing ApoV stimulated in R5 or 
SFM. Error bars represent mean ± SD. One-way ANOVA with Bonferroni post-
correction test performed on AUC: ns = not significant; ****P < 0.0001. Samples were 
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4.6 Concluding remarks 
• B16- or LLC-exposed to doxorubicin, 5FU, and gemcitabine release 
procoagulant ApoV. The fibrin generation of ApoV is significantly greater 
than their (dying or living) cells of origin.  
 
• The procoagulant activity of ApoV generated from different drugs such as 
5FU is dependent on TF expression and PS exposure on their surface. In 
addition, multiple murine and human tumour cell lines generated similar 
procoagulant ApoV apart from the lymphoma cell line EL4.  
 
•  The intrinsic coagulation pathway is not required for the in vitro 
procoagulant activity of tumour ApoV. Nevertheless, in some cases, the 
procoagulant activity by ApoV was enhanced in FXI-depleted plasma. 
 
• The extrinsic (TF:FVII) pathway and prothrombinase (FX:FV:FII) are both 
crucial for the procoagulant activity of tumour-derived ApoV. Potentially 
present in the ApoV pellet, DNA is not important for their procoagulant 
activity. 
 
• Endogenous FV present on the ApoV is functional but is not required for the 



















Chapter V - Results:  






Melanoma is the most malignant type of skin cancer. Similar to most solid 
cancers, the invasion of melanoma cells from the primary site to the draining LN 
marks the first steps of metastasis [84, 326]. Metastatic LN almost always show 
accumulation of melanoma cells within the subcapsular sinus of draining LN [327]. 
Our laboratory has shown previously that the CD169 molecule present on the 
subcapsular sinus macrophages binds EV via their surface sialic acids [35, 309].  In 
addition, Saunderson et al. have shown that there is an enhanced immune response 
in CD169-deficient mice upon immunisation with B cell derived-exosomes. Given 
that CD169+ macrophages are located in the subcapsular sinus of the LN, it is likely 
that this positioning would lead to interactions with invading tumour cells, and / or 
their vesicular products. We therefore investigated the potential participation of 
CD169 in tumour invasion into the draining LN.  We hypothesise that either (i) sialic 
acid-rich EV released by tumour cells may interact with CD169 and hence modulate 
the immune response to the tumour, or (ii) sialic acid-rich tumour cells [328] 
migrating from the primary site to the draining LN interact directly with CD169 and 
thus facilitate the invasion. This chapter first explores the effects of CD169 in 
melanoma tumour growth and its implication in ApoV immunisation. We also 
investigated the possible effects of CD169 in B16 melanoma tumour invasion into 
the draining LN using a mouse tumour model previously generated (MR, Muhsin, 
BBiomedSc (Honours), 2012; Appendix B). Melanoma invasion was analysed by 
immunohistochemistry of LN sections from CD169-/- and wild-type mice.  
 
5.2 The effects of CD169 on tumour growth and the 
immune response to tumour ApoV 
We first determined if CD169 could impact upon primary tumour growth 
using a standard s.c. flank implantation model. Inoculation of B16F1 cells into the 
flank of each mouse strain resulted in tumour growth that reached humane 
endpoints (150 mm2) by 16 and 22 days for C57BL/6 wild-type and CD169-/- strains 
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respectively (Figures 5.1A and 5.1B), however there was no significant difference 
observed in primary tumour growth rates between the two strains. We have 
previously shown that there was an enhanced immune response in CD169-/- mice 
upon immunisation with EV prepared from primary or transformed cells [35, 309]. 
We therefore determined if CD169 played a role in modulating the immune 
response to sialylated vesicles and could alter the immune response to melanoma. 
Similar to MV and exosomes, ApoV display high levels of sialic acids (Figure 3.3) and 
ApoV represent the most immunogenic extracellular vesicle fraction, as compared 
to exosomes and plasma membrane-derived microvesicles (Figure 3.7). We 
therefore immunised CD169-/- and C57BL/6 mice with ApoV prepared from 
ovalbumin-pulsed B16 cells and challenged with B16-OVA in the opposite flank 
seven days later. Immunisation with ApoV provided significant protection for both 
strains of mice, as compared to the PBS immunised group. Tumour growth was not 
detected in 2/6 and 4/6 in wild-type and CD169-/- mice, respectively, and protection 
was sustained for up to 70 days. However, there was no significant difference in 















Figure 5.1 The influence of CD169 on primary tumour growth and in the 
anti-cancer immune response. At day zero, C57BL/6 (wild-type; circles) or 
CD169-/- (squares) mice were immunised s.c. in the flank with either PBS (open 
symbols) or 25 µg of B16-derived ApoV pulsed with ovalbumin (OVA; closed 
symbols). At day seven, the mice were challenged s.c. in the opposite flank with  
1 × 105 B16-OVA cells and monitored until tumour size reached 150 mm2 
(horizontal dashed line), or at the final day of the study (day 70). (A) Percent 
survival of the mice. PBS: C57BL/6 vs. CD169-/- (not significant; ApoV C57BL/6 
vs. CD169-/- (not significant) by Mantel-Cox test. (B) Tumour size scores for every 




5.3 Previous work on tumour metastasis and CD169 
(Muhsin MR, BBiomedSc (Hon), 2012) 
We previously performed and optimised experiments to determine the most 
effective inoculation route for generating LN metastases (MR, Muhsin, BBiomedSc 
(Honours), 2012; Appendix B). We determined that mice injected with B16 
melanoma cells s.c. in the forelimb displayed melanoma-invaded draining LN 
(axillary and brachial). In addition, the model showed that there was no tumour 
invasion within any non-draining LN, visceral tissue, or any other major organ 
examined (data not shown). Using the cell line B16F1-green fluorescent protein 
(GFP) to inoculate mice, we then attempted to quantify the invaded areas within the 
draining LN by epifluorescent microscopy (MR, Muhsin, BBiomedSc (Honours), 
2012; Appendix B). However, although the GFP marker was highly expressed in 
vitro, we could not observe it in vivo. To counter the issue, we stained the sections 
with haematoxylin and eosin (H&E) which gave a clear discrimination of the invaded 
areas. In addition, to ensure that tumour demarcation of tumour margins was 
correctly placed, we labelled sections with leukocyte common antigen (CD45). As 
expected, melanoma invaded areas within the draining LN showed a distinct 
reduction in areas labelling uniformly with the CD45 marker, however, infiltrating 
CD45+ leukocytes were present within the tumour invaded areas. We then 
performed the experimental s.c. tumour model with CD169-/- and wild-type mice 
and compared the percentage area of tumour metastasis in their draining LN. 
Preliminary results indicated that there was a significant reduction in percentage 
invasion in CD169-/- mice (MR, Muhsin, BBiomedSc (Honours), 2012; Appendix B). 








5.4 Confirming the impact of CD169 on tumour 
metastasis  
We first generated the forelimb metastatic LN model using the cell line 
B16F10-LacZ. We have used X-gal to detect the enzyme β-galactosidase. Similar to 
the previously used B16F1-GFP cell line, the β-galactosidase marker was detectable 
and stable in vitro (Figure 5.2A and 5.2B). However, the marker was downregulated 
in vivo, even though H&E revealed obvious indications of tumour invasion (Figures 
5.2C and 5.2D). We therefore compared the LN tumour invasion in CD169-/- and 
wild-type mice using H&E staining (Figure 5.3). The study was carried out with the 
quantifying observer (MRMS) blinded to the experimental settings. At least 10 
sections were generated for each LN prior to staining. Although there was a modest 
reduction in tumour infiltration in the CD169-/- strain, this failed to reach statistical 
































Figure 5.2 The stability of LacZ expression in B16-LacZ in vitro and in vivo. 
(A) B16 and (B) B16-LacZ stained with X-gal in vitro. (C & D) serial sections of 
B16-LacZ invaded draining LN (brachial). Sections were stained with either H&E 
(C) or X-gal (D). Arrows indicate the presence of melanin. All sections were at 






Figure 5.3 The marking of tumour invaded areas within tumour LN. Wild-
type or CD169-/- mice were injected s.c. in the forelimb with 1 × 106 B16 
(melanoma) cells and euthanised at day 12 post-injection. Draining brachial LN 
were removed, sectioned, and stained with H&E. (A) A representative example 
of the areas of melanoma invasion within a brachial draining LN section from a 
CD169-/- mouse were shaded (black). (B, C, and D) 4.5× magnified areas from the 
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Figure 5.4 Quantification of cutaneous melanoma metastasis in C57BL/6 wild-
type and CD169-/- mice. C57BL/6 wild-type or CD169-/- mice were injected s.c. 
under the forelimb with 1 × 106 B16F10 cells and euthanized at day 12. Draining 
brachial and axillary LN were removed, sectioned (6-7 µm thick) and stained with 
H&E. (A) Total areas of draining axillary and brachial LN analysed for the calculation 
of the percent of melanoma invasion in (B). (B) Melanoma-invaded areas were 
calculated with respect to the entire associated LN area using the software Image J 
and expressed as a percent of total LN area. Error bars represent ± SD. A parametric 
unpaired t-test was used to analyse the data collected; ns = not significant. Results 




5.5 Developing a flow cytometric method to quantify 
melanoma invasion in LN 
 Even though the microscopy method allowed determination of reliable 
parameters (namely: morphology, melanin deposition, and size of tumour cells), this 
method was time consuming. In parallel, it was discovered that, using a flow 
cytometric approach, B16 melanoma cells could be discriminated from the LN 
leukocytes, allowing their quantification in invaded LN. Although there was a minor 
size (Forward Scatter; FSc) overlap between leukocytes and B16 cells, there was 
almost no overlap in Side Scatter profiles, and both cell types exhibited a distinctive 
combinated FSc / SSc (Side Scatter) profile (Figure 5.5). Additionally, B16 cells 
exhibited higher autofluorescence than LN leukocytes cells under channels with 
excitation wavelengths of 450, 525 and 530 nm. Leukocytes were stained for the 
leukocyte common antigen CD45 (using CD45.1-APC-Cy7; Figure 5.6A). Although 
the CD45.1 marker is unique to leukocytes, there was a non-specific binding of the 
antibody with certain tumour cells. Therefore, this experiment should be repeated 
using a different antibody for CD45. Finally, using the autofluorescence approach, in 
vitro samples of known tumour-to-lymphoid cell ratios were generated (Figure 
5.6B). This method could potentially detect low levels of tumour cells in LN. Figure 
5.5C represents a graph of known percentage tumour cells (Figure 5.6B) (input) 
against the experimental percentage value (output). 
 Although clear discriminations were observed between lymphoid cells and 
B16 cells using autofluorescence and size, it was required to find a specific marker 
for B16 cells. Figure 5.2 and previous data (Appendix B) demonstrated that markers 
such as LacZ or GFP from transgenic B16 cell lines could not be reliably detected on 
all tumour cells in vivo. Therefore, in attempt to discriminate B16 cells from 
leukocytes, the transgenic cell line B16F0-OVA was tested. As seen in Figure 5.7A, 
OVA was below the detectable limit. We have also used fixation and 
permeabilisation of the cells to facilitate the accessibility of the antibodies to the 
intracellular level of the cells. Unfortunately, OVA remained below the detectable 
level (Figure 5.7B).  
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Since integrin expression levels in tumour cells are usually higher compared 
to healthy primary cells [322], we compared B16 cell and lymphoid cells, in vitro, 
using the various integrin subunits as a parameter (Figures 5.8 and 5.9). As 
expected, the expression of the integrin subunit were higher in B16 cells and could 
potentially serve as a discriminatory parameter for invading B16 into the LN. 
However, we have not been able to generate the invasion model to test the integrin 
marker due to a reported viral hepatitis (MHV), Aspicularis spp., and Syphacia 






































Figure 5.5 Size comparison between murine melanoma B16F0 and lymph 
node (LN) cells by flow cytometry. (A) Melanoma B16F0 cells or LN cells were 
analysed independently, or following admixing, by flow cytometry. Percentages 
of events (cells) are shown beside the gates of each cell type. (B) Analysis of size 
distribution (by forward scatter; FSc) among B16F0 and LN cells. Ungated 
samples represent all events within either B16F0 or LN samples whereas gated 
samples represent peaks specific to B16F0 or LN cells; gates are shown in (A). 









































































































































Figure 5.6 In vitro quantification of B16 and LN cells by flow cytometry.        
(A) Melanoma B16 cells (blue) and LN cells (grey) were independently analysed 
by flow cytometry and compared for autofluorescence against selected violet and 
blue filters (530/30, 450/50, and 525/50). B16 and lymphoid cells were stained 
for the leukocyte common antigen using anti-mouse CD45.1-APC-Cy7 antibody 
(using the red 780/60). (B) Composition of samples prepared containing different 
ratios of B16 and lymphoid cells. (C) Known percentage value of B16 cells (input) 
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Figure 5.7 Detection of OVA in B16F0-OVA cells in vitro by flow cytometry. 
(A) Melanoma B16F0-OVA (black line) or B16F10 cells (gray) were stained with 
biotinylated anti-OVA antibody and detected with SA-APC. (B) Prior to staining, 
the cells were treated with a buffer to fix and permeabilise the cells (Fix/Perm). 
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Figure 5.8 Analysis of integrin proteins expression level between 
melanoma B16F0 and LN cells in vitro. Melanoma B16F0 (blue) or LN cells 
(orange) were stained with biotinylated anti-mouse integrin subunits CD49d 
(α4), CD49f (α6), CD51 (αV), or CD29 (β1) and detected with SA-APC. Unstained 


























































Figure 5.9 Analysis of CD49f (α6) integrins on B16 and LN cells. Equal number 
of B16 and LN cells were mixed and treated with anti-CD49f-bio and then with SA-
APC. The samples were analysed using flow cytometry using the violet laser 
channel V525/50 (for autofluorescence) and R670/14 (APC). LN cells showed no 
autofluorescence but a moderate CD49f expression. Autofluorescence and CD49f 
expression were significantly higher for B16 cells. Each population was gated and 
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5.6 Concluding remarks  
• Although not significant, the absence of CD169 improves the survival rate 
when ApoV were immunised prophylactically prior to tumour inoculation. 
 
• The invasion of B16 melanoma tumour cells from the primary tumour site 
(forelimb) into the draining LN (brachial and axillary) is reduced when 
CD169 is absent. However, this failed to reach a statistical significance. 
 
• Using flow cytometry, B16 cells exhibited higher SSc / FSc parameters and 
autofluorescence compared to LN leukocytes cells in vitro. In addition, the 
integrin subunits V, and  were markedly higher on B16 cells, as 
compared to LN leukocytes in vitro. This finding is yet to be tested in vivo 
using autofluorescence, size, and integrin level expression as parameters to 
quantify invasion of B16 cell into the draining LN. Flow cytometric methods 
could be an alternative quantification method to the immunohistochemically 






















Chapter VI:  





Cancer treatments remain to be sporadic in their success rates. In addition, 
patients undergoing cancer treatments, such as chemotherapy may experience 
unfavourable side effects such as (but not limited to) pain, anaemia, infection, or 
most importantly lethal blood clots. Therefore, much research is currently needed 
to minimise anti-cancer treatments and therefore improve their efficacy. On the 
other hand, whilst the interest towards the study of EV has increased exponentially 
over the past decade, numerous types of EV (and thereby their raison d’être) remain 
to be identified. Furthermore, tumour-released EV are now becoming the central 
dogma of EV research. We therefore set out to direct our focus on EV and what 
consequences chemotherapy may cause to the biology of tumour-released EV and 
their functionality in vitro and in vivo. 
It is now becoming more evident that EV play important roles in multiple 
biological systems. For example, it is now clear that intercellular trafficking can be 
achieved by EV in bone calcification, immune tolerance and activation, neuron-glia 
communication, wound repair, and haemostasis [116, 329-333]. Furthermore, EV 
have been implicated in numerous pathological conditions such as viral and prion 
transfer, cardiovascular disease, thrombosis, autoimmune diseases (e.g. rheumatoid 
arthritis and multiple sclerosis), sickle cell anaemia, and most importantly cancer 
[334-340]. Cancer-derived EV are becoming the most attractive faction due to their 
constitutive release by cancer cells [341]. While our understanding in EV is rapidly 
growing, studies have led to the invention of many different names for the released 
EV which reflect their specific function. This phenomenon was described by the EV 
experts Steven Gould and Graca Raposo as the “imperfect nomenclature for EV” 
[342]. Eventually, this has led to the convergence of two or more different types of 
EV with an identical term. For example, as defined in the introduction chapter, 
exosomes are vesicles that bud into the endosomes and are subsequently released 
when the multivesicular body product fuse with the plasma membrane [343]. 
Interestingly, others categorise exosomes as any secreted vesicle that may serve a 
function [112], or as the (70,000 – 100,000 ×g) ultracentrifugation speed they are 
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purified at [343, 344]. Similar issues are observed with MV and ApoV; a study from 
Del Conde et al. refers to their 200,000 ×g PPP-derived EV faction as MV [292]. 
Indeed their highest pre-depletion step was 5,000 ×g and thus small MV would have 
still been present. However, since their EV pool was likely to also contain both MV 
and exosomes, then perhaps the term MV is not the more accurate nomenclature 
[109, 116, 345]. Hence, one of the main objectives of this research was to create a 
distinguishable phenotypic and functional profile for the three tumour-derived EV 
selected: exosome, MV, and ApoV. In addition, despite their importance in 
chemotherapy and cancer, mechanisms orchestrated by tumour-derived ApoV in 
anti-cancer immunity or thrombosis remain largely unknown. For this reason, this 
research has put more attention towards the ApoV faction.  
 
6.02 Molecular comparison of the three EV: exosomes, 
MV, and ApoV 
 The first part of chapter III was the phenotypic characterisation of the three 
EV types: exosomes, MV, and ApoV. The cell line of choice was B16 melanoma as it 
is one of the frequently studied tumour cell lines and mimics human melanoma 
features such as metastasis, immune suppression, and thrombosis [308, 346]. In 
addition, it is a relatively easy cell line to culture in the laboratory. The first step 
undertaken was to visualise the structure of the B16-derived EV by electron 
microscopy. Cryo-EM was the method of choice as this method allows the 
visualisation of samples in their native state using cryogenic temperatures (-180◦C; 
ref. [347]). Alternative microscopy techniques could alter the true nature of 
samples. Exosomes are a classic example where they were thought to be “cup 
shaped” in morphology [341, 344]. This was, however, later demonstrated by the 
newer technique of cryo-EM that the cup-shape morphology was due to an artefact 
related to the chemical fixatives used for transmission electron microscopy [341]. 
In addition to EV structure, cryo-EM allowed the determination of the size of the EV 
studied in this research. The size range of B16-derived exosomes overlapped with 
the range displayed by previously published B16-derived exosomes [348]. 
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Interestingly, although ApoV and MV were purified under identical conditions and 
centrifugation speeds, the ApoV range was slightly larger than that of MV (Figures 
3.2A and 3.2B). We measured the particle sizes using two different methods to 
confirm that the size difference was not due to artefacts, or the measurement bias 
of a single method. The advantage of using cryo-EM to measure the EV is that 
contaminating particles can be excluded; only EV particles are measured.  
Although DLS confirmed the size range, this technique generates a 
monomodal distribution and the software assumes that all particles are spherical 
and non-aggregated. Hence the cryo-EM method is advantageous as it quantifies 
every EV particle compared to DLS. Thus, the larger mean sizes detected by DLS may 
not be as “true” diameters compared to the cryo-EM method (Figure 3.2). In 
addition, our isolation techniques using differential centrifugation and sucrose 
cushions ensure the removal of the larger apoptotic faction (apoptotic bodies; 1 – 5 
µm) making these vesicles a rare contaminant of the ApoV pool. The size range 
difference in MV and ApoV could reflect to their release mechanism. As mentioned 
before, MV release is thought to be important for intercellular communication 
whereas ApoV is a mechanism for dying cells to package cellular components for 
recycling or clearance [349]. Both mechanisms are tightly regulated; however, it 
could be that ApoV are slightly larger due to their (dying) cell of origin packaging all 
cellular content into the ApoV. On the other hand, intercellular messages by MV may 
not contain a larger “all dying cell’s” cargo. 
Another potential explanation for the subtle size difference could relate to 
the mechanism of their shedding. Initially, the shedding mechanism of MV and ApoV 
is thought to begin with the influx of extracellular calcium whereby the calcium-
dependant protein calpain becomes activated [350, 351]. This leads to the 
disruption of the membrane cytoskeleton [351]. After that, phospholipids (such as 
PS) become externalised and the consequential loss of phospholipid asymmetry 
becomes imminent [111, 352]. The budding process of MV and ApoV is then 
achieved by actin-myosin interactions [111]. However, the mechanism by which the 
ApoV buds off remains unclear and current literature suggest that it is linked to 
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caspase activation [167]. As mentioned in section 1.7, caspase-3 can cleave ROCK-1 
transforming it into a constitutive truncated form.  ROCK-1 then activates MLC and 
experiments have suggested that when ROCK-1 is inhibited, blebbing is not 
observed upon apoptosis [167]. Therefore, the larger bleb size of ApoV may be 
controlled by activated ROCK-1 since caspase is activated upon cell death. 
Nevertheless, a similarity between the geometrical means of ApoV and MV was 
observed.  
  The first phenotypic analysis performed for the three EV types was by using 
flow cytometry to detect surface molecules. Conventional flow cytometric methods 
cannot measure particles <300 nm in size making it difficult to exclude dust and 
contaminating nano-particles [353]. Hence, EV were conjugated to calibrated beads 
of known and relatively large size to facilitate their detection. The tetraspanin family 
proteins CD9 and CD81 were the first to be analysed (Figure 3.3). They are both 
glycoproteins known to complex with integrins and are suspected to be involved in 
cell motility, adhesion, and proliferation [354]. Although they are abundantly 
expressed, tetraspanin receptor function is yet to be identified. In addition, de novo 
mouse cancer models have shown that tetraspanins are important for tumour 
initiation, promotion, metastasis, and (sometimes) angiogenesis [354]. 
Interestingly, our data (mass spectrometry and flow cytometry) show that the level 
of CD9 expression is highest and lowest within exosomes and ApoV respectively, 
with MV being the intermediate. Interestingly, this coincided with the recent study 
by Osteikoetxea et al., where they compared exosomes, MV, and apoptotic bodies 
derived from BV-2 murine microglial cells [355]. However, their purification speed 
for MV was 12,600 ×g which may be concerning as low-speed gives a chance for 
contaminating large artefacts. Nonetheless, Osteikoetxea et al. proposed a method 
to distinguish their chosen EV using lipid assays and although there were overlaps 
between the lipid contents of their three EV types, the lipid parameter could be a 
great addition to our study. Our finding on CD9 expression level was particularly 
interesting for two reasons: (i) a potential marker for non-ApoV EV and, (ii) its 
relationship to cancer metastasis. However, a series of studies by Miyake et al. 
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showed an inverse correlation between the expression of CD9 and cancer metastasis 
in melanoma, breast, and lung cancers [356-358]. 
The higher expression in integrin proteins α4 and β1 may implicate them to 
be as pro-metastatic [359]. Integrins are transmembrane molecules that bind 
directly to components of the extracellular matrix providing the necessary pull for 
cell motility and adhesion [359, 360]. The expression level of integrin subunits is 
sometimes upregulated in certain cancer cell types to promote metastasis and 
angiogenesis [361]. In fact, the highest expression level of β1 integrin was found in 
exosomes, interestingly, the levels of α2,6-linked sialic acids (Figure 3.3). The 
increase in sialylation in cancers is well documented, and increased levels of 
sialylation in proteins such as β1 integrin has been reported which Seales et al. 
suggested it may contribute to tumour invasion [362]. Since, MV had the highest β1 
expression compared to ApoV and exosomes and all three EV displayed α2,6-linked 
sialic acid expression, this makes an attractive site for future metastatic studies 
using β1 and α2,6-linked sialic acid as parameters to compare the three EV types.   
The elevated expression of sialic acids in cancer cells increases their surface 
negative charge resulting in intercellular repulsion; a possible mechanism for 
haematogenous spread of cancer [257]. Interestingly, the increased level of sialic 
acids is not only associated with cancer progression and metastasis, but also with 
chemotherapy resistance [363, 364]. In addition, CD44 is a glycoprotein expressed 
in a large variety of isoforms in many cells [365]. The detectable CD44 level could 
also contribute to their metastatic potential possibly via cell adhesion, migration, 
and seems to be important in early metastasis [366]. This provides a potential 
mechanism by which chemotherapy-exposed cancer cells use to metastasise. Thus, 
all these detectable and elevated markers point to the commonly known idea that 
tumour-derived-EV are largely pro-metastatic [353, 367-369]. However, the direct 
comparison between EV derived from non-tumour cell lines and tumour cell lines 
for the markers we analysed remains to be performed.  
Since these B16-derived EV are rich in surface adhesion molecules they could 
use that adhesive property to deliver their (potentially present) oncogenic cargo. 
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For example, glioma-derived EV have been known to carry mRNA, micro RNA and 
proteins that contribute to tumour growth [368, 370]. Moreover, the uptake of 
glioma-derived MV, containing oncogenic epidermal growth factor receptor, by 
endothelial cells have been known to greatly alter the nature of the endothelial cells 
in a manner that elevates tumour angiogenesis [370]. Another pro-metastatic 
mechanism of tumour cells that may be exploited by tumour-derived EV due to their 
adhesive profile is by delivering immunosuppressive molecules. Tumour-derived 
EV can reduce a local immunogenic reaction via the induction of apoptosis to T cells 
if the death ligand FasL is present on the EV surface [371]. Alternatively, tumour-
derived EV also have the ability to either halt the differentiation of DC from 
monocytes (thereby turning them into immunosuppressive) or as discovered by 
Valenti et al., inhibit cytotoxic responses induced by NK cells [372, 373].  
Remarkably, the expression level of CD147 on all the three EV types was 
much higher than their cell of origin (Figure 3.3B). This was to no surprise as 
previous work in our laboratory showed that CD147 is enriched in ApoV from 
melanoma B16 and lymphoma EL4 cells [374, 375]. CD147 is present in almost 
every cell in the body, and although it is involved in adhesion and tissue remodelling, 
it has been implicated in cancer metastasis [376]. Acting as an Extracellular Matrix 
Metalloproteinase Inducer as a main role, CD147 is thus also referred to as 
“EMMPRIN”. Matrix metalloproteinases (MMP) are extracellular enzymes that 
degrade over 40 substrates. In vertebrates, there are at least 25 different MMP 
enzymes and they are involved in many disease and developmental-related 
processes [377]. For example, MMP14 is involved in angiogenesis, skeletal and lung 
development, whereas the role of MMP17 remains unclear but has been identified 
to be overexpressed in breast cancer cells and promotes their proliferation [377, 
378]. Once matrix metalloproteinases (such as MMP1, MMP2, and MMP11) are 
induced by CD147, the enzymes help break the extracellular matrix thus aiding in 
the proliferation of tumour cells [376, 379]. Thus, the high expression of CD147 on 
the B16-derived EV could help metastasis of such tumours using MMP induction.  In 
addition, the remarkably elevated level in EV compared to their cell of origin makes 
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it an excellent potential marker for tumour-derived EV, as seen in previous studies 
[310, 312]. 
One of the greatest assets in this research was the full quantitative proteomic 
analysis by mass spectrometry (Figure 3.4, Table 3.1, and Appendix A). The 
abundance of heat-shock proteins in the exosome faction was also previously 
observed [380, 381]. The high level enrichment of histones in exosomes was another 
notable finding. It was previously thought that histones are markers of apoptosis 
since they are nuclear-associated proteins [106, 382]. In fact, a proteomic study of 
DC-derived exosomes by Théry et al. have detected histones in exosomes [106]. 
Despite this, they hypothesised that their presence may be due to the natural and 
spontaneous apoptosis among the DC, contaminating the preparation of their DC-
derived exosomes. However, it is now commonly known that histones can localise 
within the cytoplasm, as well as the nucleus [383], and histones within exosomes 
has been observed [384]. Even though apoptotic materials may contaminate our 
B16-derived exosomes, it is unlikely that our sample is heavily contaminated with 
MV, ApoV or apoptotic bodies, since the proteomic study demonstrated an 
enrichment of histones with exosome fraction, compared to MV and ApoV.  
Since MV and ApoV are purified under the same speeds, we cannot rule out 
the possibility that some ApoV from spontaneous deaths could contaminate the MV 
pool, or vice versa, by the spontaneous release of MV from cells during their 
exposure of doxorubicin. However, during exosome purification, most of MV, ApoV, 
and apoptotic bodies are effectively depleted by an initial 453 ×g, 3,200 ×g,        
25,000 ×g differential centrifugation, and finally 0.2 µm filtration. It is still unclear 
regarding the function of exosomal histones.  Due to evidence that exosomes could 
contain RNA materials, we hypothesise that highly positively charged histones may 
act as a chaperone for nucleic acid material [341, 368]. It has been proposed that the 
presence of RNA materials in exosomes may be due to the fact that MVB contain 
RNA-induced silencing complexes accumulating sites [385, 386] and there is a direct 
interaction between histones and RNA [385]. Moreover, a study by Müller et al. 
suggests that the histone H3 modification is necessary for exosome release [387]. 
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Therefore, this makes exosomes and histones an interesting topic for research and 
surely requires further attention.  
Mass spectrometry also revealed that ApoV expressed the melanoma 
pigment protein PMEL at a higher level than MV and exosomes [388]. This was 
interesting as ApoV pellet from B16F1 cells consistently contained pigment, 
whereas MV or exosomes weakly displayed pigmentation (data not shown). It would 
be of interest to see if the PMEL remains detectable in ApoV derived from B16F10 
as this cell line does not have the black pigment in vitro, as observed in our 
experiments. Glyceraldehyde 3-phosphate dehydrogenase (G3PD) was also 
enriched within the ApoV faction. In addition to being an enzyme that catalyses the 
break-down of glucose during glycolysis and activation of transcription, G3PD is also 
involved in the initiation of apoptosis [389]. Interestingly, it has been reported that 
G3PD is localised to mitochondria and may induce mitochondrial membrane 
permeability, an early apoptotic mechanism [390]. This leads to the release of pro-
apoptotic factors such as cytochrome c and apoptotic inducing factor. The ion 
intensities of G3PD were lowest on the MV faction compared to the 3.5-fold increase 
in ApoV. Because the enzyme is involved in multiple cellular mechanisms one would 
expect to have a small base line of G3PD to be detected in all three EV types. 
Regardless, the involvement of G3PD in apoptosis and its high level in ApoV 
indicates that our purified EV types have a low chance of being cross-contaminated.  
 
6.03 The anti-cancer effects induced by B16-derived EV 
Tumour antigens can be captured via numerous sources of materials such as 
apoptotic cells, heat-shock and soluble proteins, and, in vaccination experiments, 
tumour-released EV [110, 373, 391-393]. These antigens are captured by APC that 
leads to the activation of a CTL-driven immune response [394]. Cross-presentation 
of antigens (such as OVA) are often observed in experimental settings as seen in the 
in vivo study by Albert et al. It was shown that it was specifically the DC that 
efficiently present antigens, derived from apoptotic cells, to stimulate an MHC-I-
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restricted CTL response [395]. Moreover, Zitvogel et al. demonstrated that DC-
derived exosomes can eradicate established tumours due to the expression of MHC-
I and -II on the surface of the exosomes [396]. The detected exosome heat-shock 
proteins, have been reported by Srivastava’s group to participate in a pro-
immunogenic action via their interaction with APC [397]. PMEL is another antigen 
that has been reported to elicit an immune response [398], however, the PMEL-
enriched ApoV have not been able to elicit an immune response in the absence of 
the exogenously supplied OVA (Figure 3.6). The highest OVA loading was found on 
exosomes but exosomes-immunised mice displayed the lowest protection against 
B16 tumour (Figure 3.7). Therefore, this suggests that the anti-cancer effect of EV is 
independent of the concentration of the loaded OVA antigen on our EV. Due to this, 
we hypothesise that the superior anti-cancer effect induced by ApoV may likely be 
linked to their ability to efficiently be noticed by the immune system. A possible 
mechanism could be linked to the high PS level detected on ApoV (Figure 3.3). As 
mentioned above, one feature of apoptosis is to not elicit an immune response. 
Apoptotic materials have been reported to have “eat me” signal (such as annexin 1 
and PS) that, once detected by phagocytes, would be efficiently phagocytosed [399, 
400]. In addition modified surface adhesion molecules (such as ICAM-3 and platelet 
endothelial cell adhesion molecule-1; PECAM-1) function as tethering proteins on 
apoptotic cells to facilitate the detection of these “eat me” signals by phagocytes 
[399, 401, 402]. Interestingly, Hoffman et al. identified that apoptotic cell clearance 
is enhanced by PS-receptor mediated micropinocytosis (a regulated form of 
endocytosis for solute molecules and antigens; ref. [403, 404]). The pathway is 
highly active among APC such as macrophages and DC [404]. Moreover, masking PS 
on MV (by annexin V) has been shown to disable their uptake by target cells. 
Therefore, the presence of PS may explain a possible mechanism for the uptake of 
the antigen OVA [292, 405]. However, because PS levels were only slightly lower 
among exosomes and MV and PS exposure is in fact a signature of nearly all EV [111, 
341, 406], this suggests that there are likely to be multiple mechanisms taking part 
in the immunogenicity of antigen-pulsed EV. Moreover, ApoV were generated in 
culture and not immediately engulfed, as expected to happen in vivo. Thus, in vitro 
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conditions may cause ApoV to become more immunogenic than in vivo generated 
ApoV. 
We next investigated if the protection elicited by ApoV remained if the cells 
generating ApoV and used at the challenge were cultured in SFM instead of FCS 
(Figure 3.8). Previous reports have shown that certain peptides present in FCS can 
provoke an anti-tumour response during immunisation experiments [407, 408]. In 
fact, our laboratory has previously demonstrated that the use of a SFM instead of 
FCS-replete medium to culture melanoma cells abolishes these FCS artefacts [315]. 
Our data indicate that although lower, the protection against cancer induced by 
ApoV remained superior to the control if the challenge cells were cultured in SFM 
(Figure 3.8). An additional variable was also added to this experiment; the further 
purification of ApoV using a sucrose cushion, which also results in a drop in vesicle 
protein yield (data not shown). A study by Webber and Clayton showed that sucrose 
cushion purification of exosomes resulted in a drop in contaminating proteins while 
the exosome yield remained constant [409]. Whether the sucrose cushion 
purification of ApoV results in a similar outcome to exosomes remains to be 
investigated. Nevertheless, it has been reported before that the use of SFM for a DC 
culture may result in changes in DC function and a drop of yield could occur [408, 
410]. We have visualised SFM-derived ApoV using cryo-EM and there seem to be no 
difference in their structure. However, there has been no reports if SFM alters the 
biogenesis or immunogenicity of tumour-derived EV. Such studies should be further 
explored and it may explain the reduction in protection observed in the 
SFM/sucrose purified ApoV.  
The therapeutic effects of ApoV in s.c. B16 mouse model remains to be 
investigated. Although using a B16-tumour model and OVA as the antigen, the 
system would not be strictly relevant to a clinical model. Hence, it would be advised 
to pulse ApoV with an antigen endogenously produced by the cell line of choice, for 
example gp100, MART-1 or trp2 [411, 412].  In 2012, a laboratory group sequenced 
and found 563 point mutations within expressed genes of B16F10 [413]. The use of 
such mutated peptides and the potency of our ApoV to elicit an immune response 
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suggests that ApoV could be applied for future experiments as potential therapeutic 
or prophylactic melanoma vaccines.  
6.04 CD169 and tumour metastasis 
Another path this research took was to investigate if primary tumour growth 
(± a prophylactic immunisation of ApoV) or tumour metastasis was influenced by 
CD169; a major lymphoid receptor for EV [35, 414]. There were no significant 
differences observed in tumour growth between C57BL/6 and CD169-/- mice, even 
following prophylactic ApoV immunisation. The CD169-/- mouse strain possesses 
macrophages within the subcapsular sinus and marginal zones of the spleen but 
these macrophages specifically lack the CD169 molecule [35]. We therefore cannot 
rule out the possibility if CD169+ macrophages play a role in cancer progression. 
Other studies that deplete the entire CD169+ macrophage population (using 
diphtheria toxin or clodronate liposomes) indicate that CD169+ macrophages are 
immunogenic [31, 250, 415, 416]. For example, the Tanaka group’s CD169+ 
macrophage depletion model showed that the cells have a critical role in the anti-
cancer effect [249]. Interestingly, they show that upon immunisation with dead 
tumour cells, CD169+ macrophages cross-present tumour antigens to CD8+ T cells 
thereby mediating a cytotoxic-mediated anti-cancer immune response. Similar to 
our system (Figure 5.1), the group used OVA as the target antigen. Therefore, it 
remains to be determined if CD169+ macrophages play a role in a ApoV-induced 
protection against melanoma growth.  
The minor decrease in the invasion of B16 cells into the draining LN of 
CD169-/- mice matched the preliminary significant results obtained previously (MR, 
Muhsin, BBiomedSc (Honours), 2012; Appendix B). Even though lymphatic shunts 
exist to bypass draining LN, the presence of tumour cells within the draining LN 
provides an important prognostic factor for cancer patients [417-419]. In fact, there 
is convincing evidence that draining LN are the best prognostic estimators for the 
status of the entire lymphatic nodal system [420]. Most metastatic mouse models 
involve the injection of tumour cells directly into the blood stream thus mimicking 
the (late) haematogenous spread of tumour cells [421]. For example, injecting 
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tumour cells into either the tail veins, spleen, or heart results in tumour growth on 
the lungs, liver, or bones respectively; i.e. the first organs encountered [422-424].  
One advantage of the metastatic model we performed is allowing the tumour 
cells to naturally invade the draining LN; the first steps of melanoma metastasis 
[425]. Our forelimb metastatic model, which follows an early protocol developed 
using a leukaemic cell line [426], produced a reliable invasion model for B16 
melanoma. Another reliable route to obtain a metastatic model is by inoculating 
tumour cells on the footpad of the mice [427, 428]. However, one major drawback 
of the footpad inoculation is that amputation of the tumour-bearing limb is required 
to allow dissemination of the tumour cells to distant sites [429-431]. There have 
been, however, several challenges faced with our short (12-day) forelimb metastatic 
model. For example, although it was anatomically difficult to obtain measurements, 
the primary tumour size (by day 12) was on the verge of ulceration, suggesting the 
tumour cell number required to induce metastatic spread to the LN was high. 
Additionally, it remains unclear if the invading tumour cells are a result of tumour 
bolus from the initial injection bolus before the formation of tumour mass. 
Therefore, the credibility of this forelimb method resulting in tumour invasion 
requires further investigation. Alternatively, to increase the tumourgenicity of B16 
cells, the solubilised tissue basement membrane (Matrigel) can be used [432]. In 
addition to the extracellular matrix proteins (e.g. collagen IV, laminin, and nidogen), 
Matrigel contains various growth factors that can sustain and encourage cellular 
growth [433]. The key feature of Matrigel, however, is the polymerisation at body 
temperatures (37°C). It is often used in in vitro cell migration assays as cells can pass 
through the Matrigel layer [434, 435]. The compound can therefore encourage 
tumour cells to metastasise rather than grow at the primary site thus ameliorating 
our metastatic model; a possible model for future experiments. 
Hood et al. have demonstrated that B16F10-derived exosomes accumulate in 
and prepare the draining LN for tumour invasion [306]. This mechanism is often 
termed “seed and soil” in metastasis, where tumour-derived EV are regarded as 
“seeds” preparing a particular site (the soil) for tumour cell invasion [436, 437]. The 
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studies suggest that tumour-derived EV facilitate invasion by enhancing 
angiogenesis and immunosuppression in situ [306, 438, 439]. Migrating melanoma 
cells are usually guided by chemokines such as CXCR3, CCR7, and CCR8, with 
integrin α4 identified as a critical adhesion molecule for LN invasion [440-443]. 
CD169 has been shown to play a major role in the capture of foreign and self-
antigens [35, 444]. Depending on the experimental setting, CD169+ macrophages 
may mediate a tolerogenic or immunogenic response to self-antigens, infectious, 
and tumour models [249, 251, 445-447]. As for the entry into the LN parenchyma, 
tumour cells are first impeded by the subcapsular sinus composed of endothelium 
with closely associated CD169+ macrophages [35, 448, 449]. Since tumour cells and 
their released EV are known to be highly sialylated (Figure 3.3; refs. [35, 309, 447, 
450]), we proposed that CD169+ macrophages interact with B16 tumour in two 
ways. First, tumour cells from the primary site could release EV in vivo that would 
drain into the draining LN and be captured by CD169. It remains unclear if the 
capture by CD169 would trigger immune activation or suppression. Our laboratory 
has previously shown that OVA-pulsed exosomes or ApoV promote a greater CTL 
immune response when CD169 is absent [35, 309]. However, our laboratory has also 
shown that tumour ApoV suppress dendritic cell responses when unpulsed with 
OVA, albeit independent of CD169 expression [309]. Therefore, and based on the 
minor decrease in B16 invasion in CD169-/- mice, it is possible that CD169 may 
facilitate the invasion by the 'seed and soil' mechanisms [436, 437]. To test this, 
simultaneous inoculation of tumour cells, together with their derived-EV, could be 
carried out.   
 The second theory we propose is the (highly sialylated) tumour cells 
themselves may be captured directly by CD169 after migration from the primary 
site. It remains unclear, however, if that interaction alters tumour invasion. The 
increased level of sialylation on cancer cells is often correlated with an increased 
metastatic state [450-452]. Moreover, blocking sialic acids in cancers have been 
shown to reduce their metastatic state [453]. Thus, our second theory could be 
tested with tumour cells with varying sialic acid levels using CD169-/- mice. 
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Failure to reach significance within our LN metastatic studies may also 
indicate that we require an increased sample size. Power calculation based on the 
variance obtained in the experiments showed that group sizes would need to be 25 
mice and 17 mice for effect sizes of 31.3% (axillary LN) and 24% (brachial LN) 
respectively to be detected with 80% power. However, the analysis stage of LN 
proved exhaustive and time-consuming. Nevertheless, B16-invaded areas in the 
draining LN were distinguished using H&E staining and corresponded to invading 
melanoma characteristics in previous studies [454, 455]. Alternatively, we 
attempted to quantify B16 invasion using the faster flow cytometry approach 
(Figure 5.5 and 5.6). Autofluorescence of tumour cells have been reported since the 
1980s and, in 2013, this phenomenon was shown to be partly due to the 
accumulation of the fluorescent vitamin riboflavin [456-458]. Moreover, it was 
identified that the accumulation was strictly cytoplasmic and that riboflavin was 
contained in vesicles coated with ATP-binding cassette sub-family G member 2 
[457]. Our LN and B16 cells were indeed distinguished from each other. Moreover, 
the additional integrin markers (CD49d, CD49f, CD51, and CD29; Figures 5.8 and 
5.9) were tested because dying cells also exhibit autofluorescence [459], making 
autofluorescence not unique to tumour cells. The in vitro results using integrin 
subunits were promising (Figures 5.8 and 5.9) and in vivo experiments would have 
been informative if the model was able to be replicated (i.e. no infectious outbreaks 
among laboratory mice). 
 
6.05 The procoagulative effects of ApoV   
The contribution of tumour vesicles to thrombosis is well described in the 
literature (see Introduction). However, little work has been done directly comparing 
different types of EV, especially MV and ApoV. A strength in our study of MV and 
ApoV was that the technology for two preparations differed with respect to only one 
variable: the inclusion of chemotherapy. Although we were unable to detect TF by 
flow cytometry or proteomics, western blot analysis revealed bands that may 
correspond to glycosylated TF band sizes previously published (Figure 3.5 and ref 
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[313]). It is important to note that the EV were purified in an identical manner for 
both western blot and flow cytometry. However, in flow cytometry and as per bead 
conjugation technical methods, 10 µg of EV were used for bead conjugation and only 
~0.03 µg was used for flow cytometric readings per sample. Therefore, one 
possibility that TF was detected by western blot may be due to that fact that 10 µg 
is used per sample. As for proteomics, trypsin was perhaps not sufficient to digest 
the TF protein into detectable peptides. Nevertheless, further analysis of the 
detected bands for TF is required to confirm that the bands indeed correspond to 
TF. 
We have shown that the procoagulative effects of tumour-derived ApoV were 
significantly hindered upon adding an anti-TF antibody or using a FVII-deficient 
plasma. This emphasised that the procoagulant effects of ApoV is largely dependent 
on TF. Similar results were observed upon blocking PS thereby making TF and PS 
the major players in the procoagulant activity of ApoV. In addition, coagulation by 
ApoV was unchanged with the inclusion of DNase I (Figure 4.10). DNA with histones 
have been reported to trigger coagulation by exposing PS on red blood cells, 
inducing platelet aggregation, causing an influx of Ca2+, and promoting prothrombin 
auto-activation [460-463].  A remarkable finding was that although TF was detected 
in B16 cells (Figure 3.5), the ability to generate fibrin by the cells was significantly 
lower than their derived ApoV (where TF was not detectable). This may be because 
most of the TF molecules on the cells are in an (inactive) encrypted form [229, 464] 
as opposed to ApoV. Moreover, the theory where TF decryption mechanism may be 
due to the presence of high PS (Section D, introduction, and refs [465-467]) may not 
be plausible in our study. In our experiments, B16 dead cells were rich in PS (Figure 
4.1) and their procoagulant activity was significantly reduced when PS was blocked 
(Figure 4.6). Moreover, the fact that the procoagulant activity of most tumour dead 
cells was lower or indifferent to that of live cells can therefore rule out PS as the 
decryption factor for TF. Therefore, the astonishing procoagulant effect of ApoV 
could be due to the small (undetectable) number of decrypted TF molecules. 
Interestingly, studies show that only 3-10 molecules of TF molecules / µm2 are 
sufficient to induce fibrin deposition under flow conditions [468, 469]. Alternatively, 
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failure to detect TF in our EV may also be due to the non-specific binding of isotype 
controls to the bead-conjugated EV, raising background signals and thereby 
masking any specific binding of the anti-TF antibody.  
For our coagulation studies, we utilised the fibrin deposition assay to 
measure the procoagulant activity of samples. Alternatively, we also measured 
thrombin, the converter of fibrinogen to fibrin (Figures 3.14 and 3.15). One 
advantage of using the TGA is that it compares your samples to a known thrombin 
activity, and is therefore wholly quantitative. It is for this reason that generated 
thrombin curves are widely used to identify most clotting deficiencies [470, 471]. 
Moreover, the TGA is ideal to test inhibitors and nearly all clinical anticoagulants. 
For example, if the sample has no AT or protein C, then the generation of thrombin 
will be elevated and/or a derivative test can identify defects sensitive to the protein 
C pathway respectively [472]. Despite the usefulness of the TGA, it was not the ideal 
choice to measure the initial TF-driven clotting time. Santucci et al. found that the 
mean TF clotting time in the blood of healthy individuals was 474 ± 98 s, and 284 ± 
86 s in patients with unstable angina [473]. Therefore, the study suggests that TF-
driven clotting occurs at a relatively faster rate making our FGA to be an ideal 
method for this study. Furthermore, our laboratory has tested murine myeloma 
(plasma cell tumour) NS/0 with NS/0 transfected with TF (NS/0-TF) in a FGA [474]. 
Fibrin generation by NS/0 was negligible, while the NS/0-TF resembled that of the 
B16-derived ApoV, thus further confirming that our optimised FGA responded to TF 
rather than other cellular factors. When 15 µg of ApoV was used to compare the 
ability of ApoV to generate fibrin or thrombin (i.e. FGA or TGA), results showed that 
fibrin generation peaked during the early (initiation) phase of the TGA (Figure 3.14). 
Interestingly, a study showed that histones can promote the generation of thrombin 
[463]. This did not appear to play a major role in our setting since MV and ApoV 
generated more thrombin at a faster rate compared to exosomes (Figure 3.15). One 
conclusion is that the high levels of PS and possibly TF may mask any effects 
contributed by the (histone-rich) exosomes. In addition, the study by Semeraro et 
al. determined that the thrombin generation by histones is platelet dependent [463]. 
Therefore, the fact that we use PPP might ensure that histone-driven mechanisms 
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make only a minor contribution. Nevertheless, this reinforces the idea that EV-
induced coagulation is largely due to TF and PS expression. However, the reason 
why MV generated more thrombin than ApoV and exosomes remains unclear.  
Using different chemotherapy drugs to generate ApoV, we revealed that 
ApoV from gemcitabine and 5FU are also procoagulant (Figure 4.2). 5FU is used for 
the treatment of a wide spectrum of cancers and is known to cause cardiac toxicities 
(e.g. angina, coronary vasospasm, myocardial infraction, and sudden death) among 
patients [475, 476]. Moreover, patients undergoing 5FU therapy can develop a 
hypercoagulable state that causes acute thrombotic events [477, 478]. Interestingly, 
5FU can cause the decline in serum protein C [479, 480], and damage the 
endothelium thus potentially exposing TF to blood [481]. However, how 5FU can 
generate highly procoagulant ApoV compared to doxorubicin and gemcitabine 
remains unknown. Even though 5FU may be present in our ApoV and dead samples, 
only the ApoV (and not dead cells) displayed the superior coagulation (Figure 4.2), 
suggesting a direct link between ApoV and 5FU. The main target of 5FU is the 
inhibition of thymidylate synthase, thereby inhibiting the nucleotide thymidine 
synthesis required for DNA [482]. To confirm if it is indeed the mechanism of action 
that generates such ApoV, the use of another thymidylate synthase inhibitor (e.g. 
Raltitrexed [483]) should be considered for future experiments. Though through a 
different mechanism, gemcitabine is another nucleoside analogue [484], and our 
data showed that gemcitabine-derived ApoV were the least coagulative of the three. 
Nevertheless, a recent meta-analysis by Qi et al. revealed that patients undergoing a 
gemcitabine treatment have the same risk of thrombosis as non-gemcitabine based 
chemotherapy [485]. On the other hand, the widely prescribed chemotherapy drug 
doxorubicin is an anthracycline antibiotic that inhibits the DNA repair mechanism 
of tumour cells [486]. It is due to the high sensitivity of all tumour cells to 
doxorubicin that it was the preferred drug of choice in this research. Our data show 
that compared to 5FU, doxorubicin generated moderately procoagulant ApoV. An 
early study by Fujihira et al. showed a clear link between doxorubicin and atrial 
thrombosis by unknown mechanisms [282]. Recent studies showed that 
doxorubicin can lead to thrombotic complication via many mechanisms such as 
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increasing the procoagulant activity of platelets, downregulation of protein C, and 
increasing TF activity in monocytes and endothelial cells [283, 284, 487]. However, 
it remains to be identified whether chemotherapeutic drugs influence the 
mechanism for ApoV release or if chemotherapy plays a part in decrypting TF on the 
ApoV. Unfortunately, little is known about the latter mechanism.  
After the observation that B16-derived ApoV are the best EV at generating 
fibrin, it was a crucial step to confirm this phenomenon using various tumour cell 
lines. Our data confirmed the procoagulant activity of ApoV generated from a wide 
variety of solid tumour cells lines. Although thrombosis is a common complication 
in solid cancers, there is a controversy amongst the literature on the rate of 
thrombotic events that can affect patients. For example, a meta-analysis by Sallah et 
al. showed only 7.8% of the 1041 patients studied developed thrombosis [488]; a 
much lower statistic than the quoted 10-50% incidences from other published meta-
analyses [489-492]. Sallah et al. then explains that such controversy rises from the 
parameters of choice that describe a clotting event in patients [488]. It is therefore 
important to take note as to the type of thrombotic complications cancer patients 
display. Nevertheless, all the meta-studies show an increased risk to develop a 
thrombotic event despite the nature of the clotting event. And since chemotherapy 
is known to increase the thrombotic rate in patients [275], then it was to no surprise 
that the ApoV tested from many (human and murine) solid tumours generated fibrin 
faster than their cell of origin (Figures 4.2-4.5).  
A review by Rautou and Mackman described that the PS-positive EV are not 
sufficient to elevate the thrombotic risk in patients and, instead, TF-positive EV are 
the key to the elevated risk [493]. This once again enforces the fact that TF-bearing 
tumour-derived ApoV act primarily on the extrinsic (TF) pathway. This goes in 
accordance with the fact that most T and B cell lymphomas do not express TF [494, 
495]. In addition, due to the observed significant coagulative hindrance of the PS-
blocked ApoV, this confirms that both PS and TF are needed to induce the observed 
fibrin generation. Even though lymphomas are blood-born cancers, thrombotic 
complications (especially with chemotherapy) are known to develop among 
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patients [276]. Monocytes and macrophages express TF when activated and 
contribute in wound repair [496]. Therefore, it is no surprise that patients with 
monocytic leukaemia have an increased risk in thrombosis [497]. In fact, compared 
to other cancers, thrombotic events are more frequent in lymphoblastic leukaemia 
patients undergoing chemotherapy [498]. Similar to other cancers, chemotherapy 
does indeed increase that thrombosis risk [273, 499]. Some studies suggest that 
treating some leukaemia cancers with chemotherapy leads to high levels of exposed 
PS and thus subsequently may cause TF decryption [500].  
One human lymphoma tumour cell line that we were only able to analyse was 
the (T cell) Jurkat lymphoma. The data indicated that Jurkat-derived ApoV are most 
likely to be TF-bearing and resemble that of the solid tumour-derived ApoV we 
tested. Moreover, the procoagulant activity by Jurkat-derived ApoV may be 
enhanced via a platelet-induced mechanism [292]. P-selectin glycoprotein ligand-1 
(PSGL-1) is a protein expressed in all white blood cells [501] and interestingly, only 
PSGL-1-positive MV can bind to platelets [292]. It would be of interest to perform a 
FGA on Jurkat-derived ApoV using a platelet-rich plasma ± an inhibitor to PSGL-1. In 
contrast, the murine EL4 T cell lymphoma lacked detectable procoagulant activity 
(Figure 4.4D). There are no records showing that EL4 cells express TF and the lack 
of procoagulant activity by EL4 remains to be compared to other murine lymphoma 
cell lines.  
Since we established that ApoV trigger the coagulation cascade, we next 
determined the coagulation factors required for the procoagulant activity to give 
further insight into the mechanisms of the procoagulant activity of tumour-derived 
ApoV (Figure 4.7). In addition to further proving the importance of the extrinsic 
pathway (FVII-deficient), the procoagulant activity of ApoV was not significantly 
suppressed when the intrinsic coagulation factors VIII and FIX were absent. 
Therefore, our findings show that the intrinsic pathway is dispensable for the 
procoagulant activity of tumour-derived ApoV. In fact, in some experiments, fibrin 
deposition by tumour-derived ApoV was slightly elevated in FVIII- and FIX-deficient 
plasmas. Reasons for this remains unknown and inconsistencies in statistical 
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significance made it more difficult to interpret and draw firm conclusions from the 
data. In addition, the manufacturer does not guarantee the depletion of more than 
99% of coagulation factors in the factor-depleted PPP. Since FIX can bind to TF at 
higher affinity than FX [502, 503], it is possible that FIX competes with FX for TF 
interaction, thereby slowing down the formation of the prothrombinase complex in 
early coagulation stages (Figures 1.5 and 1.6).  In light of this, our laboratory 
investigated the FIX phenomenon further by testing ApoV in a FGA using FIX-
deficient plasma with the inclusion of 1, 5, or 25 µg/mL FIX [504]. Significance was 
not reached but there was a small reduction in fibrin deposition when 25 µg/mL of 
FIX was supplemented.  
We then directed the study towards the importance of 'endogenous' FV in the 
procoagulant activity of tumour-derived ApoV (Figures 4.11, and 4.12). FV is a 
critical factor for the prothrombinase complex (FVa:FXa:FII; Figure 1.5, 
introduction). However, we (Appendix A) and previous studies have detected FV in 
tumour-derived EV by mass spectrometry [319-321]. Due to the revelation of the 
origin of FV being bovine by mass spectrometry, it was necessary to test if FV 
contributed to the fibrin generation activity by ApoV. Using ApoV stimulated in the 
absence of serum proved that although present, FV was dispensable for the 
procoagulant activity of tumour-derived ApoV (Figure 4.12). An early study claimed 
that bovine aortic endothelium cells can synthesise FV if cultured in vitro [505]. The 
study cultured the bovine samples using FCS and concluded (without the use of a 
SFM) that the aortic-derived FV was not functional, thus strongly suggesting that the 
FV was due to FCS contamination as shown in our study.  Interestingly, ApoV that 
were prepared for mass spectrometry were subjected to differential 
ultracentrifugation, sucrose cushion, and dialysis purification. Which suggests that 
tumour-derived ApoV provide a favourable strong binding site for FV likely due to 
their PS-rich nature (Figure 3.5 and ref [506]). This mechanism strongly mimics the 
binding of activated platelets to FV/FVa in the blood [507, 508]. Therefore, this 
ability strongly implicates ApoV to potentially be prothrombotic in chemotherapy 
patients by playing a role in the formation of the prothrombinase complex.  
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6.06 TF and metastasis 
Depending on where ApoV are released in the body, their effects could be 
different. For example, when ApoV were injected s.c., they protected against cancer 
unlike their intravenous injection which immediately caused thrombotic shock in 
the mice, unless heparin was included in the preparation (data not shown). The 
presence of TF on ApoV may contribute to metastasis, since TF-mediated 
coagulation aids cancer progression [509, 510]. In 1995, Bromberg et al. engineered 
a human melanoma cell line to express high TF then mutated the transmembrane 
region of the TF molecule to inhibit TF from initiating coagulation [509]. 
Interestingly, despite the inability of the extracellular mutant to initiate coagulation, 
metastasis was enhanced – suggesting a coagulation-independent role for 
metastasis by TF. Later studies suggested that the formation of the TF:FVIIa complex 
was necessary to induce metastasis via the inhibition of apoptosis, promoting cell 
adhesion, and angiogenesis [511-513]. With the addition that metastatic tumour 
cells can upregulate TF up to ~1000-fold compared to non-metastatic cells [514], TF 
can be considered as a potent pro-metastatic molecule. Therefore, the expression of 
TF in ApoV marks them not only as potential thrombotic, but also, as paradoxically 











6.07 Overall Conclusion and Future Directions 
We have focused on the least appreciated type of EV, ApoV. We demonstrated 
that ApoV could play a major role in tumour biology. Currently, it is a routine to give 
high thrombosis-risk patients anti-platelet or general anti-coagulant therapy [515, 
516]. Despite the fact that it lowers fatalities due to thrombotic complications, 
suppressing the coagulation cascade can result in excessive bleeding in patients 
[517]. Therefore, there is a pressing need to efficiently lower thrombotic risk, whilst 
minimising bleeding in cancer patients. Although chemotherapy kills tumour cells, 
dying tumours release numerous ApoV that may significantly elevate the thrombotic 
risk in cancer patients. This research clearly showed that tumour-released ApoV are 
strongly procoagulative. It remains to be identified, however, if radiotherapy-
induced ApoV behave similarly to the ApoV tested in this research. We have yet to 
also see if that procoagulant activity is similar under flow conditions. In addition, 
designed in vivo experiments with ApoV and coagulation would further elucidate the 
procoagulative activity of tumour-derived ApoV. Nevertheless, we propose that if 
the TF on ApoV is specifically inhibited, it will lead to a better prognosis for cancer 
patients with high risk of thrombosis. It is necessary, however, to develop a TF-
inhibitor that targets ApoV without altering the endogenous TF of the host. Such 
development requires the identification of a unique surface marker on tumour-
derived ApoV that would act as a secondary target “safety lock” of the TF inhibitor. 
We did not, however, discover a unique marker for B16-derived ApoV, but rather a 
variance in protein-expression profile. This therefore does not rule out the 
possibility that ApoV-derived from other tumour cells indeed possess unique 
markers. In future, the analysis of the three EV types should be focused on the 
proteins involved in their unique mechanism of release. For example, the endosomal 
sorting complexes required for transport (ESCRT) machinery is exclusive to 
exosome release and ESCRT I, II, and III have been used before to confirm the purity 
of the exosome fraction [111, 518]. The exact machinery involved in MV and ApoV 
release is not entirely understood and thus provides a challenge to identify and 
distinguish MV from ApoV. Although the MLC protein is required for the release of 
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MV and ApoV, a clear understanding of the initiation and formation of MV and ApoV 
remains to be identified [167, 519].  
 In addition, repeating certain experiments blinded should be considered. 
For example, in prophylactic vaccination studies, the manual measurement of the 
tumours should be done blinded. A similar scenario is observed with the 
measurement of the three vesicles using cryo-EM images; perhaps the use of an 
independent user for measurements could be considered. 
This research also revealed a potential use of ApoV for vaccination against 
cancer. Currently, exosomes have been the centre of focus as a utility therapeutic 
vaccines. For example, two phase 1 clinical trials have been carried out using DC-
derived exosomes from patients with either advanced melanoma or non-cell lung 
carcinomas (expressing melanoma-associated antigens; MAGE) [520]. The 
exosomes were loaded with MAGE. Although an anti-tumour response was observed 
in most patients, only 50% and 33% of the melanoma and lung patients, 
respectively, showed stabilisation of the disease [520]. In another phase 1 clinical 
trial, colorectal carcinoma-derived exosomes from patients have been loaded with 
the carcinoembryonic antigen (CEA) [521]. Although minor clinical benefits were 
observed in only 10% of the patients, there was a CEA-specific CTL response in 75% 
of the patents [521]. Thus, exosomes have not yet reached a satisfactory level for 
their therapeutic benefit which opens a door for the use of ApoV. The mechanisms 
of ApoV to induce superior immunogenicity against cancer remains to be elucidated. 
An investigation in cancer-derived ApoV immunogenicity has a potential to improve 
EV-based therapy against cancer. 
Furthermore, the number of studies and their findings on circulating EV in 
cancer patients remains controversial. There is, however, a growing consensus that 
cancer patients display an increased level of circulating EV in their blood, and the 
level of EV detected in patients may be directly proportional to disease progression 
[344, 522-525]. Although the EV isolated from cancer patients display 
prometastatic, angiogenic, and/or procoagulant markers [341, 526, 527], it remains 
difficult to identify and distinguish the subsets of the isolated EV, especially between 
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ApoV and MV. Exosomes are relatively smaller than MV and ApoV, therefore patient-
derived exosomes are easier to be characterised [528]. Since the yield of ApoV is 
highest upon chemotherapy treatment, one would hypothesise that isolating and 
analysing ApoV from chemotherapy patients may be informative for patients’ 
prognosis. It is therefore required to develop techniques that can rapidly 
characterise tumour-derived ApoV isolated from patients. 
Finally, there was no significance in the effect of CD169 in tumour growth 
and metastasis, further experiments are advised. More specifically, the flow 
cytometric approach to quantify metastasis in LN ought to be revisited in an 
appropriate in vivo setting. In addition, polymerase chain reaction can be used to 
differentiate lymph node cells from B16 cells using B16-specific gene markers such 
as  PMEL [388]. 
Overall, this research has demonstrated that tumour-released EV play 
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Supplementary Table S1: Full proteomic analyses of B16-derived extracellular vesicles Sucrose cushion purified B16F1-
derived apoptotic vesicles (ApoV), microvesicles (MV), and exosomes (Exo) were subjected to mass spectrometry and data 
processed and searched against the mouse reference sequence database using the MASCOT, Sequest HT, and MS Amanda search 
engines. The TOP3 precursor ion intensities [69] of the highest 553 protein intensities identified using the Proteome Discoverer 
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AbstrAct
Extracellular vesicles (EV) are lipid particles released from eukaryotic cells into 
the extracellular fluid. Depending on the cell type or mechanism of release, vesicles 
vary in form and function and exert distinct functions in coagulation and immunity. 
Tumor cells may constitutively shed vesicles known as exosomes or microvesicles 
(MV). Alternatively, apoptosis induces the release of apoptotic blebs or vesicles 
(ApoV) from the plasma membrane. EV have been implicated in thrombotic events 
(the second highest cause of death in cancer patients) and tumor vesicles contribute 
to the anti-cancer immune response. In this study, we utilized the well characterized 
B16 melanoma model to determine the molecular composition and procoagulant 
and immunogenic potential of exosomes, MV and ApoV. Distinct patterns of surface 
and cytoplasmic molecules (tetraspanins,  integrins, heat shock proteins and 
histones) were expressed between the vesicle types. Moreover, in vitro coagulation 
assays revealed that membrane-derived vesicles, namely MV and ApoV, were more 
procoagulant than exosomes–with tissue factor and phosphatidylserine critical for 
procoagulant activity. Mice immunized with antigen-pulsed ApoV and challenged 
with B16 tumors were protected out to 60 days, while lower protection rates were 
afforded by MV and exosomes. Together the results demonstrate distinct phenotypic 
and functional differences between vesicle types, with important procoagulant 
and immunogenic functions emerging for membrane-derived MV and ApoV versus 
endosome-derived exosomes. This study highlights the potential of EV to contribute 
to the prothrombotic state, as well as to anti-cancer immunity.
IntroductIon
Extracellular vesicles (EV) are lipid bilayer-
enclosed particles released by most mammalian cell 
types [1, 2]. The biological roles attributed to EV are 
ever-increasing, placing EV research as a dominant field 
within immunology, hematology and cancer cell biology. 
Depending on their cell of origin, EV differ in protein and 
lipid composition, buoyant density, and biochemical and 
structural properties [1–3]. In addition, mechanisms of 
their formation and release from parental cells are crucial 
parameters for the classification of EV [3–5]. Together 
with expanding knowledge in the field of EV research, 
controversies have arisen concerning the diversity and 
the physiological relevance of circulating EV [2]. For 
example, the number and type of circulating EV, their 
half-lives in biological fluids, and the roles of vesicles in 
thrombosis and cancer progression are still hotly contested 
[6–10].
Exosomes, one of the smallest EV fractions, 
are released from a large spectrum of living cells 
and typically range from 50–200 nm in diameter 
[1–3]. The inward budding of cell membranes inside 
intracellular endosomes leads to the formation of 
                   Research Paper
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multi-vesicular bodies (MVB) which can then fuse 
with the cell membrane to release exosomes [1, 2]. A 
larger fraction of EV (100–1000 nm diameter), directly 
shed from the surface of a healthy cell’s membrane, 
are the microvesicles (MV) [1, 11]. Cells undergoing 
apoptosis are also known to release different types of 
EV that may range from 0.1–5 μm in diameter [12, 13]. 
The apoptotic fractions of EV that share a similar size 
range to MV, termed apoptotic vesicles (ApoV), display 
immunogenic activity [11, 14, 15]. Unlike exosomes, MV 
and ApoV are generated by the outward budding of the 
plasma membrane facilitated by the externalization of 
membrane phosphatidylserines (PS) [11, 16]. 
While EV release from primary cells may require 
activation, transformation, immortalization, or the 
initiation of cell death, most tumor cell lines studied 
constitutively release EV [4, 12, 17–28]. Tumor-derived 
EV are well known for their diverse biological functions, 
including immune suppression/activation, angiogenesis, 
tumor metastasis [20, 29–32], and are additionally 
implicated in triggering the coagulation cascade 
[10, 33, 34]. Moreover, tissue factor (TF) expression 
and PS exposure contributes to EV procoagulant activity 
[10, 23, 34, 35]. The four-fold increased risk of developing 
venous thromboembolism (VT) in cancer patients may be 
linked to the formation of tumor, or normal host tissue-
derived EV [36, 37]. In particular, the fact that this risk 
is increased to around six-fold in patients receiving 
chemotherapy implicates tumor-derived ApoV [38]. 
However, the pathogenicity of chemotherapy-associated 
thrombosis remains poorly understood. Our study set 
out to clarify the phenotype of EV released from a well 
characterized tumor cell line, to investigate the potential 
for EV types to contribute to cancer-induced thrombosis 
and anti-cancer immunity. Of these vesicles, ApoV 
generated following the exposure of a tumor cell to 
chemotherapy are the least studied tumor-derived EV. 
Using murine B16 melanoma as a model, we 
compared and characterized exosomes, MV, and ApoV, 
with respect to their size, morphology, molecular 
composition, and their ability to induce coagulation and 
immunity. We generated a distinguishable expression panel 
for the three EV fractions using various parameters such as 
tetraspanins, integrins, sialic acids, PS, heat shock proteins 
and histones. Importantly, we show that ApoV are released 
in greater quantities from dying cells compared to MV 
and exosomes from living cells. Membrane-derived EV 
(i.e. MV and ApoV) were superior at triggering thrombin 
and fibrin production via the extrinsic TF pathway of the 
coagulation cascade. Antigen-pulsing experiments showed 
that ApoV represent the most immunogenic fraction of 
EV and were able to provide long term protection of mice 
against B16 tumor challenge. 
results
Purification and sizing of EV
We first visualized purified B16-F1-derived EV 
using cryo-electron microscopy (cryoEM; Figure 1A –1C; 
exosomes composite image). As shown in Figure 1D, 
exosomes were the smallest of vesicles exhibiting a 
diameter range of 51–478 nm (geometric mean; GM 135.5 
nm ± 65.5 SD), MV had a range of 67–677 nm (GM 210 
nm ± 114 SD), and ApoV had a range of 103–816 nm 
(GM 330 nm ± 147 SD). Similar values were determined 
using dynamic-light scattering (DLS): exosomes; range 
of 78–164 nm (GM 117.4 nm ± 32 nm); MV range 
122.4–459 nm (GM 258.6 nm ± 112.8 SD), and ApoV 
220–531 nm (GM 357 nm ± 112.1 SD; Figure 1E). 
The yield of ApoV, as determined by protein, was 
consistently higher than the other EV per mL of culture 
fluid (Figure 1F). 
Mass spectrometry and flow cytometry reveal 
a distinguishable panel for ApoV, MV, and 
exosomes
To further characterize B16-F1-derived EV, we 
analyzed their surface for a number of proteins including 
tetraspanins, adhesion molecules such as integrins 
and CD44, sialic acids, and the clotting factors TF and 
PS by flow cytometry (Figure 2A). Sucrose cushion-
purified exosomes, MV and ApoV were dialyzed (10,000 
Da cut off) and analyzed by mass spectrometry using 
a LTQ Orbitrap XL mass spectrometer (Table 1 and 
Supplementary Table 1). As illustrated in Figure 2D, EV 
differed in the abundance of a number of proteins, with 
particular enrichment of histones and heat shock proteins 
in exosomes, as compared to MV and ApoV. Notably, the 
ten most abundant ion scores in exosomes included the 
histones (H2A, H2B, H3.1 and H4), heat shock proteins 
(GRP78 and HSC71) and the tetraspanin CD81. Only 
ApoV showed enrichment for the melanoma tumour-
associated antigen PMEL (Figure 2D and Supplementary 
Table 1). The raw data for the total 553 proteins identified 
by mass spectrometry are represented in Supplementary 
Table 1. By both flow cytometry and mass spectrometry, 
ApoV showed low expression of the tetraspanin protein 
CD9, while MV exhibited intermediate CD9 expression 
and exosomes the highest CD9 expression. All three EV 
were positive for the tetraspanin protein CD81 (Figure 
2A), but with higher CD81 ion intensities obtained for 
exosomes, as compared to MV and ApoV (Table 1). 
In terms of integrin molecules, EV did not express 
detectable αV subunits. Exosomes showed the highest 
expression for the α4 subunit followed by MV, then ApoV. 
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The β1 integrin subunit was highest in MV followed by 
exosomes, then ApoV (Figure 2A and Supplementary 
Table 1). While low levels of α6 were detected in all 
three vesicles, MV showed the highest expression for 
α6 (Figure 2A and Supplementary Table 1). Although 
positive, no differences in CD44 expression levels were 
detected between the three EV. All three EV showed high 
level sialic acid expression, which may contribute to the 
capture of extracellular vesicles in lymphoid tissue [39]. 
ApoV showed the highest level of PS expression followed 
by MV, then exosomes. Because the levels of TF were 
below the detectable limit for three EV, we confirmed 
the functionality of the TF-specific polyclonal antibody 
by labeling TF-transfected EL4, as well as the parental 
B16-F1 line, in the presence or absence of soluble TF-Fc 
protein. The results showed detectable TF expression on 
EL4-TF and parental B16-F1 cells and the specificity of 
the labeling was demonstrated by a loss in binding of 
the antibody to cells in the presence of excess, soluble 
TF-Fc protein (Figure 2B). The vesicular nature of our 
preparations was confirmed by the presence of CD147 and 
the coat protein clathrin by western blot and proteomic 
analysis. As expected from previous reports [25, 26, 40], 
there was a preferential association of CD147 and clathrin 
with vesicles, as compared to the B16 parental cell line 
(Figure 2C, Table 1 and Supplementary Table 1).
Fibrin generation potential of EV
Since tumor-derived EV have been implicated 
in cancer-related thrombosis, we next determined the 
procoagulant potential of the three types of EV using 
a fibrin generation assay (Figure 3A). ApoV generated 
significantly more fibrin as compared to MV and exosomes. 
Based on normalized protein content, exosomes were the 
least coagulative of the EV types. Despite the inability to 
detect TF by flow cytometry (Figure 2A), the activity of 
procoagulant ApoV was inhibited by anti-TF antibody and 
annexin V (Figure 3B). Furthermore, the importance of TF/
extrinsic pathway, was confirmed using coagulation factor 
VII depleted (FVII-) plasma (Figure 3C).
Density fractionation of ApoV
To rule out that contaminating macromolecules were 
contributing to the procoagulant activity of melanoma 
Figure 1: Cryo-electron microscopy, size range and yield of B16-F1-derived vesicles. (A) Exosomes (Exo), (b) microvesicles 
(MV) or (c) apoptotic vesicles (ApoV) were purified by differential centrifugation of cell supernatant from live or doxorubicin-treated 
B16-F1 cells and extracellular vesicles (EV) visualized by cryo-electron microscopy. Original magnification ×20,000. Bars represent 20 nm 
(for Exo), and 100 nm (for MV and ApoV). Diameter of all three vesicle types determined by (d) cryo-electron microscopy (n = 150 vesicles) 
with a bin width of 5 nm and by (e) dynamic light scattering. (F) Yield of Exo, MV, and ApoV per mL of tissue culture; error bars represent 
mean ± SD. One-way ANOVA with Bonferroni post-correction test performed: ns = not significant; **P < 0.01, ***P < 0.001. Results are 
representative of three experiments.
Oncotarget56282www.impactjournals.com/oncotarget
Table 1: Proteomic analyses of B16-derived extracellular vesicles (top 50 scores)
Accession (gi) Protein Description Exo MV ApoV
568893484 histone H4 3.37 0.14 0.08
31981690 heat shock cognate 71 kDa protein  2.70 0.22 0.09
28316760 histone H2B type 1-B  2.49 0.10 0.05
256773209 histone H2A.V  2.14 0.08 0.03
254540166 78 kDa glucose-regulated protein precursor  1.87 0.12 0.06
755495449 immunoglobulin superfamily member 8 isoform X1  1.42 0.14 0.06
148277591 syntenin-1 isoform 2  1.41 0.10 0.02
755502152 LOW QUALITY PROTEIN: uncharacterized protein LOC105244409  1.27 0.15 0.01
30061339 histone H3.2  1.25 0.04 0.00
19526794 CD81 antigen  1.20 0.11 0.06
755490905 LOW QUALITY PROTEIN: ubiquitin-40S ribosomal protein S27a-like isoform X1  1.01 0.20 0.08
6671509 actin, cytoplasmic 1  1.00 1.00 1.00
149273202 glyceraldehyde-3-phosphate dehydrogenase  1.00 0.42 1.30
568901980 MLV-related proviral Env polyprotein-like  0.99 0.22 0.06
755511141 MLV-related proviral Env polyprotein  0.98 0.21 0.06
755496111 LOW QUALITY PROTEIN: uncharacterized protein LOC105244006  0.79 0.44 0.06
16716569 protease, serine, 1 precursor  0.68 0.45 0.41
51491845 clathrin heavy chain 1  0.50 0.07 0.10
6755901 tubulin alpha-1A chain  0.46 0.12 0.26
6679439 peptidyl-prolyl cis-trans isomerase A  0.43 0.09 0.16
258547156 programmed cell death 6-interacting protein isoform 3  0.41 0.04 0.01
6680297 dnaJ homolog subfamily A member 1  0.40 0.01 0.00
45504394 integrin beta-1 precursor  0.39 0.12 0.08
7106439 tubulin beta-5 chain  0.38 0.09 0.17
568907654 tubulin alpha-4A chain isoform X1  0.37 0.12 0.20
126032329 elongation factor 1-alpha 1  0.35 0.20 0.43
171846253 transmembrane glycoprotein NMB precursor  0.34 0.02 0.06
21450277 sodium/potassium-transporting ATPase subunit alpha-1 precursor  0.33 0.32 0.26
568960833 pyruvate kinase PKM isoform X1  0.32 0.11 0.28
755509256 alpha-enolase isoform X1  0.31 0.10 0.18
22165384 tubulin beta-4B chain  0.30 0.05 0.12
13430890 histone H1.4  0.30 0.01 0.00
269914154 uncharacterized protein LOC239673  0.29 0.05 0.03
238637279 4F2 cell-surface antigen heavy chain isoform b  0.28 0.24 0.15
114326554 integrin alpha-4 precursor  0.28 0.06 0.04
226874906 14-3-3 protein epsilon  0.27 0.06 0.05
6677813 40S ribosomal protein S8  0.25 0.02 0.01
6753060 annexin A5  0.24 0.08 0.23
9845257 histone H1.2  0.24 0.02 0.00
755550334 14-3-3 protein zeta/delta isoform X1  0.23 0.05 0.05
9789937 dnaJ homolog subfamily A member 2  0.23 0.02 0.01
6680744 sodium/potassium-transporting ATPase subunit beta-3  0.23 0.18 0.16
116014342 basigin isoform 2 precursor  0.22 0.22 0.16
568917832 14-3-3 protein beta/alpha isoform X1  0.21 0.04 0.05
755506225 CDK5 regulatory subunit-associated protein 2 isoform X10  0.20 0.04 0.05
31543976 14-3-3 protein gamma  0.20 0.05 0.05
6756037 14-3-3 protein eta  0.19 0.04 0.05
17647499 hemoglobin subunit beta-2  0.19 0.04 0.07
60687506 fructose-bisphosphate aldolase C  0.19 0.09 0.10
568962761 guanine nucleotide-binding protein G(i) subunit alpha-2 isoform X1  0.19 0.11 0.06
Sucrose cushion purified B16F1-derived apoptotic vesicles (ApoV), microvesicles (MV), and exosomes (Exo) were subjected 
to mass spectrometry and data processed and searched against the mouse reference sequence database using the MASCOT, 
Sequest HT, and MS Amanda search engines. The TOP3 precursor ion intensities [69] normalised to β-actin of the highest 
50 protein intensities present in the exosome samples are represented for all EV types. Additional proteomic data for the total 
553 proteins identified in the three EV types are shown in Supplementary Table 1.
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EV, we further purified the highly procoagulant ApoV 
fraction using a 30% sucrose/D2O cushion and assayed 
fractions by fibrin generation assay (Figure 4A). Only 
the ρ ≤ 0.21 g/ml interface exhibited procoagulant 
activity making it unlikely that non-vesicle associated 
proteins, polyphosphates or nucleic acids contributed 
to the observed fibrin generation initiated by ApoV. We 
next subjected ApoV to a continuous sucrose gradient 
and tested different density fractions for fibrin generation 
(Figure 4B). Although there was some heterogeneity 
within the coagulative ApoV fractions, the 1.12–1.15 g/
cm3 density range encompassed the most procoagulant 
fractions. 
Thrombin generation potential of EV
To further confirm the procoagulant ability of the 
three B16-F1-derived EV types, we subjected purified 
vesicles to the thrombin generation assay (TGA; 
Figure 5A). Although results indicate that ApoV and 
MV were faster than exosomes at generating thrombin, 
significance between samples was not seen (Mean lag 
time: ApoV 15.89 min ± 1.34 SD; MV 15.89 min ± 
0.16 SD; exosomes 20.22 ± 4.96 SD). Similar to our 
fibrin generation assay (Figure 3), thrombin generation 
was retarded for all EV by the inclusion of neutralizing 
anti-TF antibody in the TGA (Figure 5B). To ensure 
that phospholipid was not limiting for the activity of 
TF, we supplemented the reaction with phospholipid 
microparticles (MP; Figure 5C and 5D). Although only 
a small decrease in lag time to peak thrombin production 
was noted following the addition of phospholipid, 
blocking TF in the presence of excess MP significantly 
reduced thrombin generation capability of ApoV.
Anti-cancer responses induced by EV 
To determine if the three EV types could play a 
role in inducing immunity against the B16 tumor we 
first immunized mice subcutaneously (s.c.) with EV 
Figure 2: Surface expression comparison of B16-F1-derived vesicles using flow cytometry. (A) Vesicles conjugated to aldehyde-
sulfate microspheres were analyzed by flow cytometry using biotinylated (bio) antibodies for the indicated tetraspanins, adhesion molecules, 
and clotting factors; bio-annexin V for phosphatidylserine (PS) and goat anti-mouse tissue factor (TF). (b) TF expression on B16-F1 cells, 
EL4, or TF-transfected EL4 (EL4-TF) as analyzed by flow cytometry. Soluble TF (sTF) was used to neutralise the anti-TF polyclonal antibody. 
Biotin was detected using streptavidin-allophycocyanin (SA-APC), and TF was detected using rabbit anti-goat IgG Alexa Fluor® 594. Grey 
shaded peaks represent BSA-bead control, goat IgG control for TF bead samples; black lines represent EV-beads or cells; dotted lines represent 
TF antibody neutralized cells. (c) Vesicle lysates were subjected to PAGE and Western blotted with goat anti-mouse CD147 (detected with 
anti-goat IgG-horse radish peroxidase (HRP), mouse anti-mouse clathrin heavy chain, and mouse anti-mouse β actin IgG-HRP (detected with 
anti-mouse IgG-HRP). MW in kDa are shown. Results are representative of at least two experiments. (d) TOP3 precursor ion intensities [69] 
normalised to β-actin (y-axis) are represented in rank order (x-axis) in the exosome proteome for the three vesicle types.
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derived from B16-ovalbumin (B16-OVA) in the flank. 
We then challenged all mice, seven days later, with 
B16-OVA cells at the opposite flank. Although the B16-
OVA cell line expresses ovalbumin at sufficient levels 
to act as a surrogate tumor antigen for protection in 
ovalbumin-vaccinated  mice [41, 42], no protection was 
observed when exogenously supplied ovalbumin was 
omitted from the vaccine B16-OVA ApoV preparations 
(data not shown). B16-OVA cells were therefore treated 
with additional soluble ovalbumin (200 µg/ml) prior to the 
isolation of vesicles. Mice immunized with OVA-pulsed 
ApoV showed the highest protection with only one mouse 
developing a B16-OVA tumor that reached maximum 
size at day 69 (Figure 6A–6B). This level of protection 
was followed by the mice immunized with OVA-pulsed 
MV, where three mice reaching maximum tumor size 
at days 36, 46, and 57. All mice immunized with OVA-
pulsed exosomes reached maximum B16-OVA tumor 
sizes at 16, 22, 28, 36, and 44 (Mantel-Cox analysis; 
MV vs. exosomes: P < 0.0022; ApoV vs. exosomes: 
P < 0.0005; ApoV vs. MV; no significance). Surprisingly, 
the weakly protective exosomes contained a greater 
quantity of ovalbumin, as compared to MV and ApoV 
(Figure 6C). Therefore, the superior protection afforded 
by ApoV was not a result of enhanced ovalbumin loading 
into this EV subtype.
dIscussIon
EV released from living and dying tumor cells 
contribute to the outcome of cancer progression in the 
host. For example, EV have been proposed to induce a 
pre-metastatic niche for cancer metastasis [4, 20, 22, 43] 
and contribute to thrombotic events, such as pulmonary 
Figure 3: Fibrin generation assays comparing B16-F1-derived EV. Equal amounts of purified EV (15 µg) were added to platelet-
poor plasma (PPP) supplemented with CaCl2 to initiate coagulation. Fibrin generation was monitored at 405 nm until the negative control 
(PBS) started to generate detectable fibrin. (A) Fibrin generation induced by B16-F1-derived ApoV, MV, and Exo. (b) Fibrin generation 
assay of ApoV with inclusion of 20 µg/mL anti-mouse TF or 100 µg/mL annexin V (AV) to block PS. (c) Fibrin generation assay of ApoV 
using factor VII depleted plasma (FVII-) and commercial PPP (Ctr). Error bars represent mean ± SD. One-way ANOVA with Bonferroni post-
correction test performed on the area under the curves (AUC): ns = not significant; *P < 0.05, **P < 0.01; ***P < 0.001, ****P < 0.0001. 
Samples were loaded in triplicate. Results are representative of at least three experiments.
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embolism deep vein thrombosis in cancer patients 
[10, 21, 33, 34, 36–38, 44]. EV-associated TF is 
responsible for the prothrombotic effect of EVs in a mouse 
model of thrombosis [34]. Less well studied is the role of 
tumor-derived EV in the induction of immune responses 
to the tumor itself. 
Our results offer clarity of the distinction 
between vesicles released from the endosome and 
plasma membrane both from living cells and under 
chemotherapeutic stress. The murine B16 cell line was 
chosen for this study as it is the most frequently used 
syngeneic tumor mouse model studied and recapitulates 
features of human melanoma including immune 
suppression and metastasis, and a variable response to 
immunotherapy [45]. 
Our study identified distinct morphological and 
phenotypic features of EV. Exosomes, the smallest 
vesicle type analyzed, displayed a similar size range 
to those previously reported for the B16 cell line [46]. 
ApoV displayed the largest size and greatest range in 
diameter, as compared to MV and exosomes (Figure 1). 
B16 melanoma-derived ApoV were significantly larger 
than ApoV released from the EL4 lymphoma cell line, 
as determined in our recent study [14], demonstrating 
that parental cell type may predetermine certain physical 
attributes of EV. DLS generates a monomodal distribution 
and the software assumes that particles are spherical and 
non-aggregated, while the cryoEM sizing technique 
employed was simple diameter measurement of individual 
vesicles at the widest point. While a small difference in 
vesicle sizing was noted between the DLS and cryoEM 
techniques, the geometric means were in fact quite similar. 
The reason for the size difference between the two plasma 
membrane-derived EV (MV and ApoV) is not entirely 
clear, but likely relates to caspase activation during the 
apoptotic response to doxorubicin. The mechanism of 
release of MV and ApoV are thought to be fundamentally 
similar, starting with asymmetric redistribution of 
membrane phospholipids, including the translocation 
of phosphatidylserine to the outer leaflet, followed by 
the budding process via actin-myosin interactions [11]. 
However, in apoptotic vesicle formation, actin-myosin 
interactions are dependent on caspase cleavage of Rho-
associated kinases 1 (ROCK1) which in turn phosphorylates 
the myosin light chain for bleb expansion [47]. 
Phenotypically, major distinctions in terms of 
molecular profiles were noted between membrane-derived 
(MV and ApoV) vesicles as compared to exosomes. 
Melanoma exosomes were strikingly enriched in histones 
and heat shock proteins, as compared to the other two EV 
types. Remarkably, this finding is similar to an earlier 
comparison of apoptotic vesicles and exosomes released 
from mouse dendritic cells, and is also consistent with 
the exosome proteome of human dendritic cells [5, 12] 
or murine and human melanoma-derived exosomes [43, 
48]. Historically, the histone content of EV was thought 
to be via contamination with apoptotic bodies [12]. 
However, histones are present in both cytoplasmic and 
nuclear pools [49] and frequently appear in exosome 
preparations [5, 12, 43, 48]. Furthermore, we consider 
that contamination of apoptotic vesicles into our exosome 
preparations was quite unlikely for the following reasons: 
(i) our exosome preparations were pre-depleted of cells, 
debris and MV using sequential 450 × g, 3200 × g and 
25,000 × g steps then filtered through a 0.2 µm filter and 
floated over a sucrose/D2O cushion prior to dialysis, and 
Figure 4: Fibrin generation assays of sucrose purified B16-F1-derived ApoV. Following differential centrifugation, B16-F1 
ApoV were further purified using sucrose gradients. The fractions (F1–14) were tested for in the fibrin generation assay, monitoring 
absorbance at 405 nm for 500 s. (A) ApoV purified in a 30% sucrose cushion/D2O. Arrow indicates the 0.21 g/cm
2 interface of the sucrose 
cushion. Vesicle-free 30% sucrose/D2O was used as a control (Ctr); error bars represent mean ± SD. (b) ApoV purified by a linear sucrose 
gradient. For each experiment, 20 µL of each fraction was assayed. Results are representative of two experiments.
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(ii) histones were present in the MV or ApoV fraction at 
ion intensities at least 20–65 fold lower than exosomes 
(Supplementary Table 1). It is surprising, given the highly 
positive charge of histones, that more links have not 
been investigated between the RNA and histone cargo of 
exosomes. We suggest that the enrichment of histones in 
exosomes may reflect a chaperone role histones for the 
nucleic acid content of exosomes [1, 2] and it is likely 
that RNA-histone interactions will become an active area 
of future research. Indeed, a direct association of miRNA 
and histones has been reported for breast cancer cell line-
derived exosomes [50] and histone H3 modification was 
suggested to be essential for exosome release [51]. 
In cancer patients, tumor vesicles have been 
implicated in thrombosis, metastatic spread and immune 
suppression [10, 20–22, 25, 29, 33, 37, 38, 43, 44]. Our 
investigation into the relative procoagulant activity of 
vesicles revealed a superior ability of ApoV to induce 
fibrin generation in platelet poor plasma, compared to 
MV and exosomes. However, in the TGA, the difference 
between ApoV and MV was less marked and failed 
to reach significance. Nevertheless, in both the fibrin 
generation and TGA, the plasma membrane-derived ApoV 
and MV displayed higher levels of procoagulant activity 
compared to exosomes. Although the fibrin generation 
and TGA differ dramatically in duration (approximately 
8 min vs. 25 min to peak fibrin or thrombin respectively) 
the same pattern was observed; MV and ApoV were more 
procoagulant than exosomes (Figures 3 and 5). It should be 
noted that that fibrin clot time precedes the peak thrombin 
production, with < 1% of total thrombin production 
required for clot formation [49, 52]. Interestingly, although 
extracellular histones have been shown to enhance 
thrombin generation in platelet-poor plasma, exosomes, 
which contained the highest content of histones, were the 
least procoagulant of the three EV types [53].
Despite the fact that EV TF was below the detectable 
limit on EV analyzed by flow cytometry (Figure 2), 
we were nevertheless able to show its importance by 
neutralization of TF function, or by removing its critical 
ligand FVII / FVIIa in our fibrin generation assay (Figure 3B 
and 3C). Fibrin generation was not completely inhibited 
in FVII-depleted plasma. However, the commercial 
source does not guarantee complete removal of FVII 
by affinity chromatography. Thus residual clotting in 
commercial FVII plasma may reflect residual FVII 
Figure 5: Thrombin generation assays B16-F1-derived EV. Platelet-poor plasma was incubated with 2.5 µg of the indicated EV 
and the reaction was initiated by the addition of FluCa reagent. (A) Thrombin generation assay of the ApoV, MV, and Exo. (b) Thrombin 
generation by three EV types blocked with 20 µg/mL anti-mouse TF antibody (αTF). Arrows indicate peak thrombin values for MV, ApoV, 
and Exo obtained in absence of anti-TF antibody. (c) Thrombin generation by ApoV with the addition of lipid microparticles (MP) ± TF. (d) 
Bar graphs represent statistical analyses between samples in terms of lag time. One-way ANOVA using Bonferroni’s multiple comparisons 
test was performed: **P < 0.01; ***P < 0.001. Samples were loaded in triplicates. Results are representative of two experiments.
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Figure 6: The anti-tumor effects of exogenously-pulsed B16-OVA vesicles on tumor growth. Mice were injected 
subcutaneously with ApoV, MV, Exo (isolated by differential centrifugation of ovalbumin-pulsed B16-OVA-derived vesicles), or PBS in the 
flank before challenged with B16-OVA cells at the opposite flank seven days later. Tumor size was recorded until tumors reached 150 mm2. 
(A) Percent survival of the four mouse groups (n = 6 mice/group). (b) Tumor size represented for individual mice. ApoV/Exo 
(P < 0.0005); ApoV/MV (not significant); MV/Exo (P < 0.0022); PBS/Exo (P < 0.004) by Mantel-Cox test. The protective results for ApoV 
were confirmed in an additional experiment. (c) OVA-pulsed Exo, MV or ApoV were probed by western blotting with rabbit anti-OVA 
and detected with donkey anti-rabbit IgG-DyLight-800. A titrated OVA standard was used to quantify the amount of OVA in each sample. 
Note, endogenously expressed ovalbumin in the B16-OVA cell line (‘Unpulsed’) is below the limit of detection by western blotting. One 
of two experiments performed.
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activity, rather than the initiation of alternate pathways 
of coagulation by ApoV. Although TF was not detectable 
by flow cytometry, it was still highly functional. It should 
be noted that only picomolar concentrations of TF are 
required for high level activity in the TGA [54]. Therefore, 
the activity of TF resembles that of cytokines, which 
are able to induce large biological activity at low molar 
concentrations. For example, only 3–10 TF molecules 
per µm2 are sufficient to induce fibrin deposition under 
flow conditions [55, 56]. Interestingly, ApoV procoagulant 
activity far exceeds that of parental tumor cell lines, 
including those overexpressing TF, when normalized for 
protein content (manuscript in preparation). Therefore, 
the activity of TF is likely critically dependent on 
the context of anionic phospholipids, particularly 
phosphatidylserine [57]. which was enriched on 
ApoV relative to MV and exosomes (Figure 2). More 
controversially, TF activity may require decryption 
through dimerization or disulfide bond formation [58]. 
A caveat with our conclusions on the relative quantity and 
activity of TF on vesicles is the semi-quantitative nature 
of the highly sensitive flow cytometric assay employed. 
For example, the same ligand density on the membranes 
of larger flow cytometric events (e.g. tumor cells) would 
generate higher fluorescent signals, as compared to 
smaller particles (i.e. 4 µm beads with immobilized EV). 
In addition, autofluorescence and non-specific binding of 
isotype controls may mask detection on antibody ligands 
on the EV preparations.
Due to genomic and epigenetic alterations, tumor 
can express neoantigens, or overexpress antigens, that 
are recognized by the immune system [30]. Additionally, 
tumor associated antigens and endogenous adjuvants 
are translocated to vesicles [15, 28, 59]. Notably, the 
release of tumor antigen on EV is one of the major 
pathways of the induction of immune responses 
against tumors [28]. In our experiments, challenge of 
mice with B16-OVA demonstrated that ApoV afford 
the highest anti-tumor protection, as compared to 
MV and exosomes. The exceptional ability of ApoV 
to protect against melanoma challenge could relate 
to products of “immunogenic cell death”, such as 
high mobility group box protein B1 (HMGB1) and 
calreticulin translocating to the ApoV pathway [59, 60]. 
However, neither HMGB1 or calreticulin were present 
in the ApoV proteome (Supplementary Table 1), 
suggesting that other as yet unidentified factors mediate 
the immunogenicity of ApoV. We cannot rule out a 
partial contribution of the PMEL tumour-associated 
antigen enriched in the ApoV proteome (Figure 2D) to 
the observed immune response, however ApoV failed 
to induce measurable anti-tumour effects in the absence 
of exogenously supplied ovalbumin. In addition, 
the products of apoptotic cell death are efficiently 
phagocytosed and processed by antigen presenting cells 
[61], with the likelihood that the abundant release of 
ApoV with high level expression of phosphatidylserine 
contributes to enhanced uptake and processing [24, 47, 
60, 62]. Although less protective than ApoV, MV were 
significantly more protective than exosomes. It is possible 
that distinct factors mediate the protection observed with 
MV and ApoV, in which case a combination of MV and 
ApoV might induce even higher levels of protection 
compared to either vesicle fraction alone.  However, 
it seems equally likely that ApoV and MV harbour the 
same immunogenic factors, but in different quantities, 
given the lower levels of protection induced by MV 
immunization, as compared to ApoV immunization. 
The poor level of protection afforded by exosomes 
is surprising given their well characterised ability to 
capture exogenously supplied antigens (see Figure 6C) 
and stimulate the immune response [1–3, 39, 63]. 
Nevertheless, our results with melanoma-derived 
exosomes closely match the level of protection afforded 
using ovalbumin-pulsed dendritic cell-derived exosomes 
with B16-OVA challenge at day 7 [64]. This may reflect a 
general lack of efficacy for exosomes within this particular 
melanoma experimental setting.
A weakness in our study was the inability to exclude 
the possibility that ApoV preparations might contain MV 
and exosomes released during the induction of cell death 
by doxorubicin. Conversely, MV preparations might 
be contaminated with ApoV resulting from normal cell 
turnover and death during cell culture. Such contamination 
might mask antigen phenotypic and functional differences 
between these EV preparations. Nevertheless, the 
techniques employed allowed for sufficient enrichment 
of the different EV preparations for the discernment of 
distinct yields, morphological, molecular, procoagulant 
and immunogenic properties between the three EV 
populations.
Our study is the first to directly compare the 
procoagulant and immunogenic properties of exosomes, 
MV and ApoV. In particular, this study highlights the 
contribution of abundantly produced ApoV to pathological 
states, and their contribution to the anti-cancer response. 
The greater yield of ApoV released from the cell, as 
compared to exosomes and MV, further emphasizes the 
potential of ApoV to contribute to the pro-thrombotic state 
of cancer patients. Cytoablative anti-cancer therapy may 
therefore enhance the risk of thrombotic events, but also 
enhance T cell and natural killer cell-mediated anti-cancer 
responses via immunogenic EV release. 
MATEriAlS AnD METhODS
Cell culture
The C57BL/6 derived melanoma cell lines B16-F1 
(ATCC, Manassas, VA) and B16-OVA (B16-F0 cell 
line transfected with the full-length ovalbumin (OVA) 
gene from Edith Lord, University of Rochester, NY 
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[65]), and C57BL/6 derived thymoma derived EL4 
cell line (ATCC, Manassas, VA) were cultured at 37°C 
with 5% CO2 in R5 (RPMI-1640 (Gibco #31800-022) 
supplemented with 5% fetal bovine serum (FCS; PAA 
Laboratories, Austria), 55 μM β-mercaptoethanol (Gibco 
#21985-023), 100 U/mL penicillin (Gibco #15140-122), 
100 μg/mL streptomycin (Gibco #15140-122), and 2 
μg/mL NaHCO3. Stable murine TF transfectants were 
produced by transfecting EL4 cells with a pcDNA3.1+ 
vector containing an Apa I insert of full length murine 
TF gene (encoding amino acids 1-294; NM_010171; 
synthesized by Genscript; Piscataway, NJ), followed 
by selection with G418. For exosome preparation, 50% 
FCS in RPMI was spun at 100,000×g overnight at 4°C 
to deplete endogenous EV. 
Vesicle preparation
B16-F1 or B16-OVA cells were incubated for 
48 hours either with (ApoV) 25 μM doxorubicin (Baxter 
Healthcare Ltd, NZ) or without (MV and exosomes) 
doxorubicin at 70% confluence (approximately 1 × 105 
cells/mL) in exosome-depleted R5 at 37°C with 5% CO2. 
In order to obtain vesicle-rich fractions, the supernatant 
was first depleted of cells and debris using differential 
centrifugation at 450 × g for five minutes, followed by 
3200 × g for 20 minutes at 4°C in a 225 mL conical tube 
(Falcon, In Vitro Technologies, Auckland, NZ). MV 
(from untreated cultures) or ApoV (doxorubicin 
treated cultures)  enriched fractions were then pelleted 
by centrifugation at 25,000 × g for one hour at 4°C. 
For exosomes, the supernatant was first depleted of 
larger vesicles at 25,000 × g for 1 hour. The remaining 
supernatant was then filtered using a 0.22 μm 
nitrocellulose filter (Cole-Parmer® #EW-02915-52) and 
exosomes pelleted at 100,000 × g for 60 minutes at 4°C. 
All vesicles were washed twice in phosphate buffered 
saline (PBS; Gibco #21600-010). Where stated, vesicles 
were further purified by either a discontinuous sucrose 
cushion or a linear sucrose gradient. Briefly, for the 
sucrose cushion, vesicles were resuspended in 10 mL of 
PBS and overlaid onto 4 mL of 30% sucrose, 200 mM 
Tris/deuterium oxide; D2O, centrifuged at 100,000 × g for 
75 minutes at 4°C and vesicles at the interphase aspirated 
(approximately 2 mL). Alternatively, for continuous 
gradient separation, the ApoV pellet was resuspended in 
1 mL of 2.5 M sucrose/20 mM HEPES, pH 7.2, and then a 
linear sucrose gradient (0.25–2 M sucrose/20 mM HEPES, 
pH 7.2) was overlaid onto the ApoV suspension and 
centrifuged at 100,000 × g for 18 hours at 4°C. Fractions 
(1 mL) were removed, and their density determined 
with an Abbe refractometer (Tokyo, Japan). The protein 
content of purified vesicles was quantified using a 
Bradford assay [14]. 
Sizing and cryo-electron microscopy analysis of 
vesicles
Purified vesicles (4 µL) were loaded onto plasma-
glowed Quantifoil 2/2 grid and blotted to remove excess 
liquid. The grid was frozen by plunging into −180°C liquid 
ethane within a Reichert KF80 plunge freezing device 
(C. Reichert, Austria) and then stored in liquid nitrogen. 
The grids were then mounted into a pre-chilled Gatan 
914 cryo holder and viewed in a JEOL 2200FS cryo-
transmission electron microscope with an omega filter. 
Zero-loss images were acquired using a filter width of 
20–25 eV via a TVIPS F416 camera. The diameters of 
the vesicles were measured using the software IMOD. 
Alternatively, vesicle size was measured using DLS 
(Zetasizer Nano-ZS; Malvern Instruments, UK).
Flow cytometric analyses of vesicles
Ten micrograms (protein content) of purified 
vesicles (MV, exosomes, or ApoV) in 100 μL of PBS 
was added to 25 μL of aldehyde-sulfate beads (4 μm 
diameter; 1.4 × 109 beads/mL; Invitrogen #A37304) 
and incubated rotating overnight at 4°C. The vesicle-
conjugated beads were then blocked with 0.5 mL of 
0.05% bovine serum albumin (BSA; Gibco #30063-572)/
PBS for 15 minutes on ice, pelleted at 7000 × g at 4°C, 
then quenched with 0.5 mL of 100 mM glycine/PBS for 
30 minutes on ice. Pelleted beads were then washed in 
1 mL of 0.05% BSA/PBS and finally resuspended in 
100 μL of 0.05% BSA/PBS. Vesicle-conjugated beads 
(3 μL/reaction) were then analyzed for α2,3- or α2,6-
linked sialic acid expression with biotinylated (bio) 
lectins 5 μg/mL MAL-II (Vector #B-1265) or 0.5 μg/
mL SNA-I (Vector #B-1305) respectively, or labeled 
with 5 μg/mL bio-rat anti-mouse CD9 (BD Pharmingen 
#558749), bio-hamster anti-mouse CD81 (BD Pharmingen 
#559518), allophycocyanin (APC)-conjugated rat anti-
mouse CD49f (BioLegend #313615), bio-rat anti-mouse 
CD49d (BioLegend #103703), bio-rat anti-mouse CD51 
(BioLegend #104103), bio-hamster anti-mouse CD29 
(BD Pharmingen #555004), goat anti-mouse TF (R&D 
#AF3178) diluted in 0.05% BSA/PBS for 15 minutes 
on ice. Following washing with 0.05% BSA/PBS, biotin 
was detected using 1 μg/mL APC-conjugated streptavidin 
(BioLegend #405207), primary anti-TF antibody was 
detected with 2 μg/mL rabbit anti-goat IgG Alexa Fluor® 
594 (ThermoFisher #A-11080). Vesicle-conjugated beads 
were resuspended in 0.05% BSA/PBS and analyzed by 
flow cytometry (BD LSRFortessa; FlowJo). For bio-
annexin V binding (BD Pharmingen #556418), annexin 
V binding buffer was used instead of 0.05% BSA/PBS. 
A murine TF-Fc (human IgG1) fusion protein was 
produced by fusing the human Ig kappa signal sequence 
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to DNA encoding amino acids 29-251 from the murine TF 
extracellular domain. This insert was cloned in frame into 
the BamHI / NheI sites of pCMV-SPORT-Fc. TF-Fc was 
produced by transient transfection in HEK293 and purified 
by Protein A affinity chromatography. Where stated, 
10 µg/mL soluble murine TF-Fc was pre-incubated with 
the primary anti-mouse TF antibody for 30 minutes on ice, 
prior to cell labelling. 
Western blotting
B16-F1 cells or EV fractions were lysed in lysis 
buffer (0.02% azide, 150 mM NaCl, 0.25% CHAPS, 
0.5% Triton-X100, 100 mM Tris, pH 8.0 plus complete™ 
protease inhibitor; Roche #11-697-498-001). Lysates 
(10 µg in 10 μL) were added to 9 µL of NuPAGE LDS 
sample buffer (Invitrogen #NP0007) and 1 µL of NuPAGE 
sample reducing agent (Invitrogen #NP0009). Samples were 
boiled and reduced. Samples were then run on a NuPAGE 
12% Bis-Tris gel (Invitrogen #NP0342BOX) in NuPAGE 
MOPS-SDS running buffer (NuPAGE #NP0001) plus 0.5 
mL of antioxidant (Invitrogen #NP0005) for two hours at 
150 V and 126 mA on ice. Electrophoresed samples were 
transferred to Amersham Protran nitrocellulose membrane 
(GE Healthcare #GE10600018) using 1 × NuPAGE transfer 
buffer (Invitrogen #NP0006) for one hour at 30 V and 170 
mA on ice. Membranes were then blocked with 1% BSA/
PBS for 1 hour, then incubated with either 0.5 µg/mL mouse 
anti-mouse β actin (Sigma #A1978), 1 µg/mL mouse anti-
mouse clathrin heavy chain (BD Biosciences #610500), or 
1 µg/mL goat anti-mouse CD147 (Santa Cruz #sc-9757) for 
2 hours and washed thrice with 0.02% Tween20/PBS for 5 
minutes each washing step. Primary antibodies were then 
detected with goat anti-mouse IgG-horse radish peroxidase 
(HRP; Sigma-Aldrich #A4416) for β actin and clathrin 
and rabbit anti-goat IgG-HRP (Sigma-Aldrich #A5420) 
for CD147. Secondary antibodies were diluted 1/1000 in 
1% BSA/PBS and applied for 1 hour. Membranes were 
washed as described above, rinsed with milliQ H2O and 
HRP signal developed with diaminobenzidine (DAB) and 
H2O2 (Sigma-Aldrich #D-4293) in milliQ H2O. Reactions 
were stopped by rinsing with milliQ H2O. All incubations 
were performed at room temperature while rocking. For 
OVA protein quantification on B16-OVA-derived ApoV, 
MV, or exosomes, membranes were blocked with 0.1% 
caseinate/PBS for 2 hours, then incubated with 5 μg/mL 
rabbit polyclonal anti-OVA (Polysciences, Warrington, 
PA, USA #23744) for 2 hours. The primary antibody was 
then detected using donkey anti-rabbit IgG-DyLight-800 
(Pierce #SA5-10044) diluted 1/10000 in 0.1% caseinate/
PBS for 1 hour.  Membranes were visualized with an 
Odyssey Fc imaging system (LI-COR, Lincoln, NE, USA). 
Quantification of OVA was performed using the Image 
studio Lite software (Lincoln, NE, USA) using titrated 
OVA (500, 250, 125, 62.5 ng) as a standard (Sigma-Aldrich 
#A5503).  
Proteomic analyses
EV prepared by differential centrifugation were 
further purified by 30% sucrose/D2O and dialyzed 
(10,000 Da cut off) against PBS to remove sucrose and 
D2O. Vesicle lysates were buffer exchanged and purified 
by the FASP (filter-aided sample preparation) method 
[66] using 0.5 ml ultrafiltration units with a molecular 
weight cut-off of 3 kDa (Millipore). Reduction, alkylation 
and tryptic protein digestion were performed on filter. 
The recovered tryptic peptides of each sample were then 
subjected to liquid chromatography coupled tandem mass 
spectrometry using an Ultimate 3000 uHPLC-system 
inline coupled to the nanospray source of a LTQ Orbitrap 
XL mass spectrometer. Raw data were processed through 
the Proteome Discoverer software (Thermo Scientific) and 
searched against the mouse reference sequence database 
(download Nov 2015 from http://www.ncbi.nlm.nih.
gov/refseq; 57928 sequence entries) using the MASCOT 
(matrixscience.com), Sequest HT (Thermo Scientific) and 
MS Amanda [67] search engines. The Percolator algorithm 
[68] was used to adjust the score threshold to an estimated 
peptide false discovery rate of 1%. Only proteins with two 
significant peptide hits were considered as significantly 
identified. Relative protein abundances between the 
different samples were estimated through using the TOP3 
approach [69]. The TOP3 intensity values were calculated 
using the Proteome Discoverer software and normalized to 
the β-actin ion intensity of each sample.
Fibrin generation assay
Purified vesicles (quantities as stated) in 20 μL 
of PBS were added to 100 μL of citrated platelet-poor 
plasma (Siemens #10446238, or obtained from normal 
donors with the approval of the regional Human Ethics 
committee) in a 96-well plate. Coagulation was initiated 
by adding 10 mM CaCl2 and the absorbance at OD405nm 
was measured every 30 seconds over 30 minutes at 23°C 
using a plate reader (Varioskan Flash, Thermo Scientific). 
All samples were performed in triplicates. Where stated, 
20 μg/mL goat anti-mouse TF polyclonal antibody (R&D 
#8686) or 100 μg/mL annexin V (eBioscience #BMS306) 
were added for blocking experiments.
Thrombin generation assay
Purified vesicles (quantities as stated) in 20 μL of 
PBS or 20 μL of thrombin calibrator (715 nM specific 
activity; Thrombinoscope #TS20.00) was added to 80 μL 
of citrated platelet-poor plasma (Siemens #10446238) in 
a 96-well plate. Henceforth, instructions were followed as 
per the Thrombinoscope software. Briefly, the plate was 
pre-warmed at 37°C in the Fluoroskan Ascent fluorometer 
(Thermo Scientific), 20 μL of FluCa (Fluo-Substrate 
containing calcium; 1:40; Thrombinoscope #TS50.00) 
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dispensed and thrombin activity measured for 1 hour. 
Where stated, 20 μg/mL rat anti-mouse TF monoclonal 
antibody (1H1; Genentech, San Francisco, CA) was added 
for blocking experiments.
Vesicle immunization and tumor implantation
B16-OVA was cultured in R5, pulsed for 48 hours 
with 200 μg/mL OVA protein (Sigma-Aldrich #A5503) 
and vesicles harvested as stated above. For generation 
of ApoV, doxorubicin was added simultaneously with 
the OVA protein. C57BL/6 mice were obtained from 
the Jackson Laboratory (Bar Harbor, ME) and bred and 
housed under specific pathogen-free conditions at the 
University of Otago Hercus-Taieri Research Unit as 
described [70]. All experiments were approved by the 
University of Otago regional animal ethics committee. 
Mice were immunized s.c. with 25 µg (in 50 µL of PBS) 
of B16-OVA-derived ApoV, MV, or exosomes in the flank. 
Seven days later, B16-OVA cells were harvested from 
logarithmically growing cultures using a cell scraper, 
filtered through a 70 μm cell strainer, and resuspended in 
PBS. Mice were then challenged with 1 × 105 B16-OVA 
cells s.c. in the opposite flank to the immunization site. 
Tumor growth was determined by measuring the length 
and width using calipers every 1–2 days. Results are 
expressed as the mean product of the tumor diameters. 
Mice were removed from the study when tumors reached 
150 mm2. Data are represented as tumor growth curves or 
as Kaplan-Meier survival plots using Graphpad Prism 6 
(GraphPad, San Diego, CA).
Statistical analysis
All statistical analyses were performed with 
GraphPad Prism 6 (GraphPad, San Diego, CA). Fibrin 
generation assays were analyzed using one-way 
ANOVA with Bonferroni post-correction test. Survival 
data were represented as tumor growth curves or as 
Kaplan-Meier survival plots and analyzed using the 
Mantel-Cox test.
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Background: Chemotherapy induces the release of apoptotic vesicles (ApoV) from the tumor plasmamembrane.
Tumor ApoVmay enhance the risk of thrombotic events in cancer patients undergoing chemotherapy. However,
the relative contribution of ApoV to coagulation and the pathways involved remain poorly characterized. In ad-
dition, this study sets out to compare the procoagulant activity of chemotherapy-induced ApoVwith their cell of
origin and to determine the mechanisms of ApoV-induced coagulation.
Methods: We utilized human and murine cancer cell lines and chemotherapeutic agents to determine the re-
quirement for the coagulation factors (tissue factor; TF, FII, FV, FVII, FVIII, FIX and phosphatidylserine) in the
procoagulant activity of ApoV. The role of previously identified ApoV-associated FVwas determined in a FV func-
tional assay.
Results: ApoV were significantly more procoagulant per microgram of protein compared to parental living or
dying tumor cells. In the phase to peak fibrin generation, procoagulant activity was dependent on
phosphatidylserine, TF expression, FVII and the prothrombinase complex. However, the intrinsic coagulation fac-
tors FIX and FVIIIwere dispensable. ApoV-associated FV couldnot support coagulation in the absence of supplied,
exogenous FV.
Conclusions:ApoV are significantlymore procoagulant than their parental tumor cells. ApoV require the extrinsic
tenase and prothrombinase complex to activate the early phase of coagulation. Endogenous FV identified on
tumor ApoV is serum-derived and functional, but is non-essential for ApoV-mediated fibrin generation.
General significance: This study clarifies the mechanisms of procoagulant activity of vesicles released from dying
tumor cells.








Coagulation is not only relevant to physiological hemostasis but is
also involved in pathological thrombotic events. There has been an
expanding interest in the ability of tumors and their extracellular vesi-
cles to contribute to both thrombotic and metastatic events [1–13]. In
particular, the fourfold risk of venous thromboembolism (VTE) in
cancer patients is increased to six to sevenfold with chemotherapy –
implicating tumor cell death in thrombotic events [14–18].
In humans, coagulation occurs through a linked series of enzymatic
steps resulting in fibrin deposition and platelet activation. Extrinsic acti-
vation occurs when tissue factor (TF) present in phosphatidylserine
(PS) enriched membranes is exposed to Factor VII (FVII)/FVIIa, leading
to formation of the ‘extrinsic tenase’ and activation of FX to FXa [19].
The intrinsic pathway is largely dependent on ‘contact activation’ by
damaged vascular surfaces or other negatively-charged surfaces such
as exposed nucleic acids or polyphosphates [20–22]. However, the
FVIII and FIX components of the intrinsic pathway act to further amplify
Xa production with 50-fold higher efficiency as compared to the extrin-
sic tenase complex [20].
While membrane bound FXa enzyme can cleave prothrombin to
thrombin, FVa enhances this reaction 300,000-fold [20]. Hepatocytes
and platelets are classically thought to be the only cellular or partic-
ulate source of circulating FV and about 20% of circulating FV is
platelet-associated [23,24]. However, several reports demonstrate
the presence of FV in extracellular vesicles released from human or
murine tumor cells [25–28]. Tumor cell vesicles may therefore pos-
sess ‘platelet-like’ activity with respect to providing an existing PS/
FVa scaffold for the formation of the prothrombinase complex. The
possible significance of endogenous FV expression is that newly
cleaved FXa may bind to FV and in the presence of exogenous pro-
thrombin, escape inhibition by tissue factor pathway inhibitor
(TFPI), a major endogenous regulator of TF-initiated coagulation
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Abbreviations: ApoV, Apoptotic vesicles; F, coagulation factor; FCS, fetal calf serum;
FGA, fibrin generation assay; PS, phosphatidylserine; R5, RPMI-1640 with 5% FCS; SFM,
serum-freemedium; TF, tissue factor; TFPI, tissue factor pathway inhibitor; TGA, thrombin
generation assay; VTE, venous thromboembolism.
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[29]. FV expression has previously been reported on the HepG2
tumor cell line, lymphocytes, endothelial cells and on kidney
mesangial cells where it was suggested to mediate fibrin deposition
at the cell surface [30,31].
Blebbing is a normal part of cellular homeostasis achieved by the
regulation of membrane tension against the tethers of the cytoskele-
ton. The formation of plasma membrane-derived extracellular
vesicles requires nucleation into spherical vesicles – a process facili-
tated by membrane delamination from the cytoskeleton [32]. In ap-
optotic cells, increased oncostatic pressure following cytoskeletal
contraction aids bleb inflation, stimulating the release of apoptotic
vesicles (ApoV) from the plasma membrane [32]. Cells undergoing
apoptosis release extracellular vesicles that may range from 0.1 to
5 μm in diameter [28,33,34]. These extracellular vesicles display im-
munogenic activity and may be a critical site for the propagation of
coagulation [28,35].
Tumor-derived extracellular vesicles are well known for their di-
verse biological functions, including immune suppression/activa-
tion, angiogenesis, tumor metastasis [36–40], and are additionally
implicated in triggering the coagulation cascade [4,7,28,41–43].
Moreover, TF expression and PS exposure contribute to extracellular
vesicle procoagulant activity [4,7,44,45] and prothrombotic effects
in vivo [46–48]. The fourfold increased risk of developing VTE in
cancer patients may be linked to the formation of tumor, or normal
host tissue-derived vesicles [5,15,28,42,43,49–54]. However, the
fact that this risk is increased to around sixfold in patients receiving
chemotherapy could implicate tumor-derived ApoV [55].
The pathogenicity of chemotherapy-associated thrombosis remains
poorly understood. In this study, we have investigated the potential of
ApoV released from dying tumor cells to contribute to coagulation. We
demonstrate the critical contribution of ApoV generated from a variety
of tumor cell lines to the activation of the extrinsic pathway of coagula-
tion, working in concert with the prothrombinase complex, while the
intrinsic pathway was dispensable for this activity. Interestingly, FV as-
sociated with ApoVwas determined to be derived from cell culture me-
dium and could not support coagulation in the absence of exogenous
plasma FV.
2. Materials and methods
2.1. Cell culture
The C57BL/6 melanoma cell lines B16-F1 and B16-F10, C57BL/6
thymoma EL4 cell line, C57BL/6 lung carcinoma LLC cell line, C57BL/6
colon carcinoma CT26 cell line, BALB/c myeloma NS/0 cell line, human
prostate carcinoma DU-145 cell line, human breast adenocarcinoma
Fig. 1. Cell viability and apoptotic analyses of doxorubicin-treated cells. (A) Cell viability was determined by resazurin assay. B16-F10 cells were treated with 0.5, 5, 50, or 500 μM
doxorubicin for 48 h or (B) treated with 30 μM doxorubicin immediately (“b5 min”), for 24 h, or 48 h. Cells were then incubated with resazurin solution and cell viability quantified
by fluorometric analysis (excitation 540 nm/emission 585 nm). Values are plotted as relative percentages normalised to the mean of untreated (live) cells. One-way ANOVA with
Bonferroni post-correction test performed, ns = not significant; ***P b 0.001; ****P b 0.0001. Error bars represent mean ± SD of triplicate samples. (C) Cells were incubated with
30 μM doxorubicin for 24 or 48 h. In selected wells, doxorubicin was added immediately prior to harvest (“b5 min”) to determine the contribution of doxorubicin to background
fluorescence of living cells. Cells were analyzed by flow cytometry for phosphatidylserine (PS) externalization using biotin annexin V staining detected with streptavidin-BV421 (SA-
BV421). Results are representative of two to four experiments.
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MCF-7 cell line, humanNCI-H460 carcinoma cell line, humanmelanoma
SK-MEL5 and human leukemia Jurkat cell line (all fromATCC,Manassas,
VA) were cultured at 37 °C with 5% CO2 in R5 (RPMI-1640 (Gibco
#31800-022) supplemented with 5% fetal calf serum (FCS; PAA Labora-
tories, Austria), 55 μM β-mercaptoethanol (Gibco #21985-023),
100 U/mL penicillin (Gibco #15140-122), 100 μg/mL streptomycin
(Gibco #15140-122), and 2 μg/mL NaHCO3. Where stated, cells were
cultured in serum-free medium (SFM) containing 1:1 RPMI-1640:
DMEM/F12 (Gibco #11320), 100 μg/mL penicillin, 100 μg/mL strepto-
mycin, 2 μg/mL NaHCO3, 1 mg/mL bovine serum albumin (BSA; Gibco
#30063-572), 5 μg/mL bovine insulin (Sigma #I-5500), 5 μg/mL bovine
holo-transferrin (Sigma #T1283-50MG), 10 nM sodium selenite (Sigma
#S5261), 50 nMhydrocortisone (Sigma#H0888), and 5 pM triiodothyro-
nine (Sigma #IRMM469-1EA). Stablemurine and human TF transfectants
were produced by transfecting NS/0 myeloma cells with pcDNA3.1+
vector containing an Apa I insert of full length murine TF gene (encoding
amino acids 1–294; NM_010171) or HindIII-ApaI insert of the full length
human TF (encoding amino acids 1-295; NM_001993.4), as previously
described [28].
2.2. Cell metabolism and PS-exposure in doxorubicin-treated cells
A total of 1 × 104 or 1 × 105 B16F10 cells in 200 μl or 3 ml R5 media
were seeded onto sterile flat bottom 96- or 12-well plates, respectively,
and allowed to adhere for 2 h. Cells were incubated with 0–500 μM
doxorubicin at 37 °C with 5% CO2. For cell viability measurement via
the resazurin assay, themediawas removed from cells containedwithin
the 96-well plate, replaced with fresh R5 and supplemented with 10%
resazurin solution (120 mg/L of resazurin, 10 mg/L methylene blue,
400 μM potassium ferricyanide, 400 μM potassium ferrocyanide in
100 mM phosphate buffer pH 7.4; all reagents from Sigma). Cells were
then incubated for four hours at 37 °C with 5% CO2. The supernatant
(150 μL) was aspirated from wells, placed in a black 96-well plate
(Nunc) and fluorescence (540 nm excitation/585 nm emission) mea-
sured at 23 °C using a plate reader (Varioskan Flash, Thermo Scientific).
For the flow cytometric analysis, the cells incubated in 12-well plates
were removed by pipetting in calcium-free PBS, washed by centrifuga-
tion at 450 × g for five minutes and resuspended in annexin V binding
buffer and labeledwith5 μg/mLbiotinylated annexin V (BDPharmingen
#556418) for 15 min on ice. Cells were then washed, resuspended (as
mentioned above), and biotin was detected using streptavidin-BV421
(BioLegend #405226) at 0.2 μg/mL concentration for 15 min on ice.
Cells were washed and resuspended, before being analyzed by flow
cytometry. The highly fluourescent nature of the hydroxy-substituted
anthraquinone chromophore doxorubicin [56] precluded multi-color
cell analysis using green to far-red channels of the BD Fortessa. There-
fore, single color analysis was carried out using the 450/50 nm violet
channel.
2.3. Cells and vesicle preparation
B16-F1, B16-F10, CT26, LLC, EL4, SK-MEL5, DU-145, NCI-H460, MCF-
7, or Jurkat cells were incubated for 48 h either with 30 μMdoxorubicin,
150 μM5-fluoruracil (5FU), or 30 μMgemcitabine (all BaxterHealthcare
Ltd, NZ) at 70% confluence (approximately 1 × 105 cells/mL) at 37 °C
with 5% CO2. ApoV yield was maximal at 48 h when cell viability had
dropped approximately 60–95% (ref. [28] and data not shown). ApoV
were prepared, quantified and characterized exactly as previously de-
scribed [28]. Briefly, the supernatant from dying cells was first depleted
of cells anddebris using differential centrifugation at 450× g for fivemi-
nutes, followed by 3200 × g for 20 min at 4 °C in a 225 mL conical tube
(Falcon, In Vitro Technologies, Auckland, NZ). ApoV enriched fractions
were then pelleted by centrifugation at 25,000 ×g for 1 h at 4 °C. All
ApoVwerewashed twice in PBS. The protein content of purified vesicles
or lysed cells was quantified using a Bradford assay [28]. The number of
cells corresponding to 1 μg of proteinwas 1700 forMCF-7 and SK-MEL5,
2000 for NCI-H460 and Jurkat, 2500 for EL4, 2700 for DU-145 and LLC,
and 3000 for B16 and CT26 cell lines.
2.4. Fibrin generation assay
Purified ApoV or cells (quantities as stated) in 20 μL of PBS were
added to 100 μL of standard citratedplatelet-poor plasma (PPP; Siemens
#10446238) in a 96-well plate. Formeasuringprothrombin time (PT) or
Activated Partial Thromboplastin Time (APTT), the reagentswere added
as per the manufacturer's instructions; 200 μL of Dade® Innovin® (Sie-
mens #B4212) or 100 μL of Dade® Actin FS (Siemens #B4218) were
used as PT or APTT reagent respectively. Where stated, FII-deficient
(Siemens #OSGR13), FV-deficient (Siemens #ORSM17), FVII-deficient
(Siemens #OTXV13), FVIII-deficient (Siemens #OTXW17), or FIX-
deficient (Siemens #OTXX17) PPP was used. Coagulation was initiat-
ed by adding 10 mM CaCl2 and the absorbance at OD405nm was mea-
sured at 15–30 s intervals over 30 min at 23 °C using a plate reader
(Varioskan Flash, Thermo Scientific). Area under the curve (AUC)
was calculated from the initiation point until the PBS control line
formed a positive slope (5% of maximum fibrin). All samples were
performed in triplicate. Where stated, 20 μg/mL goat anti-mouse TF
polyclonal antibody (R&D #AF3178), 20 μg/mL polyclonal goat IgG,
or 100 μg/mL annexin V (eBioscience #BMS306) were added for
blocking experiments.
Fig. 2. Morphology of B16-F1-derived apoptotic vesicles and their procoagulant activity.
(A) Apoptotic vesicles (ApoV) were purified by differential centrifugation of cell
supernatant from doxorubicin-treated B16-F1 cells as described [28] and visualized by
cryo-electron microscopy. Original magnification 20,000×. Bars represent 50 nm.
(B) ApoV (15 μg) were added to platelet poor plasma (PPP) then CaCl2 was added to
initiate coagulation. A fibrin generation assay (FGA) was performed by monitoring
absorbance at 405 nm and the first derivative of the curve was plotted (arbitrary units).
For the thrombin generation assay (TGA), ApoV were incubated with PPP and the
reaction initiated by the addition of FluCa reagent. Samples were loaded in triplicate.
Results are representative of at least two experiments.
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2.5. Thrombin generation assay
Purified ApoV (quantities as stated) in 20 μL of PBS or 20 μL of
thrombin calibrator (715 nM specific activity; Thrombinoscope
#TS20.00) were added to 80 μL of PPP (Siemens #10446238) in a
96-well plate. Henceforth, instructions were followed as per the
Thrombinoscope software. Briefly, the plate was pre-warmed at
37 °C in the Fluoroskan Ascent fluorometer (Thermo Scientific),
20 μL of FluCa (Fluo-Substrate containing CaCl2; Thrombinoscope
#TS50.00) was dispensed, and thrombin activity measured for 1 h.
2.6. FV function assay
Purified ApoV (15 μg) in 12 μL PBS, 12 μL FCS, R5, or SFMwere added
to wells of a black 96-well plate (Nunc). The samples were supplement-
ed with 50 mM HEPES, 1 μg/mL BSA, 100 mM NaCl, 10 pM FXa
(Haematologic Technologies Inc. #HCXA-0060), 500 nM prothrombin
(Haematologic Technologies Inc. #HCP-0010), 50 μM thrombin sub-
strate Boc-L-FPR-ANSNH-C2H5 (SN-20; Haematologic Technologies
Inc. #SN-20). CaCl2 (5mM) was added to initiate the reaction that was
immediately measured fluorometrically (excitation 352 nm/emission
470 nm) at a periodical cycle of 10 s for 1 h at 23 °C using a plate reader
(Varioskan Flash, Thermo Scientific).
2.7. Statistical analysis
All statistical analyzes were performed with GraphPad Prism 6
(GraphPad, San Diego, CA) using one-way ANOVA with Bonferroni
post-correction test.
3. Results
3.1. Fibrin and thrombin generation by ApoV
Treatment of tumor cells with chemotherapeutic drugs results in the
induction of cell death, blebbing of the plasma membrane, with subse-
quent release of blebs as ApoV [28,57]. We first analyzed impairment
of reductive cell metabolism (resazurin assay) and PS exposure
(annexin V binding) as indicators of apoptosis in doxorubicin-treated
B16-F10 cells (Fig. 1). Treatment of B16 cells with doxorubicin resulted
in a significant loss of viability that was maximal at 48 h and this
timepoint also corresponded to peak PS exposure (Fig. 1).We next visu-
alized purified B16-F10-derived ApoV by cryo-electron microscopy
(CryoEM; Fig. 2A; composite image). To confirm that ApoV were able
to exert procoagulant activity, we compared the ability of tumor-
derived ApoV to generatefibrin and thrombin, by subjecting the vesicles
to a fibrin generation assay (FGA) and thrombin generation assay
(TGA). As shown in Fig. 2B, fibrin generation was a rapid event with
peak time for ApoV determined as 1.83 min (±0.33 SD), compared to
the thrombin peak time of 19.89 min (±0.87 SD). For comparison,
ApoV were tested together with standard APTT and PT reagents
(Fig. S1A). Using thefirst derivative curves of triplicate 15 s readings, ex-
trapolated peak times were determined as PT 22.8 s (±0.00 SD, n= 2),
APTT 103.3 s (±8.47 SD, n = 2), and ApoV 117.0 s (±7.81 SD, n = 2).
3.2. Fibrin generation of tumor-derived ApoV is governed by TF and PS
activity
To confirm that our FGA was sensitive to TF activity, we transfected
the NS/0 myeloma cell line with human or murine TF (NS/0 Hu-TF or
Fig. 3. The procoagulant activity of ApoV is dependent on TF-pathway and PS. (A) Equal amounts of NS/0, human tissue factor (TF)-transfected NS/0 (NS/0 Hu-TF), or murine TF-
transfected NS/0 (NS/0 Mu-TF) live cells, or, purified B16-F10 ApoV (15 μg) derived using (B) doxorubicin (Dox), or (C) 5FU either with the addition of 20 μg/mL anti-mouse TF
antibody or 100 μg/mL annexin V (AV) to block PS were added to PPP and subjected to a FGA. One-way ANOVA with Bonferroni post-correction test performed on the area under the
curves (AUC): ***P b 0.001, ****P b 0.0001. Error bars represent mean ± SD of triplicate samples. Results are representative of at least three experiments.
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NS/0 Mu-TF respectively). NS/0 TF transfectants generated greatly
enhanced levels of fibrin, as compared to non-transfected NS/0
(Fig. 3A). A neutralizing antibody against TF, or the addition of annexin
V to block PS residues, significantly suppressed the procoagulant
effects of melanoma B16-derived ApoV, generated using either
doxorubicin or 5FU (Figs. 3B, C, S1B). Since doxorubicin and 5FU-
generated ApoV induced rapid fibrin generation (Figs. 2B, 3B, and C),
we next determined if ApoV derived from tumor cells exposed to vari-
ous chemotherapy drugs exhibited similar procoagulant activity in
comparison to their corresponding cells (live or dead; Fig. 4A and B).
ApoV generated from 5FU- or doxorubicin-treated B16 or LLC cells
were significantlymore procoagulant than their (live or dead) cell of or-
igin. ApoV derived from cells exposed to 5FU induced the highest coag-
ulation effect, as opposed to the gemcitabine-treated ApoV with the
least coagulative property (with doxorubicin-generated ApoV as an
intermediate).
3.3. Superior procoagulant activity of tumor-derived ApoV compared to pa-
rental cells
To test the procoagulant effects of tumor-derived ApoV, we selected
a range of murine tumor cells and used doxorubicin as a model drug. As
seen in Fig. 5A-C, ApoV derived from melanoma B16, colorectal CT26,
and lung LLC tumor cell lines were significantly more procoagulant
than their cell of origin (live or dead). T cell lymphoma EL4 (live or
dead) or EL4-derived ApoV failed to generate detectable fibrin
(Fig. 5D). To further confirm this result, we selected human tumor cell
lines and compared the procoagulant effects of intact cells with their
ApoV (Fig. 6A–D). Doxorubicin-treated melanoma SK-MEL5, prostate
DU-145, lung NCI-H460, and breast MCF-7 cell lines released ApoV
that were significantly more procoagulant than their cell of origin.
This finding was also confirmed using the lung NCI-H25 cell line (data
not shown). When input levels of protein content of pro-coagulant
ApoV and intact cells were increased from 15 μg to 60 μg,
procoagulant activity induced by ApoV remained superior to that of
dead cells, but ApoV procoagulant activity was not significantly differ-
ent from that induced by living cells (Fig. S2). In addition, annexin V
was able to significantly reduce fibrin generation when cell numbers
were further increased (Fig. S2), emphasizing the critical role of PS in
the procoagulant activity of intact cells and ApoV.
3.4. Factors V and VII are critical for the procoagulant activity of tumor
ApoV
To further investigate the mechanisms of the procoagulant effects
induced by tumor-derived ApoV, we subjected ApoV to the FGA using
coagulation factor-deficient plasma preparations (Figs. 7A, B, and S1C).
There was no consistent reduction in coagulation using plasma-
deficient for the FVIII and FIX components of the intrinsic coagulation
cascade in the experiments performed. However, the procoagulant
effects of ApoV was significantly reduced when the extrinsic factor
FVII was removed – affirming the importance of TF/FVII pathway in
the procoagulant effects of tumor-derived ApoV (Fig. 3B and C). Inter-
estingly, there was a small but consistent enhancement within the
procoagulant effect of ApoV generated from B16-F10, DU-145, and
NCI-H460 cells using the FIX-deficient plasma. The critical requirement
for the prothrombinase complex was demonstrated using FV-deficient
plasma (Fig. 7).
Fig. 4. The procoagulant activity of chemotherapy-generated ApoV. (A) B16-F10 or (B) LLC cell lines were treated with doxorubicin (Dox), 5-fluorouracil (5FU), or gemcitabine (Gem) to
generate ApoV. ApoV were then purified by differential centrifugation of cell supernatant. ApoV, live or chemotherapy-exposed cells (15 μg) were then subjected to a FGA. One-way
ANOVA with Bonferroni post-correction test performed on the area under the curves (AUC): ns = not significant; *P b 0.05; **P b 0.01; ***P b 0.001; ****P b 0.0001. Error bars
represent mean ± SD of triplicate samples. Results are representative of at least three experiments.
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3.5. ApoV harbor functional FV derived from fetal calf serum
We and others have previously detected FV in tumor-derived extra-
cellular vesicles bymass spectrometry [25–28].We therefore further in-
vestigated the possibility that endogenous FV could be contributing to
the observed procoagulant activity of ApoV. As noted above for Fig. 7,
the procoagulant effects of ApoV in FV-deficient plasmawas significant-
ly reduced, indicating that even if FV was endogenously expressed on
vesicles, it would likely be unable to compensate for a loss of exogenous
FV in the FGA. To further investigate the possibility that ApoV-
associated FV was functional in some circumstances, we added ApoV
to assay buffer containing FXa, prothrombin and thrombin substrate
(Fig. 8A). While strong FV activity was observed using ApoV isolated
from FCS-cultured cells, ApoV derived from SFM-cultured cells did not
exhibit detectable FV activity. The addition of FCS to SFM-prepared
ApoV reconstituted FV activity, demonstrating that bovine sera-
derived FV/FVa could function as a coagulation factor together with
ApoV membranes. There was no significant difference in fibrin genera-
tion between ApoV derived from FCS- or SFM-cultured cells (Fig. 8B).
4. Discussion
Thrombosis in cancer patients is attributable to a number of physical
factors relating to the association of tumor with the surrounding vascu-
lature, but also encompass a systemic hypercoagulable state [15–18].
Risk may be raised by host or iatrogenic intervention such as catheteri-
zation, chemotherapy and surgery that contributes to physiological
changes. In addition, cancer stage and histological typemay also impact
on thrombotic risk [15]. The imposition of chemotherapy on a body al-
ready burdened with a procoagulant state may further perturb the
hemostatic balance leading to a depression in endogenous anti-
coagulant factors, such as protein C and anti-thrombin [58], elevation
of procoagulant host factors, and alterations in lipid profiles that
might predispose patients to cardiovascular complications [59]. Chemo-
therapy damages the vascular endothelium exposing underlying colla-
gen and TF, and may induce expression of TF on endothelial cells [15].
Activation and damage to endothelial, platelet and erythrocyte mem-
branesmay result in the formation of extracellular vesicles that contrib-
ute to the local clot formation, or to systemic hypercoagulability [43,49–
52]. A further possibility is that chemotherapy engenders the release of
procoagulant factors [61], including extracellular vesicles from the
tumor itself [28,42,53].
While the causes of cancer related thrombosis are likely wide-
ranging and multifactorial; including both host and tumor contribu-
tions, it was intriguing to note that vesicles released from dying tumor
cells were the most potent procoagulant fraction released from a
range of tumor cells. Interestingly, of the three chemotherapeutic
drugs tested, ApoV prepared from gemcitabine treated tumor cells
displayed the lowest procoagulant activity. However, in terms of clinical
outcomes, a recent meta-analysis suggested that gemcitabine poses a
similar risk for thrombosis, as compared to other standard chemothera-
peutic treatments [61].
We have previously noted a contribution of TF-expressing ApoV to
thrombin generation in PPP [28]. In this study, FGA was an early event
that peaked even when thrombin was below the limit of detection in
the TGA (see Fig. 2B). The specificity of the FGA for detection of TF
was further confirmed using ApoV prepared from control or TF gene
transfected B cell lines (see Fig. 3 and data not shown). It has previously
been noted that fibrin deposition can occur when b1% of total thrombin
production has been generated [62,63], therefore the fact that fibrin gel
Fig. 5. The procoagulant activity of murine tumor-derived ApoV. (A) B16-F10 (B) CT26, (C) LLC, or, (D) EL4 cell lines were treated with doxorubicin to generate ApoV. ApoV were then
purified by differential centrifugation of cell supernatant. ApoV, live or chemotherapy-exposed cells (15 μg) were then subjected to FGA. One-way ANOVA with Bonferroni post-
correction test performed on the area under the curves (AUC): ns = not significant; **P b 0.01; ***P b 0.001; ****P b 0.0001. Error bars represent mean ± SD of triplicate samples. A
positive control (0.1 U human thrombin) was included for the EL4 experiment. Results are representative of at least three experiments.
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formation is measurable within seconds of the addition of ApoV is not
surprising. One weakness of our studies is that these were carried out
in PPP under static conditions and do not take into account the added
complexities offibrin and platelet complexes forming underflow condi-
tions. For example, the in vivo function of peak thrombin produced after
initial fibrin deposition formation likely performs vital hemostatic func-
tions, such as crosslinking of fibrin clots with further downstream coag-
ulation factor and platelet activation [62,63].
Vesicles released from tumor cells are a possible enriched source
of procoagulant anionic phospholipid, which may explain the en-
hanced rates of thrombosis in sufferers of both lymphomas and
solid cancers [14,64]. The procoagulant activity of ApoV exceeded
that of intact, living tumor cells, as well as that of intact tumor cells
treated with chemotherapeutic reagents. Bearing in mind that our
assays compared equivalent levels of protein-normalized ApoV and
cellular material, it appears likely that normalized preparations of
ApoV would contain a relatively greater enrichment of a surface
area of exposed anionic phospholipids that would have enhanced
the coagulation factor-dependent activity of ApoV. This was consis-
tent with the ability of annexin V to block coagulation in the FGA.
In contrast, intact and dying/dead cells might be expected to contain a
greater quantity of procoagulant material including nuclear material
(histones and DNA), as well as other negatively charged substances
such as RNA and polyphosphates [7,20–22,25–28]. Nevertheless, given
the superior ability of ApoV to contribute to coagulation, the potential
contribution of these cell-bound factors to overall levels of coagulation
induced by intact tumor cells is likely minimal.
Fibrin gel formation induced by ApoV was not only critically depen-
dent on extrinsic pathway-related plasma factors, but also the
prothrombinase complex. In contrast the overall contribution of the in-
trinsic factor FVIII and FIX to fibrin generationwas negligible. Neverthe-
less, apoptotic tumors and tumor-derived microvesicles have been
shown to be capable of activating the intrinsic pathway in a purified co-
agulation factor assay [42,65]. However, an important difference in our
study was that we utilized PPP preparations containing physiological
concentrations of coagulation factors, together with matched plasmas
selectively depleted of certain coagulation factors. Thus, our findings
clearly show that the initial, rapid fibrin generation induced by ApoV
can proceed independent of the intrinsic factors FVIII and FIX. Surpris-
ingly, in some experiments, the absence of FIX enhanced fibrin genera-
tion (see Fig. 7). Since FIX binds to TF with a higher affinity than FX [67,
68], it is possible that FIX competes with FX for access to TF, thus
inhibiting initial fibrin generation.
Recent studies have identified Factor V on extracellular vesicles from
human or murine tumor cells [25–28]. In our recent proteomic analysis
of melanoma extracellular vesicles, we found either bovine-specific FV
sequences, or FV peptides that were ambiguous with respect to species
identity (ref. [28] and data not shown). However, our experiments
showed that FV activity in ApoV preparationswasmost likely due to up-
take of bovine FV from the culture medium by ApoV. Although ApoV-
associated bovine FV was active in a FV functional assay, the presence
of bovine FVonApoVdid not alterfibrin generation time in experiments
carried out in FV-replete PPP. In addition, the significant reduction in fi-
brin generation of ApoV in PPP depleted of FV, suggests that ApoV-
Fig. 6. The procoagulant activity of human tumor-derived ApoV. (A) SK-MEL5 (B) DU-145, (C) NCI-H460, or, (D) MCF-7 cell lines were treated with doxorubicin to generate ApoV. ApoV
were then purified by differential centrifugation of cell supernatant. ApoV, live or chemotherapy-exposed cells (15 μg) were then subjected to the FGA. One-way ANOVAwith Bonferroni
post-correction test performed on the area under the curves (AUC): ns = not significant; **P b 0.01; ***P b 0.001, ****P b 0.0001. Error bars represent mean ± SD of triplicate samples.
Results are representative of at least three experiments.
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associated FV is not sufficient to support the initial events of coagula-
tion. Given that functional bovine FV was carried over into ApoV puri-
fied by differential centrifugation and serial washing steps, and that
the addition of bovine serum to ApoV purified in the absence of serum
reconstituted substrate conversion in the FV assay, we propose that
ApoV present a surface composition highly receptive to FV binding. In
our recent study, FV remained associated with ApoV following differen-
tial centrifugation, sucrose cushion purification and overnight dialysis
[28]. Therefore, in addition to platelets, this study suggests that circulat-
ing extracellular vesicles may contribute a source of particulate-
associated FV. Platelet-associated FV present in intracellular alpha-
granules derives from megakaryocyte endocytosis of circulating FV
[24,68]. In contrast, ApoV appear to directly interact with circulating
FV/FVa, most likely due to their extensive exposure of PS [28]. Although
resting platelets do not bind or express FV/FVa on their surface, activa-
tion induces PS exposure and FV binding to the platelet surface [23,24].
In this way, activated platelets and ApoV both have the potential to
provide a surface receptive for FV/Va binding and assembly of the
prothrombinase complex.
Although present on monocytes and monocytic leukemias [49,53],
TF activity is lacking from most B and T cell lymphomas [64,69]. In
agreement with this, murine NS/0 B cell and EL4 T cell lymphomas
lacked overt activity in the rapid fibrin generation assays, unless
transfected with murine or human TF genes (Figs. 3 and 5; and ref.
[28]). In contrast, ApoV from the human T cell lymphoma cell line
Jurkat exhibited procoagulant activity that was dependent on the
presence of FVII. This is consistent with previous data on the Jurkat
cell line possessing TF-dependent activity [71].
Our studyhas confirmed that ApoV contribute amajor component of
the procoagulant activity of dying tumor cells. Together with our recent
study showing that ApoV are produced in greater amounts and exhibit
superior procoagulant activity to microvesicles and exosomes released
from living cells [28], this study suggests that the ApoV released from
dying tumor cells may be a critical component of the increased throm-
botic risk in patients undergoing chemotherapy.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbagen.2016.11.020.
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Supplementary Fig. 1.
Additional controls for fibrin generation by tumor apoptotic vesicles. ApoV produced from doxorubicin treated B16-F10 were purified 
by differential centrifugation of cell supernatant. (A) ApoV (15 μg), PT, or APTT reagents were added to standard PPP and the first 
derivatives of the FGA curves were plotted. (B) ApoV (15 μg) either with the addition of 20 μg/mL anti-mouse TF antibody or a goat 
IgG control were added to standard platelet poor plasma (PPP). (C) ApoV (15 μg) were added to either a prothrombin-deficient (FII-) 
PPP or standard PPP and CaCl2 added to initiate coagulation. One-way ANOVA with Bonferroni post-correction test performed on 
the area under the curves (AUC): ns = not significant; **P < 0.01; ****P < 0.0001. Samples were loaded in triplicate. Results are 
representative of two experiments.
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Supplementary Fig. 2.
Procoagulant comparison of high and low doses of ApoV and their cell of origin. ApoV were purified by differential centrifugation of 
cell supernatant derived from doxorubicin-treated B16-F10 cells. ApoV, doxorubicin-exposed (dead), or live cells (15 μg or 60 μg) 
were added to PPP with the inclusion of 100 μg/mL annexin V (AV) to block PS prior to initiation of the FGA. One-way ANOVA with 
Bonferroni post-correction test performed on the area under the curves (AUC): ns = not significant; **P < 0.01; ****P < 0.0001. Error 
bars represent mean ± SD of triplicate samples. Results are representative of two experiments.
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a b s t r a c t
Metastasis to the lymph node is a frequent and early event in tumour dissemination. Tumour soluble
factors, including extracellular vesicles, condition host organs for metastatic tumour spread, thereby
facilitating tumour cell migration and survival. In the peripheral lymphatics, extracellular vesicles are
captured via their sialic acids by lymph node macrophages expressing the CD169 (sialoadhesin) mole-
cule, thereby suppressing the immune response. We hypothesised that the CD169 molecule could
modulate primary tumour growth and invasion into the regional lymph node by altering the immune
response to tumour extracellular vesicles, or by directly interacting with invading tumour cells. No
significant difference was noted in primary tumour growth between wild-type and CD169/ mice, and
protection against tumour challenge with tumour extracellular vesicle immunisation was similar be-
tween the strains. Subcutaneous implantation of B16 (F1 or F10) into the ventral-carpal aspect of fore-
limb resulted in melanoma infiltration into the axillary and brachial lymph nodes. CD169/ mice
displayed a lower level of metastatic lymph node lesions, however this failed to reach statistical sig-
nificance. Although CD169 participates in the immune response to tumour antigen and appears to be a
positive prognostic marker for human cancers, its role in modulating melanoma growth and metastasis is
less clear.
© 2017 Elsevier Inc. All rights reserved.
1. Introduction
Melanoma metastasises readily to other sites with only 15% of
patients with metastatic disease surviving beyond five years [1].
Regional lymph node metastasis is a frequent and early event in
many human cancers, particularly melanoma, and is a critical factor
in the staging of melanoma patients [1e4].
Recent work suggests that tumour-derived extracellular vesicles
prepare tissues including lymph nodes for invasion, and contribute
to suppression of the immune response [5e9]. Extracellular vesi-
cles released in the peripheral tissues enter the lymphatic system
and are transported to the subcapsular area and medulla of the
regional lymph node [8,10,11]. CD169 expressing macrophages trap
extracellular vesicles at the subcapsular sinus and modulate the
immune response to extracellular vesicle-associated antigen [8,10].
We have previously shown that exosomes and apoptotic vesicles
from lymphoma and melanoma cells are targeted via a2,3 linked
sialic acid to CD169þ marginal metallophilic macrophages in
spleen, or subcapsular sinus macrophages in the lymph node [8,10].
Binding is mediated by the CD169 sialoadhesin (MOMA-1) mole-
cule, a member of the sialic acid binding Ig-like lectin (Siglec)
family. In the absence of CD169: vesicle interactions, immune re-
sponses to apoptotic vesicles and exosomes are heightened, sug-
gesting a suppressive role for CD169 in the immune response [8,10].
We therefore investigated the potential of CD169 to participate
in tumour progression, including spread to the lymph node. We
propose that there are two possible mechanisms by which CD169
could mediate tumour progression: (i) CD169 uptake of tumour
sialic acid rich extracellular tumour vesicles [8] could result in
modulation of the anti-cancer response to the tumour, or (ii) CD169
could interact directly with migrating tumour cells and facilitate or
inhibit their invasion into the lymph node parenchyma. In this
manuscript, we have addressed the possible interaction of the
CD169 molecule with tumour progression. Although there was a
trend for CD169/ mice to resist metastatic melanoma to the
regional lymph node, this failed to reach statistical significance.* Corresponding author. P.O. Box 56, Dunedin 9016, New Zealand.
E-mail address: alex.mclellan@otago.ac.nz (A.D. McLellan).
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While CD169þ lymph node macrophages undoubtedly contribute
to the immune response to cancer [8,10e20], the contribution of
the CD169 molecule to melanoma progression is less clear.
2. Materials and methods
2.1. Cell culture and apoptotic vesicle preparation
The C57BL/6- derived melanoma cell lines B16-F1-GFP [21]
(Jason Waithman, University of Western Australia), B16-F10-LacZ
[22] (Ann Chambers, University of Western Ontario) and B16-F0-
OVA transfected with the full length ovalbumin (OVA) gene
(Edith Lord, University of Rochester, NY [23]) were cultured at 37 C
with 5% CO2 in R5: RPMI-1640 (Gibco #31800-022) supplemented
with 5% fetal bovine serum (FCS; PAA Laboratories, Austria), 55 mM
b-mercaptoethanol (Gibco #21985-023),100 U/mL penicillin (Gibco
#15140-122), 100 mg/mL streptomycin (Gibco #15140-122), and
2 mg/mL NaHCO3.
2.2. Mice and metastatic melanoma lymph node studies
C57BL/6 mice, originally obtained from Jackson Laboratories
(JAX, USA) and CD169/mice on a C57BL/6 background, (from Paul
Crocker; University of Dundee, Scotland) were bred at the Hercus
Taieri Resource Unit (HTRU; University of Otago), under specified
pathogen-free conditions [24]. Mice (wild-type or CD169/) were
injected with 1  106 B16-F10 cells in 25 mL PBS either subcuta-
neously (s.c.) into the ventral-carpal aspect of the forelimb, s.c. in
the ear, or intradermally (i.d.) in the flank. Mice receiving tumour
cells in the ear or flank were first anaesthetized using Ketamine
(75mg/kg) and Domitor (1 mg/kg) on a heating pad set to 37 C and
mineral oil applied to the eyes. Antisedan (1 mg/kg) was adminis-
tered following tumour implantation [24]. Mice were monitored
daily for pain symptoms, dehydration, and weight loss before
euthanasia by CO2 asphyxiation at day 12 (for the forelimb and ear
groups) and 14 (for the flank group). Immediately following
euthanasia, draining and non-draining lymph nodes were excised,
transferred into a plastic mould containing Optimal Cutting Tem-
perature (OCT) freezing media (SAKURA Finetek, USA) and frozen
at 80 C for at least 24 h. Sections (6e7 mm thick) were prepared
using a cryostat (Leica CM 1850 UV). Lymph node tumour invasion
by melanoma cells were measured using the area calculation
function of ImageJ (National institute of Health, USA) with the
operator (M-RMS) blinded to the treatment and mouse strains. All
animal studies were approved by the University of Otago Animal
Ethics Committee.
2.3. Immunohistochemistry
Lymph node tissue sections (see above) were fixed in 1% para-
formaldehyde/PBS for 10 min, rinsed in PBS and stained with
Meyer's haematoxylin (Sigma #MHS1) and eosin (Thermofisher
#6766007) and mounted in warm (60 C) glycerol/gelatine. For
CD45 detection, 25% ethanol/75% acetone fixed sections blocked
with 1% goat serumwere labelled with biotinylated rat anti-mouse
CD45 (BioLegend #103103) or with rat IgG2b, k isotype control
(BioLegend #400603) antibody at 1 mg/mL in 1% goat serum/PBS for
30 min followed by 1 mg/mL streptavidin-horseradish peroxidase
(SA-HRP; Roche #10354000) in 1% goat serum/PBS for 30 min.
Sections were then washed once with 0.05% Tween20/PBS, once
with PBS and developed with AEC substrate (Sigma #A5754) for
10e20 min.
2.4. Apoptotic vesicle immunisation and tumour challenge
Apoptotic vesicles were harvested and quantified exactly as
previously described [25]. Briefly, B16-OVA cells at 70% confluency
(approximately 1  105 cell/mL) were incubated 48 h with 25 mM
doxorubicin (Baxter Healthcare Ltd, NZ) and 200 mg/mL OVA pro-
tein (Sigma-Aldrich #A5503) in vesicle-depleted R5 at 37 C with
5% CO2. To obtain apoptotic vesicle-rich fractions, the supernatant
was depleted of cells and debris using differential centrifugation at
450  g for five minutes and then 3200  g for 20 min at 4 C.
Apoptotic vesicles were then pelleted by centrifugation at
25,000  g for one hour, and washed twice in phosphate buffered
saline (PBS; Gibco #21600-010). Mice were immunised s.c. with
either 50 mL of PBS or 25 mg of apoptotic vesicles (in 50 mL of PBS) in
the flank. Seven days later mice were challenged with 1  105 B16-
OVA cells s.c. (grown in serum free medium [26]). Tumour size is
expressed as the mean product of tumour diameters. Mice were
removed from the study when tumours reached 150 mm2 or at day
70, the final day of the study. Statistical analyses were performed as
detailed in the figure legends using GraphPad Prism (GraphPad, San
Diego, CA).
3. Results
3.1. The effect of CD169 on primary tumour growth and the immune
response to tumour extracellular vesicles
We first determined if CD169 could impact upon primary
tumour growth using a standard s.c. flank implantation model.
Inoculation of B16-F1 cells into the flank of each mouse strain
resulted in tumour growth that reached humane endpoints
(150 mm2) by 16 and 22 days for C57BL/6 wild-type and CD169/
strains respectively (Fig. 1A and B), however there was no signifi-
cant difference observed in primary tumour growth rates between
the two strains. We have previously shown that there was an
enhanced immune response in CD169/ mice upon immunisation
with extracellular vesicles prepared from primary or transformed
cells [8,10]. We therefore determined if CD169 played a role in
modulating the immune response to sialylated vesicles [8,10] and
could alter the immune response to melanoma. Apoptotic vesicles
are enriched for sialic acids and represent the most immunogenic
extracellular vesicle fraction, as compared to exosomes and plasma
membrane-derived microvesicles [25]. We therefore immunised
CD169/ and C57BL/6 mice with apoptotic vesicles prepared from
ovalbumin-pulsed B16 cells and challenged with B16-OVA in the
opposite flank seven days later. Immunisation with apoptotic ves-
icles provided significant protection for both strains of mice, as
compared to the PBS immunised group (p < 0.0001 for C57BL/6 and
p < 0.0005 for CD169/ mice respectively). Tumour growth was
not detected in 2/6 and 4/6 in wild-type and CD169/ mice,
respectively, and protection was sustained for up to 70 days.
However, therewas no significant difference in protection observed
between the two strains (Fig. 1A and B).
3.2. The impact of CD169 expression on lymph node B16 melanoma
metastasis
We performed a pilot experiment to determine the most
effective inoculation route for generating lymph node metastases.
C57BL/6 mice were injected s.c. in the forelimb, ear, or i.d. in the
flank with B16-F1 melanoma cells and lymph nodes examined
macroscopically, sectioned and analysed by microscopy. As shown
in Fig. 2A and D, the forelimb inoculation method yielded melanin-
positive draining axillary and brachial lymph nodes in 6/6 mice
inoculated. In the ear group, 5/6 mice showed positivity in the
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Fig. 1. The influence of CD169 on primary tumour growth and in the anti-cancer immune response. At day zero, C57BL/6 (circles) or CD169/ (squares) mice (were immunised
subcutaneously (s.c.) in the flank with either PBS (open symbols) or B16-derived apoptotic vesicles (ApoV; closed symbols) pulsed with ovalbumin (OVA). At day seven, the mice
were challenged s.c. in the opposite flank with 1 x 105 B16-OVA cells and monitored until tumour size reached 150 mm2, or at the final day of the study (day 70). (A) Percent survival
of the mice. (B) Tumour size scores for every individual mouse from each group. Results are from six mice / group.
Fig. 2. Development of a lymph node metastatic melanoma model. C57BL/6 mice were injected with 1  106 B16-F1 either s.c. in the forelimb (A), s.c. in the ear (B), or
intradermally (i.d.) in the flank (C). Mice were monitored daily and euthanized using CO2 asphyxiation at day 12 for the s.c. forelimb and ear groups, and day 14 for the i.d. flank
group. (D) Axillary (top) and brachial (bottom) draining lymph nodes (dLN) from the forelimb, (E) auricular dLN from the ear tumour group, and (F) inguinal dLN from the flank
tumour group were dissected along with their respective non-draining LN. (G) The number of mice with a detectable tumour in draining LN. Results are representative of six mice/
group.
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draining auricular lymph node (Fig. 2B and E). Only 3/6 of the mice
in the i.d. flank group showed positivity within the inguinal lymph
node (Fig. 2C, F and 2G). Tumour invasion into non-draining lymph
nodes was not observed in any of the groups (data not shown). The
results were confirmed by sectioning and haematoxylin & eosin
staining (Fig. 3AeC). As predicted, a clear infiltration of tumour cells
was observed within the draining lymph node of the s.c. models
(Fig. 3A and B), as compared to naïve lymph node (Fig. 3C). To
confirm that the invading tumour margins were correctly placed
for the s.c. groups, we used melanoma cell lines transfected with
the marker green fluorescent protein (GFP) or b-galactosidase (B16
F1-GFP and B16 F10-LacZ respectively), although these markers
showed consistent expression in vitro, there was a marked down-
regulation on tumour cells in vivo (data not shown). We therefore
labelled sections with Leukocyte Common Antigen (CD45) to
ensure proper demarcation of tumour margins (Fig. 3DeF). Mela-
noma invaded areas within the draining lymph node showed a
distinct reduction in areas labelling uniformly with the CD45
marker, however, infiltrating CD45þ leukocytes were present with
the tumour invaded areas (Fig. 3DeF). We next inoculated C57BL/6
and CD169/ in the forelimb with B16-F10 melanoma and ana-
lysed the total tumour area of the draining axillary and brachial
lymph node in strains. Although there was a modest reduction in
tumour infiltration in the CD169/ strain, this failed to reach sta-
tistical significance (Fig. 4).
4. Discussion
Our investigation has covered four aspects of potential interac-
tion of melanoma with the CD169 molecule: (i) the growth of the
primary tumour, (ii) the induction of an anti-cancer response by
melanoma extracellular vesicles, and (iii) metastasis to the regional
lymph node. None of these parameters was significantly altered by
the absence of CD169. It should be noted that in the CD169/
mouse model utilised in this study, splenic marginal zone and
lymph node marginal zone macrophages were still present, but
selectively lacked the CD169 sialoadhesin molecule [27,28].
Therefore, our study does not rule out a role for these macrophages,
but makes it unlikely that the CD169 molecule plays a major role in
melanoma progression, or in the immune response to melanoma
extracellular vesicles. In contrast, other studies have depleted the
CD169þ macrophage populations (or dendritic cells), using diph-
theria toxin or clodronate liposomes and have demonstrated a
positive role for CD169þ macrophages in the immune response
[12,14,16,17,19,20,29,30]. Overall, these studies suggest that CD169þ
macrophages exert a major influence on the immune response, but
that this effect is independent of CD169 surface expression.
The detection of draining lymph node metastasis is crucial in
diagnostic staging of melanoma and other cancers. The study of
tumour cells within the lymph node is also relevant to under-
standing the immune response to cancer, with both immune acti-
vation and immune suppression identified in positive lymph nodes
[31]. The most commonly utilised model of melanoma metastasis
in the mouse model is haematogenous spread to the lungs [32]. A
challenge for the study of mouse melanama models is the devel-
opment of a skin-draining lymph node model resulting in a reliable
one-hit metastasis to the draining lymph node [33]. This mirrors
challenges in mapping and predicting melanoma migration in
humans [3], where only a few anatomical primary tumour positions
offer predictability for sentinel lymph node positivity [3,34]. In this
study, we determined that B16 forelimb inoculation, as described
over 35 years ago for a leukaemic cell line [35], resulted in a reliable
invasion of lymph nodes in 32 mice tested. Anatomical placement
of tumour implants has been shown to impact markedly on
Fig. 3. Analysis of regional lymph node metastasis by microscopy. C57BL/6 mice were injected with 1  106 B16-F1 either s.c. in the forelimb, s.c. in the ear, or i.d. in the flank.
dLN from each group were dissected, sectioned (6e7 mm thick), and stained with haematoxylin & eosin (H&E). Representative sections from the draining (A) brachial LN from the
s.c. forelimb group, (B) auricular LN from the s.c. ear group, and (C) negative control section of a naïve LN. Yellow dashed lines indicate areas of melanoma cells within LN. Results are
representative of six mice/group. (DeE) draining invaded LN (brachial) were stained with haematoxylin (blue) and anti-mouse CD45 (red). Zones that are rich in melanoma cells
and scarce CD45-positive cells are marked by “M”. Zones with CD45þ leukocytes as a majority are marked with “L”. Arrows indicate melanoma cells within CD45-rich areas. Sections
are visualised under 20  objective lens. Results are representative of four to six mice/group.
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metastatic potential, with intradermal or footpad inoculation fav-
oured over subcutaneous flank implantation [36e39]. In this study,
we did not investigate the mechanism of melanoma spread to the
lymph node. Despite the formation of a palpable primary tumour in
the carpal region (Fig. 2A), at least some invading tumour cells may
have originated from the original injection bolus, prior to the for-
mation of a primary tumour mass. Therefore the value of this cur-
rent method for modelling primary tumour to lymph node spread
requires further investigation. The distinctive larger size of invaded
lymph nodes is consistent with a recent study demonstrating
increased lymph node size due to expansion of fibroblastic reticular
cells of lymph nodes underlying primary B16 melanomas [40].
The prognostic significance of CD169þ macrophages in cancer
outcomes has been investigated by several groups. The presence of
CD169þ macrophages in the lymph node tended to support better
patient outcomes [41e43], whereas circulating CD169þ monocytes
and skeletal-associated CD169þ monocytes in prostate cancer ap-
pears to be associated with pathogenic outcomes [44,45]. There-
fore, although there lacks a consensus on the role of CD169þ
macrophages in modulating tumour invasion and anti-cancer im-
munity, their presence in lymph nodes may predict better out-
comes in a range of human cancers. One major weakness is that our
study was likely underpowered to detect subtle changes in the
tumour progress. Nevertheless, given the modest differences in
tumour progression between the control and CD169/ mice in
several experimental settings, it does indicate that any effect may
be weak. While our study does not rule out a role for a possible
interaction of tumour cells and their vesicles with CD169, it dem-
onstrates that in the B16 model, this interaction does not appear to
affect tumour progression, nor the immune response to tumour
extracellular vesicles.
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Fig. 4. Quantification of cutaneous melanoma metastasis in C57BL/6 wild-type and CD169¡/¡ mice. C57BL/6 wild-type or CD169/ mice were injected s.c. under the forelimb
with 1  106 B16-F10 cells and euthanized at day 12. Draining brachial and axillary LN were removed, sectioned (6-7 mm-thick) and stained with H&E. (A) Total areas of draining
axillary and brachial LN analysed for the calculation of the percent of melanoma invasion in (B). (B) Melanoma-invaded areas were calculated with respect to the entire associated
LN area using the software Image J and expressed as a percent of total lymph node area. Error bars represent ± SD. A parametric unpaired t-test was used to analyse the data
collected; ns: not significant. Results shown from eight mice/group and are representative of two experiments.
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